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CHAPTER 1
Introduction
1. Allogeneic hematopoietic stem cell transplantation
During the past fifty years, allogeneic hematopoietic stem cell transplantation (SCT) 
has evolved to an effective, personalized form of cellular immunotherapy with the 
potential to cure various hematological malignancies and inherited disorders of 
the hematopoietic system. The implementation of hematopoietic stem cell ther-
apy allowed treatment of cancers with high-dose radio- and chemotherapy result-
ing in increased tumor eradication, but also  replacement of the patient’s bone 
marrow (BM) resulting in restoration of the hematopoietic and immune system 1. 
Although the first SCT attempts were in severe immune-deficient patients, progress 
in the field of human leukocyte antigens (HLA) allowed this new form of therapy 
in immune-competent cancer patients as well. Matching of HLA between donor 
and recipient prevents strong allogeneic immune responses that have deleterious 
effects on healthy tissues causing severe graft-versus-host disease (GVHD). How-
ever, despite HLA-matching of donor and recipient, both GVHD as well as the cura-
tive graft-versus-tumor (GVT) response are observed in these transplantations. The 
main target antigens in HLA-matched allogeneic SCT are minor histocompatibility 
antigens (MiHA). These MiHA are peptides derived from intracellular proteins 
encoded by polymorphic genes, reflecting genetic variation among individuals. 
MiHA are presented by major histocompatibility antigens (MHC) on antigen pre-
senting cells (APC) and expansion of MiHA-specific cytotoxic T lymphocytes (CTL) 
precedes clinical remission in patients 2-4. When MiHA-specific T cells recognize 
hematopoietic-restricted MiHA, an antitumor immune response, known as the 
GVT effect, can be established. However, recognition by MiHA-specific T cells of 
ubiquitously expressed MiHA can lead to GVHD. Therefore, transplant-related 
complications such as GVHD and infections remain major drawbacks of SCT. 
Clinical and experimental research to optimize the curative effect of SCT and to 
minimize the risks of SCT have led to several adjustments in the transplant pro-
cedure. The conditioning regimen administered prior to SCT has been adjusted 
over the years, leading to benefit of elderly patients 5 or patients with specific 
types of malignancies 6. The standard conditioning regiments were myeloab-
lative, causing BM ablation due to complete loss of hematopoietic stem cells. 
Nowadays when possible, reduced intensity conditioning (RIC) is used, which is 
non-myeloablative, but does allow engraftment of donor hematopoietic cells. In 
addition, to reduce the risks associated with SCT, complete or partial depletion 
of T cells from the graft has been implemented successfully. However, T cells 
are not only mediators of GVHD, they also mediate the beneficial graft-versus-
tumor (GVT) reaction. To restore this GVT function, delayed add back of T cells 
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can be given in the form of donor lymphocyte infusion (DLI) either preemp-
tively 7 or therapeutically to treat relapses (reviewed in 8). DLI might not only 
improve GVT function, but also results in earlier conversion to complete donor 
chimerism and faster immune recovery capable to fight off infectious diseases. 
Efforts to further improve the therapeutic effect of allogeneic SCT are ongoing. 
The newest developments, such as combining allogeneic SCT with vaccination 
strategies and/or adoptive T cell therapies targeting tumor-expressed MiHA, are 
promising therapeutic interventions capable of enhancing the GVT effect with-
out inducing GVHD. Furthermore, the clinical outcome of allogeneic SCT and DLI 
is  influenced by polymorphisms in genes involved in the immune system. This 
chapter describes the current understanding of genetic polymorphisms that are 
responsible for generating MiHA-specific T cell responses as well as polymor-
phisms in signal molecules playing a major role in allo-immune responses after 
allogeneic SCT. 
2. GVHD pathogenesis and non-HLA polymorphisms
One of the major complications of allogeneic SCT is a multistep process known 
as GVHD. The process is clinically divided in two forms, acute and chronic GVHD. 
In the acute form donor T cells infiltrate target organs, in general the gastrointes-
tinal tract, liver and skin. Chronic GVHD typically develops late (>100 days) after 
allogeneic SCT and is characterized by widespread fibrosis, mostly within liver 
and skin 9;10. 
The mediators of GVHD are alloreactive donor T cells. In case of an HLA matched 
allogeneic SCT, T cells recognize antigens presented by MHC on APC. However 
the first trigger in the pathogenesis of acute GVHD is the creation of an inflamma-
tory environment in healthy tissues 9;12. During conditioning, prior to SCT, usually 
radiation and chemotherapy are applied which compromise the integrity of the 
tissues (Figure 1, phase 1). This results in release of pro-inflammatory cytokines, 
such as tumor necrosis factor α (TNFα) and the interleukins (IL)-1 and -6. Further-
more, in this early phase the gastrointestinal tract integrity is damaged, allow-
ing translocation of bacterial products such as lipopolysaccharide (LPS) into the 
bloodstream. These factors activate both the innate immune system as well as 
the adaptive immune system, and create an inflammatory environment in which 
the MiHA- specific T cells become activated. In the second phase, both host and 
donor APC present alloantigens to donor T cells (Figure 1, phase 2). Dependent 
on the nature of cytokines released in the first phase either an inflammatory 
environment can arise (TNFα, IL-6, IL-1), or a more immunosuppressive environ-
ment is established under influence of IL-10. Moreover, tissue damage in phase 
3 occurs in case of presentation of a ubiquitous or epithelial expressed MiHA to 
specific T cells in an inflammatory environment. In this phase, alloreactive effec-
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During the first phase, prior to allogeneic SCT, 
tissue damage occurs due to conditioning such 
as chemotherapy and radiotherapy. Bacterial LPS 
translocates into the circulation and is sensed by DC 
in the tissues.  HLA, co-stimulatory-, chemokine-, and 
PAMP-receptors on DC are upregulated and cytokines 
are produced creating an inflammatory environment. 
In the second phase, the DC mature and migrate to 
lymphoid tissues where they can activate alloreactive T 
cells that develop into effector T cells. In phase three, the 
effector T cells leave the lymphoid tissues and migrate 
to their target tissues where they attack their target 
cells. More tissue damage occurs, thereby amplifying 
the immune response as already initiated in phase 1. 
Animation: 
T cell activation
 by DC 11
Figure 1. The 3 stage pathogenesis of acute GVHD.
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. 
tor CTL will kill normal cells in inflamed tissues and produce interferon γ (IFNγ) 
(Figure 1, phase 3). Once tissue damage has occurred, additional cytotoxic cellular 
components become involved such as natural killer (NK) cells, macrophages and 
other effector T cell subsets. Although Th1 CD4+ T cells and CD8+ cytotoxic T cells 
are recognized as the main effectors of GVHD 13-15, other T helper cells belong-
ing to both Th17 and Th2 subsets might play a role as well 16-18. In this phase, 
cytokines that have a function in T cell proliferation (IL-7, IL-23) are important. 
In addition, cellular and bacterial components translocate the mucosal barrier 
which are able to activate components of the innate immune system such as the 
pathogen-associated molecular pattern (PAMP) receptors Dectin-1 and NOD2, 
thereby further enhancing GVHD severity.
3. How to study SNPs associated with disease
Many components of the immune system are known in which genetic polymor-
phisms can influence the outcome of allogeneic SCT. These genetic polymor-
phisms, that vary between individuals, are known as single nucleotide polymor-
phisms (SNPs). SNPs may lie within coding, non-coding sequences or in between 
genes potentially leading to an amino acid change. The genetic variations can lead 
to functional differences or changes in expression level of the protein. Studying 
non-HLA polymorphisms that play a role in disease is nowadays mostly done by 
genome-wide association studies (GWAS). GWAS compare patterns of genetic 
variations between diseased and non-diseased individuals. Genetic regions can 
be identified by the association of two or more loci on a chromosome with lim-
ited recombination between them. Studying the SNPs that are located within this 
region, can lead to the identification of polymorphic genes that play a role in dis-
ease. Advances in the field of SNP genotype sequencing and the documentation 
of this information in the International HapMap project 19 has been instrumental 
20.  
It is important to confirm the results obtained by GWAS in different patient 
cohorts, since the associations documented by GWAS are very much context 
dependent and difficult to confirm and reproduce.  For conformation tagSNPs 
can be useful tools, since these are usually located in intergenic regions and 
represent SNPs in a region of the genome with high linkage disequilibrium to a 
certain gene associated to disease. The use of tagSNP selected from well defined 
populations in the HapMap project has allowed to transfer findings between dis-
tinct study groups 21. 
However, functional studies that elucidate the influence of a SNP on the function 
or expression of a gene associated with disease are the ultimate validation of 
GWAS results as will be the case for SNP involved in the immune system and their 
possible role in the outcome of allogeneic SCT. 
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4.1  Non-HLA polymorphisms that play a role in the conditioning  
 phase prior to allogeneic SCT (Table 1).
In the first phase of the pathogenesis of GVHD the release of bacterial products 
from the intestine during GVHD can be sensed by intracellular PAMP receptors 
such as TLR, NOD2 or Dectin-1. The most well known group of intracellular PAMP 
receptors is composed of the Toll like receptor (TLR) family. The Thr399Ile poly-
morphism of TLR-4 gene was studied in non-T cell depleted SCT recipients. These 
patients appeared to have an increased risk for severe acute GVHD when the 
polymorphism was present in either the donor or recipient 22.  
Another family member, TLR-9, was studied in acute myeloid leukemia (AML) patients 
receiving an allogeneic SCT. The T1468C polymorphism in TLR-9 influenced overall 
survival (OS) when the gene was homozygous for the C allele at the 1468 position 23. 
Another PAMP receptor, NOD2, is encoded by the CARD15 gene and plays a 
role in the immune response to intracellular bacterial LPS by recognizing the 
muramyl dipeptide (MDP) leading to activating of NFκB. NOD2 is expressed 
by two cell types that are at the site of inflammation during GVHD: APC and 
epithelial cells 24. In two independent cohorts it was found that polymorphisms 
in both the donor and recipient NOD2 had an effect on acute GVHD and treat-
ment related mortality (TRM) in recipients receiving a partial T cell depleted 
graft 25 as well as in recipients of a non-T cell depleted graft 26. In addition, a 
trend towards increased incidence of bacteremia was observed as well as severe 
GVHD in the gastrointestinal tract. Also of importance is Dectin-1, expressed 
on DC and belonging to the C-type lectin family. Dectin-1 initiates immune 
responses towards fungal pathogens, including Candida sp. and Aspergillus 
sp., by sensing 1,3-β-glucans 27-29. A polymorphism in this molecule, the Y238X 
coding SNP, leads to a higher risk to be colonized with Candida sp. comparing 
to individuals with wild type Dectin-1 30. Recipients of a partial T cell depleted 
graft with this specific Dectin-1 polymorphism were also more likely to be col-
onized with Candida sp.31. In addition, a higher incidence of acute GVHD was 
observed in patients who were colonized but did have the wild type Dectin-1 32. 
In addition to PAMP receptors, cytokines such as interleukin-1 (IL-1) and IL-6 
play an important role in the conditioning phase, the T cell priming phase as 
well as in the effector phase of GVHD and GVT. One of the cytokines that are 
involved in the early phase is IL-1. The IL-1 family plays a central role in the 
regulation of the immune system and hematopoietic activities. IL-1 is released 
by macrophages under the influence of the presence of LPS in the circulation, 
which can occur due to tissue damage during the conditioning phase. Although 
no polymorphisms in the IL-1β gene are known to date that influence alloge-
neic SCT outcome, polymorphisms in the IL-1α gene can influence the produc-
tion of the cytokine. A 46 base pair variable number tandem repeat (VNTR) in 
Proefschrift Broen_2.indd   14 18-3-2012   15:41:44
15
 NON-HLA IMMUNOGENETICS IN STEM CELL TRANSPLANTATION
1
CH
A
PT
ER
Phase Gene Polymorphism Outcome SCT
1
NOD2 SNPs 8,12 and 13 Increased acute GVHD
Increased TRM
Increased incidence of bacteremia
Dectin-1 SNP Y238X Increased Candida sp. colonization
Increased acute GVHD
TLR-4 Thr399Ile Increased severe acute GVHD
TLR-9 SNP T1468C Increased OS
IL-1α 46 bp VNTR Increased chronic GVHD
IL-1α Position 511 Improved OS
Decreased TRM
IL-6 174G Increased chronic GVHD (CC pheno-
type)
Increased severe acute GVHD (GX 
phenotype)
2
IL-10 592A/A Decreased risk of grade III or IV 
acute GVHD
Decreased risk for death in remis-
sion
CCR5 32 gene deletion Decreased acute GVHD
CCR6 tagSNP rs2301436 Decreased chronic GVHD
Increased invasive fungal disease
CCR6 SNP rs3093023 Decreased chronic GVHD
3
IFNγ CA repeat element Inconclusive effect on acute GVHD
IL-7R 1237A/G SNP 
(rs1494555)
Increased TRM
IL-7R SNP 510C/T Increased grade III and IV acute 
GVHD
IL-23R 1142G>A 
(rs11209026)
Inconclusive effect
Table 1. Genetic polymorphisms in immunomodulatory genes that can influence 
the clinical outcome of allogeneic SCT
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intron 6, modulates gene expression depending on the number of repeats 33. 
The VNTR polymorphism in the IL-1α gene was studied in relation to the out-
come of allogeneic SCT and is an independent risk factor for chronic GVHD 
34. In addition, a polymorphism at position 511 was found to associate with 
improved survival and decreased TRM in an unrelated donor SCT cohort 35. 
Importantly, IL-1α regulates other cytokines in the conditioning phase such as 
IL-6. In the conditioning phase prior to allogeneic SCT, IL-6 can act either as a pro-
inflammatory or an anti-inflammatory cytokine. Especially tissue damage leads 
to the production of IL-6 by keratinocytes, T cells and macrophages/monocytes 
and precedes the appearance of other cytokines in the circulation. The IL-6 174 G 
polymorphism in the IL-6 gene is associated with both acute and chronic GVHD. 
Cavet et al showed in a cohort patients receiving a graft from a sibling donor that 
recipients homozygous for the G allele at position 174 were more likely to develop 
chronic GVHD, while patients with the G allele showed a trend to develop higher 
grades of acute GVHD 36. These results were confirmed in independent studies 
37;38. In addition, Karabon et al showed that the IL-6 174 G allele also led to higher 
serum levels of active IL-6 in patients who developed severe acute GVHD 6 weeks 
after transplantation 38. 
4.2  Non-HLA polymorphisms that play a role in the T cell priming 
 phase post allogeneic SCT (Table 1).
During the first phase of the pathogenesis of GVHD an inflammatory environ-
ment is created in which, during the second phase host and donor APC pres-
ent antigens to donor T cells. Dependent on the nature of cytokines released in 
the first phase either an inflammatory environment or an immunosuppressive 
environment can arise under influence. An important modulator of the immune 
response is IL-10 which is primarily produced by monocytes, regulatory T cells 
(Treg) and T helper 2 cells (Th2). Its immunosuppressive effect is executed by the 
down regulation of Th1 cytokines (IFNγ, IL-2, IL-3, TNFα and GM-CSF), MHC class 
II antigens and costimulatory molecules on macrophages 39, reviewed in 40). 
The IL-10 gene is highly polymorphic leading to several conserved haplotypes in 
which SNPs and microsatellites are grouped. Interestingly, the 592A/A recipient 
genotype was associated with a decreased risk of grade III or IV acute GVHD as 
well as with a decreased risk for death in remission 41.  
In the second phase of the pathogenesis of GVHD, immune cells migrate to their 
priming sites. Here chemokines act as a chemoattractants to guide the migra-
tion of cells. Increased expression of several chemokine receptors, CCR5, CXCR3, 
CCR1 and CCR2, was observed in case of acute GVHD 42. The chemokine recep-
tor CCR5 is involved in GVHD, directing T cells to non-malignant tissues. Murine 
studies have shown that T cells migrate to the liver, a GVHD prone organe, under 
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guidance of CCR5 43. A 32 nucleotide deletion in the CCR5 gene is described that 
has an impact on the development of GVHD. Recipients of a HLA-matched trans-
plant carrying the deletion developed less frequently acute GVHD than recipients 
without the deletion 44. 
Also polymorphisms in the chemokine receptor CCR6 have been studied in rela-
tion to allogeneic SCT outcome. CCR6 is known to chemo-attract T-, B cells and 
immature DC to peripheral tissues with mucosal surfaces and lymphoid organs 
45. Kochi et al showed that two different polymorphisms, both located within the 
CCR6 gene and in linkage disequilibrium with CCR6 tagSNP rs2301436, regulate 
the expression of CCR6 46. We analyzed the impact of the these CCR6 SNPs in 
partial T cell depleted allogeneic SCT and found that the GG genotype is associ-
ated with less chronic GVHD and increased invasive fungal disease 47. 
4.3 Non-HLA polymorphisms that play a role in the effector         
 phase  post allogeneic SCT (Table 1).
In an inflammatory environment CTL can cause tissue damage to either healthy 
tissue (phase 3 in GVHD) or tumor tissue (GVT). In this phase, cytokines that play 
a role in T cell effector function and proliferation are important. In addition, cellu-
lar and bacterial components are released that activate PAMP receptors creating 
a positive feedback loop. 
Post-SCT, large numbers of IFNγ-producing T cell clones can be found and serum 
levels of IFNγ increase before and during GVHD 48. The IFNγ gene has a CA repeat 
element (microsatellite) in the first intron of which 3 different alleles exist. These 
different alleles are associated with different levels of IFNγ in vitro, in case of 
allele 2 the highest amount of IFNγ is produced by activated PBMC 49. Cavet et al 
studied the role of this intron 1 polymorphism in a cohort of patients receiving 
grafts from sibling donors. They found that recipients homozygous for intron 1 
allele 3 (lower IFNγ production) had more severe acute GVHD 36. Another study 
regarding intron 1 allele 2 genotypes showed that the IFNγ intron1 allele 2 geno-
type was an independent and protective factor associated with a decreased risk 
of grade II–IV acute GVHD 50. However, in the study of Socie et al no effect of the 
IFNγ polymorphism was observed on the outcome of allogeneic SCT 37. 
The effector cells that cause tissue damage in phase 3 of the GVHD pathogen-
esis need cytokines for their maintenance. Interleukin-7 (IL-7) is required for 
the development and maintenance of cells in the lymphoid lineage 51. Polymor-
phisms in the IL-7 receptor (IL-7R), can influence the outcome of allogeneic SCT. 
The IL-7R contains four non-synonymous SNPs of which the donor 1237 A/G 
SNP (rs1494555) is associated with TRM in a cohort of HLA matched, unrelated 
donors (MUD). The other known SNP were not associated with outcome of SCT, 
and results could not be confirmed in a cohort of HLA matched, related donors. 
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Both the 1237 A/G SNP, as well as the 510 C/T SNP were associated with grade III 
and IV acute GVHD 52. 
As of yet, there are no functional consequences known for the non-synonymous 
SNPs which are located in different exons of the IL-7R gene, as is the case for poly-
morphisms in the receptor of interleukin-23 (IL-23). IL-23 is one of the hallmark 
cytokines involved in the T helper 17 (Th17) response, a T helper subset distinct 
from Th1 and Th2 cells. IL-23 induces proliferation of Th17 cells and stabilizes 
their phenotype 53. Th17 cells play an important role in infectious complications 
that can occur post transplantation, such as fungal infections 54. These cells might 
play a role in the pathogenesis of GVHD in mouse models17;18;55;56, but this has not 
been confirmed in a human setting 48. 
The IL-23R has been studied extensively in several chronic inflammatory diseases 
in which Th17 cells are implicated 57;58. Polymorphisms in the receptor are linked 
to several chronic inflammatory diseases, such as Chrohn’s disease and rheuma-
toid arthritis 20. The well known IL-23R SNP located in exon 9, 1142G>A, was asso-
ciated with a reduced risk of acute GVHD in a cohort receiving an HLA-matched 
graft from a sibling donor as well as in a cohort of recipients receiving a graft 
from an unrelated donor 59-61.  Also death in remission was lower 60 as was the 
risk of fungal infections 59.  Other studies of the 1142G>A SNP did not confirm the 
protective role of this SNP in clinical outcome of allogeneic SCT 47;62;63.
Although GVHD, as well as the GVT reaction, is a complicated multistep process, 
it might prove to be somewhat controllable by the choice of donor. Numerous 
studies on the effect of non-HLA polymorphisms on allogeneic SCT show that 
patients might benefit from typing for these particular SNPs when looking for 
a suitable stem cell donor. However, further research on the consequences for 
gene functionality due to the described polymorphisms is required. 
5.1  Non-HLA polymorphisms form the immunogenetic base for  
 MiHA
The polymorphisms, playing a role in the pathogenesis of GVHD, are located 
within genes or regulatory elements of cytokines, chemokines and its receptors 
or PAMP-receptors. A different class of non-HLA polymorphisms that influence 
the clinical outcome of allogeneic SCT are those that underlie MiHA.  The thera-
peutic GVT effect of allogeneic SCT is largely dependent on recognition of MiHA 
by donor-derived CD8+ T cells and MiHA-specific CTL expansion precedes clinical 
remission in patients treated with DLI 3;4;64.  MiHA are the main target antigens 
in HLA matched allogeneic SCT and can directly determine the specificity of the 
allogeneic response towards tumor cells or healthy tissues. However, alloreactive 
CTL responses induced upon DLI generally lack tumor specificity and are often 
accompanied by GVHD. Therefore, it would be highly beneficial to direct T cell 
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immunity towards MiHA that are selectively expressed on malignant cells.
5.2  Identification of MiHA: towards genetic based high through- 
 put systems. 
MiHA reflect the genetic variation among individuals and can theoretically origi-
nate from any autosomal polymorphic gene. In addition, a specific class of MiHA 
originate from the Y-chromosome, playing an important role in female-donor-
male-recipient (FDMR) transplantations 65;66. MiHA originate from polymorphic 
cellular proteins that, after processing in the immune-proteasome, are presented 
by MHC molecules at the cell surface of APC (Figure 2). Donor T cells recognizing 
the peptide-MHC complex as foreign can, in an inflammatory environment, 
induce a potent immune response. In most cases the MiHA are encoded by a 
non-synonymous SNP leading to an amino acid change, resulting in a novel immu-
nogenic epitope 67-70. However, SNPs can also lead to frameshifts 71, stopcodons 
72 or alternative splicing 73;74 by which novel immunogenic epitopes are formed 
(reviewed in 75. Finally, homozygous gene deletions can lead to the formation of 
Figure 2. Genetic polymorphisms form the basis of MiHA
MiHA are peptides derived from intracellular proteins encoded by polymor-
phic genes. They are presented by MHC on APC.
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immunogenic epitopes 76 recognized by donor T cells. Table 2 summarizes auto-
somal HLA class I-restricted MiHA and the type of polymorphisms they originate 
from, as well as the method used to identify the MiHA. 
To date identification of novel MiHA is a laborious, time consuming process that 
needs improvement to allow identification of therapeutically interesting MiHA 
at a large scale. All conventional identification processes make use of MiHA-
specific CTL clones cultured from patients post allogeneic SCT or DLI. Several 
strategies have been used to identify new immunogenic MiHA. Early strategies 
used peptide elution libraries constructed from MiHA+ recipient APC. The eluted 
peptides are then studied using biochemical fractionation and mass spectromet-
ric sequencing to elucidate the amino acid composition. This approach yielded 
several MiHA, all HLA class I restricted, such as HA-1, HA-2, HA-3, SMCY, ADIR and 
PANE1 65;67;68;72;77;78. 
A different approach that relies on cDNA libraries constructed from MiHA+ recipi-
ent APC. The cDNA library is expressed in eukaryotic cells that are subsequently 
screened for recognition by the MiHA-specific CTL. DNA sequencing and epitope 
mapping of the MiHA-encoding cDNA can lead to the molecular identification of 
the MiHA. Successful attempts have led to the identification of HB-1, ACC6, ECFG, 
HY.B8 and HY.B52 74;79-82. A recent modification of the cDNA expression cloning, 
leading to a more rapid process, has made it possible to identify the first HLA 
class II restricted MiHA 83;84. 
A different approach to identify MiHA makes use of the genetic basis of the poly-
morphisms, which are usually inherited in a Mendelian fashion 85. Genetic linkage 
analysis uses correlations in inherited markers in specially selected individuals 
from families studied in the Centre d’Etude du Polymorphisme Humain (CEPH). 
This approach has led to the identification of LRH-1, ACC1-Y and ACC2 69;71, all 
HLA class I restricted MiHA. A variation of this approach, genome-wide zygosity-
genotype correlation, makes this technique more suitable for high throughput 
identification of multiple MiHA 86. The genome-wide zygosity-genotype correla-
tion  assay was used to identify CD19L, an HLA class II restricted MiHA 87. Most 
recent developments in the field of MiHA identification have focused on the use 
of GWAS to identify the polymorphism that forms the basis of the MiHA. This 
approach appeared to be suitable for high throughput identification of HLA class I 
restricted MiHA and holds much promise for future identification purposes 73;88;89. 
For now, all MiHA that are molecularly defined, make use of MiHA-specific T 
cell clones isolated from patients post allogeneic SCT or DLI. However, also 
reverse immunology strategies have been explored. This strategy makes use of 
algorithms that predict proteosomal cleavage, thereby predicting immunogenic 
epitopes from polymorphic genes in silico. Subsequently, the peptides can be 
synthesized and HLA binding studies performed to reveal whether the potential 
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Table 2. Autosomal HLA class I restricted MiHA: underlying type of 
polymorphisms and identification method used.
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Non-synonymous SNP
HA-1 A2 VLHDDLLEA 68 Peptide elution
HA-1 B60 KECVLHDDL(L) 91
HA-2 A2 YIGEVLVSV 67, 92 Peptide elution
HA-3 A1 VTEPGTAQY 78 Peptide elution
HA-8 A2 RTLDKVLEV 93 Peptide elution
HB-1H B44 EEKRGSLHVW 94 cDNA expression cloning
HB-1Y B44 EEKRGSLYVW 70 Reverse immunology
ACC1-Y A24 DYLQYVLQI 69 Genetic linkage analysis
ACC1-C A24 DYLQCVLQI 89 GWAS
ACC2 B44 KEFEDDIINW 69 Genetic linkage analysis
C19orf48 A2 CIPPDSLLFPA 95 cDNA expression cloning
HEATR B8 ISKERAEAL 96 Genetic linkage analysis
Frameshift
LRH-1 B7 TPNQRQNVC 71 Genetic linkage analysis
Stopcodon
PANE1 A3 RVWDLPGVLK 72 Peptide elution
Alternative reading frame
ECGF B7 RPHAIRRPLAL 80 cDNA expression cloning
ADIR A2 SVAPALALAFPA 77 Peptide elution
ARHGDIB B7 LPRACWREA 97 GWAS
Alternative splicing
ACC6 A3 SLPRGTSTPK 98 GWAS
ZAPHIR B7 IPRDSWWVEL 73 GWAS
Homozygous gene deletion
UGT2B17 A29 AELLNIPFLY 99 cDNA expression cloning
UGT2B17 B44 AELLNIPFLY 76 cDNA expression cloning
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MiHA actually binds to the HLA molecule of interest. Once the HLA-binding MiHA 
is selected, tetramers can be produced and patient samples examined to identify 
T cells specific for the MiHA. A disadvantage of the in silico predication is that 
it focuses on non-synonymous SNP leading to amino acid changes and thereby 
creating novel epitopes. Epitopes originating from frameshifts or alternative 
splicing are mostly missed. An advantage of this approach is that the selection 
of polymorphic genes can be restricted to genes exclusively expressed by hema-
topoietic cells, leading to restricted, non-GVHD inducing, expression patterns of 
the MiHA. Furthermore, the frequency in which the polymorphism occurs can 
be selected to ensure an optimal donor/recipient disparity rate 90. However, to 
date reverse immunology approaches have only yielded MiHA that are variations 
of previously known MiHA 70;91, but have not yet yielded novel MiHA suitable 
for future immunotherapeutic applications. If reverse immunology approaches 
are to be further employed for the discovery of MiHA relevant to the immuno-
therapy of hematologic malignancies, some hurdles have to be taken before this 
can be implemented into a high throughput method. For the development of 
adjuvant tumor-specific immunotherapy after SCT it is important to enlarge the 
spectrum of molecularly identified MiHA that are selectively expressed in the 
hematopoietic system and in hematologic malignancies.
6. MiHA-specific T cells in the graft-versus-tumor response  
 in hematopoietic and solid malignancies. 
Allogeneic SCT has become the treatment of choice for patients with various 
hematological malignancies 99;100. Patients suffering from chronic myeloid leuke-
mia (CML) who received a BM transplantation showed prolonged leukemia-free 
survival. These patients benefit highly from DLI. However, allogeneic SCT is not 
the treatment of choice in most CML patients, nowadays since treatment with 
tyrosine kinase inhibitors induce impressive and longlasting clinical responses 101. 
When allogeneic SCT was utilized, an increased risk for relapse was observed 
using T cell-depleted grafts, showing a very important role of alloreactive T cells 
recognizing MiHA in this group of patients 102. The isolation and characteriza-
tion of MiHA-specific T cell from a CML patient has led to the identification of 
the MiHA LRH-1 71 and ACC2 69. Also isolation of MiHA-specific T cells from AML 
patients post allogeneic SCT has led to the identification of the several MiHA: 
HA-1 68, HA-2 92, ACC1 69 and ACC6 74. Recently, studying alloreactive responses in 
a transplanted myelodysplastic syndrome (MDS) patient led to the identification 
of 10 new MiHA among which ARHGDIB 89. 
Clear evidence for a graft-versus-leukemia (GVL) effect mediated by MiHA-
specific T cells is observed both in the myeloid leukemia’s, and in lymphoblastic 
leukemia’s 103. This has led to the identification of HB-1, from a CTL isolated from 
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a B cell acute lymphoblastic leukemia (ALL) 79 as well as to identification of PANE1 
from a CTL isolated from a B cell chronic lymphoblastic leukemia (CLL) 72.
In patients suffering from multiple myeloma (MM) a graft-versus-myeloma 
(GVM) effect can also be induced 104;105 by alloreactive donor T cells targeting 
MiHA expressed on myeloma tumor cells in the bone marrow (BM). Again, the 
GVM effect can be boosted by DLI and DC vaccination while the risk of inducing 
GVHD was limited 6;106. Several MiHA-specific T cells were isolated from trans-
planted MM patients that have led to the molecular identification of MiHA being 
ADIR77 and ECGF80 and CD19L 87.
The graft-versus-lymphoma effect has received limited attention. The existence 
of a graft-versus-lymphoma effect was first suggested by Jones et al in patients 
suffering from non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD) 107. 
This study and others show that lymphoma patients benefit from allogeneic SCT 
and possibly DLI (reviewed in108).  However, the role of MiHA-specific T cells in 
this process is less clear. To date, no MiHA have been molecularly identified and 
characterized from a lymphoma patient.
 The applicability of allogeneic SCT in solid tumors is investigated as well 109;110. 
Only a few tissue-restricted MiHA have been described which are aberrantly 
expressed on solid tumors, including HA-1, ECGF-1, BCL2A1, LRH-1, C19orf48 
and ZAPHIR 73;95;111-113.  Several studies have explored allogeneic SCT after non-
myeloablative or RIC with or without DLI as curative treatment for metastatic 
renal cell carcinoma (RCC), and objective response rates varied from 0% to 53%. 
However, substantial transplantation-related mortality and toxicity due to GVHD 
was observed 109;114-116 and currently allogeneic SCT is no longer used or explored 
as a therapeutic option for metastatic RCC patients. However, characterization 
of MiHA-specific T cells from metastatic RCC patients have led to identification 
of the MiHA C19orf48 95 and ZAPHIR 73 of which the expression is not limited to 
RCC only but can also be found on hematological malignancies such as CML. Allo-
geneic SCT has also been explored in other solid tumors such as melanoma, and 
breast, brain, and colon carcinoma.110;117-120 However, results of allogeneic SCT in 
patients with solid tumors are poor and did not lead to the implementation of 
allogeneic SCT as a standard therapy for patients with solid tumors. 
7.1  MiHA as tools in (posttransplantation) immunotherapy
We have seen that the outcome of allogeneic SCT can be influenced by genetic 
polymorphisms in signal molecules involved in immune responses or that cause 
MiHA. However, to date the detection of the first category of non-HLA polymor-
phisms has not changed the allogeneic SCT strategy, although selection of donors 
based on suitable polymorphisms might be an option in the future. MiHA on the 
other hand, are explored as tools in posttransplantation immunogenic strategies 
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which may ultimately result in improved treatment of allogeneic SCT recipients. 
Although MiHA are not deliberately mismatched when looking for a suitable SCT 
donor, several studies provide evidence that this may be beneficial for the recipi-
ent 121-123. The MiHA-specific T cell responses might prove indispensible when 
aiming at the induction of a selective GVT effect with minimal risk for GVHD by 
post-transplant immunotherapy, creating a targeted immune response. Further-
more, the MiHA-specific responses can be monitored during and after therapy to 
assess the efficacy of therapy. Using MiHA in immunotherapy implicates that the 
recipients as well as the donor should be genotyped for the allelic variant of the 
targeted MiHA to select for disparities. Moreover, HLA type determines which 
MiHA are of interest as well as the type of malignancy since MiHA expression 
levels can vary. Enlarging the panel of MiHA will expand these possibilities to 
identify suitable recipient/donor pairs for specific types of malignancies. 
7.2  Adoptive T cell transfer using MiHA-specific T cells
Several strategies to implement MiHA in post-transplantation immunotherapy 
are explored. One of these strategies is adoptive T cell transfer in which tumor 
cells are directly targeted by MiHA-specific T cells. The MiHA-specific T cells are 
ex vivo expanded and subsequently infused into the patient.  Several successful 
experiments performed in mice, showing that MiHA-specific T cells of a single 
specificity can eradicate malignant murine hematopoietic cell lines without 
inducing GVHD in spite of the ubiquitously expression pattern of the targeted 
MiHA 124. Mice studies using human tumor cell lines and human MiHA-specific 
T cells show that , adoptive T cell transfer of HY.A2-specific CTL are capable of 
efficiently targeting solid tumor cells in a three-dimensional micro tumor model 
111. The first trial using adoptive T cell transfer as post-transplantation immuno-
therapy to treat relapsed leukemia patients showed promising results. During 
this trial, using ex vivo expanded MiHA-specific CD8+ T cells, several patients 
achieved complete remission.  However, also pulmonary toxicity was observed 
which correlated with expression levels of the MiHA-encoding gene P2RX7 in 
lung tissue 125. 
The main drawback of adoptive T cell transfer therapy is the limitation to produce 
sufficient quantities of specific T cells. Therefore, opposed to the ex vivo expan-
sion of isolated MiHA-specific T cell clones a different strategy can be followed 
making use of T cells expressing a recombinant T cell receptor (TCR). HA-2-TCR 
modified T cells are cytolytic towards HA-2+ target cells which correlates with the 
number of specific TCR at the cell surface 126;127.
7.3  DC-based vaccination targeting MiHA
DC are the most potent APC of the immune system and they can activate a cyto-
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toxic response by T cells towards antigens. Therefore, DC show great potential as 
tools in immunotherapy and to improve the GVT reaction. Moreover, a directed 
immune response towards tumor restricted antigens without the induction of 
GVHD, can be achieved using DC. In case of DC vaccination as posttransplanta-
tion immunotherapy, DC can either be generated from cells isolated from the 
donor or recipient. These DC can be pulsed with MiHA-peptide or transfected 
with MiHA-encoding mRNA. Upon transfusion back into the patient the loaded 
DC present MiHA to effector lymphocytes (CD4+ T cells, CD8+ T cells, and B cells), 
initiating a cytotoxic response against MiHA+ targets. Many clinical studies using 
autologous DC loaded with melanoma-specific antigens to vaccinate melanoma 
patients have been performed (reviewed in 128). DC vaccination as posttransplan-
tation immunotherapy can be applied to boost the immune response induced by 
SCT and DLI. Either donor DC loaded with MiHA antigen can be used, or recipient 
DC that present endogenous antigens. In vivo also both of these DC types play a 
role in the immune response 129. 
Although recipient DC, still present post RIC, are responsible for initial priming of 
the T cells. donor DC may drive the expansion of the T cell compartment by cross 
presentation. Vaccinations with unloaded recipient derived DC in MM patients 
demonstrated that RIC followed by partial T cell-depleted allogeneic SCT does 
boost the GVM  6 and also MiHA-specific T cells could be observed in the BM 
of this patient 130. Next step might be to specifically load the DC with MiHA that 
are known to be expressed on the specific malignancies. Overes et al showed 
that LRH-1 encoding RNA-electroporated DC stimulated LRH-1 specific CTL to 
proliferate and to produce IFNγ 131. Ex vivo loading of autologous or allogeneic DC 
with either MiHA-encoding RNA or MiHA peptide could overcome the challenges 
that are still presented by the use of adoptive transfer of MiHA-specific T cells. 
Moreover, the DC vaccines could be manipulated prior to infusion to improve the 
overall immune response and specifically the MiHA-specific immune response.
Several approaches are being explored to improve the induced immune response 
by DC vaccines. One strategy makes use of antibodies that block immune 
response inhibitors such as programmed death-1 (PD-1) and CTL-associated anti-
gen 4 (CTLA-4). Blocking PD-1 signaling increases proliferation of MiHA-specific T 
cells as well as their IFNγ production when cocultured with PD-ligand 1 (PD-L1)+ 
leukemia cells 132. This finding suggests that applying PD-1 blocking antibodies 
in combination with DC vaccination may lead to an enhanced MiHA-specific 
immune response making it an appealing new immunotherapeutic strategy fol-
lowing allogeneic SCT in patients with recurrent or relapsed disease. A similar 
approach explored the use of CTLA-4 blocking antibodies in patients suffering 
from advanced melanoma. This study showed that the combination of melanoma 
associated antigen MART-1 peptide-pulsed DC and CTLA-4 blocking antibod-
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ies results in objective and durable tumor responses at the higher range of the 
expected response rate with either agent alone 133. These results show promise 
for the use of CTLA-4 blocking antibodies in combination with DC vaccination to 
induce enhanced MiHA-specific T cell responses in patients following allogeneic 
SCT. A drawback of the use of blocking antibodies might the development of 
serious GVHD. 
A more targeted approach was described by Hobo et al. Their studies showed 
that knockdown of PD-L1 and PD-L2 on monocyte-derived DCs by siRNA results in 
improved MiHA-specific T cell proliferation and cytokine production 134. A phase 
I clinical trial is developed to explore the safety and efficacy of this approach to 
boost MiHA-specific T cell responses post allogeneic SCT. The use of siRNA to 
knock down other inhibitory molecules on DC to augment expansion of tumor-
specific T cells is a first step to optimize DC vaccines. Further developments involve 
RNA transfection technology to increase the number of antigens presented by 
overexpressing HLA molecules. To improve the capacity to direct helper and 
effector responses, the expression of specific cytokines could be manipulated as 
well as the signals of costimulatory molecules, adhesion molecules and migra-
tory signals. Together this may improve posttransplantation immunotherapy by 
DC vaccination.
8.  Scope of this thesis
Allogeneic SCT followed by DLI is established as an effective treatment for patients 
with hematological malignancies and in the past this therapy has been explored 
as an experimental treatment for solid tumors as well. Efforts to improve this 
highly personalized form of immunotherapy focus on the genetic characteristics 
of donor and recipient to identify polymorphisms of the immune system that 
can influence the outcome of allogeneic SCT.  The general aim of this thesis is to 
improve the GVT reaction while decreasing the risk for GVHD and infectious com-
plications. In Chapter 2 we show that polymorphisms in the chemokine receptor 
CCR6 influence clinical outcome of allogeneic SCT. Our study is the first to show 
an association with the donor GG genotype of the CCR6 polymorphisms and the 
occurrence of less chronic GVHD but increased incidence for inflammatory fungal 
disease (IFD). This study adds to the knowledge of the influence of non-HLA poly-
morphisms on the immune system and may lead to changes in donor selection 
prior to allogeneic SCT. 
A different class of non-HLA polymorphisms is that by which MiHA are generated. 
In Chapter 3 the identification of the novel MiHA ZAPHIR is described. This MiHA 
was identified using a MiHA-specific T cell isolated from a metastatic RCC patient 
with partial regression of lung metastases after RIC- allogeneic SCT. GWAS was 
used in the identification process showing the potential of this technique in the 
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search for more MiHA. Interestingly, ZAPHIR represents a new target antigen for 
the development of adjuvant immunotherapy for RCC and hematological malig-
nancies after allogeneic SCT. In addition to the identification of a new MiHA, this 
chapter shows also the effort to use allogeneic SCT and DLI in patients with solid 
tumors.  
Chapter 4 shows the use of allogeneic SCT and DLI, followed by DC vaccination as 
a therapy for MM patients. We could show that DC vaccination results in boost-
ing or increased trafficking of MiHA-specific CTL to the BM of the MM patient. 
Since the therapeutic effect of allogeneic SCT and DLI is largely dependent on 
recognition of MiHA by donor-derived CD8+ T cells, monitoring of multiple MiHA-
specific CD8+ T cell responses may prove to be valuable for evaluating the efficacy 
of allogeneic SCT and posttransplantation immune therapeutic strategy. 
Chapter 5 describes the combinatorial encoding MHC multimer technique for 
the concurrent detection of MiHA-specific CD8+ T cells in peripheral blood of 
SCT recipients. This technique allows simultaneous monitoring of several MiHA-
specific T cells in a limited amount of patient material. Efficacy of the allogeneic 
SCT and other posttransplantation immune therapy can be measured quickly 
and accurately by this technique. In addition, we determined the potential value 
of combinatorial encoding MHC multimers in MiHA identification on a set of 75 
hematopoietically restricted predicted candidate MiHA.  Finally, in Chapter 6 
we studied whether disparate MiHA are associated with improved clinical out-
come. The retrospective study, described in this chapter, shows that, especially in 
patients transplanted for MM, an autosomal MiHA disparity on DNA level associ-
ates with increased relapse-free survival (RFS) in sibling transplants. This finding 
illustrates the importance of MiHA and is an important indication that patients 
could benefit from a donor mismatched for MiHA. In addition, this indicates that 
MiHA-based immunity should be further boosted by post transplant immuno-
therapy. 
In conclusion, this thesis investigates the effect of non-HLA polymorphisms on 
the clinical outcome of allogeneic SCT. A special focus lies on the class of non-HLA 
polymorphisms that generate MiHA and this thesis describes the identification, 
immunomonitoring and their role in allogeneic SCT. 
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Abstract
Graft-versus-host disease (GVHD) and fungal infections are frequent complica-
tions after allogeneic hematopoietic stem cell transplantation (HSCT). Single 
nucleotide polymorphisms (SNPs) in genes of the immune system can influence 
the inflammatory cascade and T cell-driven alloimmune reactions after HSCT, and 
thus increasing the incidence of GVHD and infectious complications. Here, we 
investigated the effect of SNPs in IL23-R and CCR6 on posttransplantation out-
come in 161 recipients of partially T cell-depleted HSCT. Remarkably, IL-23R SNPs 
were not associated with clinical outcome, but we found that disparities in the 
CCR6 tagSNP rs2301436 and SNP rs3093023 are independently associated with 
the occurrence of chronic GVHD (cCVHD) and invasive fungal disease. In multi-
variate analysis, patients receiving a transplant from a homozygous rs2301436 
G allele donor showed less cGVHD (odds ratio [OR] 0.16; P=0.002), as was the 
case for a homozygous donor rs3093023 G allele (OR: 0.24 P=0.005). In parallel, 
this GG genotype at rs2301436 in donors was associated with a higher incidence 
of invasive fungal disease at day 100 after HSCT (OR 3.59; P=0.008). This study 
shows that CCR6 SNPs can be used to predict clinical outcome, and that polymor-
phisms in the CCR6 gene may influence T cell-mediated immune reactions after 
HSCT.
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Introduction
Graft-versus-host disease (GVHD) and fungal infections remain major causes of 
morbidity and mortality in allogeneic hematopoietic stem cell transplantation 
(HSCT) 1. The pathophysiology of acute GVHD (aGVHD) is a multistep process 
involving tissue damage and cytokine release induced by pre-transplant con-
ditioning followed by alloreactive T cell expansion, trafficking and destruction 
of target tissues by effector T cells 2. The pathogenesis of cGVHD is even more 
complex and has not yet been fully defined 3;4. Recent insights have challenged 
the paradigm of GVHD being almost exclusively a Th1 mediated immune disorder 
as studies have shown a role for Th17 responses in acute as well as cGVHD. Simi-
larly new insights have emerged in the field of antifungal immunity showing a 
pronounced role of Th17 responses, including the release of cytokines IL-17 and 
IL-22, in fungal defenses complementing Th1 responses. 
The IL-23/Th17 pathway is a new player at the crossroads of innate and adap-
tive immunity 5. Th17 cells are induced by the release of IL-1β, IL-6, and TGFβ 
from APC, and further expansion is enhanced by IL-23, although controversy still 
exists because of the considerable differences seen in animal and human studies 
6. Th17 CD4+ T cells are characterized by expression of retinoid-related orphan 
receptor-γt (RORγt) and the chemokine receptors CCR4 and CCR6 7. CCR6 expres-
sion has recently been shown pivotal for Th17 migration to the gut in inflam-
matory bowel disease and the joints in rheumatoid arthritis 8. Th17 responses 
seem predominantly involved in host  barrier defenses of the skin and mucosa 9, 
enhancing the innate immunity against extracellular microorganisms, including 
fungi, through increased phagocyte recruitment and production of antimicrobial 
peptides 10. However, this pathway is also reportedly involved in the occurrence 
of different autoinflammatory and autoimmune diseases 5;11. Therefore, the 
IL-23/Th17 axis is now studied with regards to transplantation complications, 
with an emphasis on GVHD and infections, although the existence of alloreactive 
Th17 cells also suggests a possible role in graft-versus-tumor (GVT) immunity 12-14. 
However, most studies on the IL-23/Th17 axis in GVHD have been performed in 
animal models 15;16 and the role in human GVHD is still controversial . 
Currently, the strongest evidence for a role of the IL-23/Th17 pathway in human 
HSCT comes from the association between a non-synonymous IL-23 recep-
tor (IL-23R) single nucleotide polymorphism (SNP), rs11209026 (Arg381Gln) in 
transplant donors and the incidence of aGVHD 17-19. This SNP is one of the now 
many so-called non-HLA polymorphisms that have been associated with HSCT 
outcome 20. Previously, we have shown that performing partial T cell depletion of 
donor transplants did not reduce the impact of nucleotide-binding oligomeriza-
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tion domain 2 (NOD2) SNPs on GVHD and treatment-related mortality (TRM) in 
the setting of HLA-matched sibling HSCT 21. In order to investigate whether SNPs 
in genes that are more directly involved in T cell-mediated immunity, including 
those involved in the IL-23/Th17 pathway, are more influenced by the T cell 
depletion strategy, we undertook a retrospective analysis on the impact of IL-
23R polymorphisms (rs11209026 and rs11805303) in a homogenous cohort of 
Dutch patients (n=161) receiving a partially T cell-depleted HSCT. In addition, 
we studied the impact of a tagSNP for CCR6 (rs2301436) and SNP rs3093023, 
as these SNPs have been associated with the occurrence of Crohn’s disease and 
rheumatoid arthritis 22;23. 
Here, we found that the IL-23R SNPs did not associate with the occurrence of 
GVHD, but we show that CCR6 tagSNP rs2301436 and SNP rs3093023 were sig-
nificantly associated with less cGVHD. In addition, CCR6 tagSNP rs2301436 was 
also associated with a higher incidence of invasive fungal disease (IFD) following 
partially T cell-depleted HSCT. 
Patients and methods
Patients and donors
One hundred and sixty-one (n=161) Dutch patients and their donors were 
included in the study. All had been admitted to our transplant unit between 
1996 and 2009 for an HLA-matched sibling, partially T cell-depleted allogeneic 
HSCT. In order to obtain the most homogenous cohort possible, we selected 
only patients receiving myeloablative conditioning. One hundred and twenty-
four (n=124) patients had been given idarubicin in their conditioning regimen. 
The characteristics of patients, donors and SCT procedures are depicted in Table 
1. Patients and donors had given their informed consent to the prospective 
collection of data and DNA samples for investigational use, which was approved 
by the Radboud University Nijmegen Medical Centre’s Institutional Review Board.
Treatment protocol
All patients had been treated according to the same protocol that has 
been described previously 21. Briefly, the conditioning regimen consisted of 
cyclophosphamide (60 mg/kg for 2 days) in combination with either total body 
irradiation (TBI 4.5 Gy for 2 days) or busulfan (4 mg/kg for 4 days). Idarubicin (42 
mg/m2 in 48 hours) was often added in these conditioning regimens to reduce 
the risk of relapse in the setting of partially T cell-depleted HSCT 24. On day 0, all  
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Table 1. Patient, donor and transplant characteristics. 
Characteristic Study group (n=161)
Median age at transplantation, years (range) 48 (19-64)
Sex, no. male (%) 104 (65)
Sex of patient/donor pair, no. (%)
- Male/female
- Other
42 (26%)
119 (74%)
Underlying disease, no. (%)
- AML/MDS
- ALL
- CML/MPS
- NHL/CLL
88 (55%)
18 (11%)
29 (18%)
26 (16%)
Advanced disease stage, no. (%) 46 (29%)
Conditioning regimen, no. (%)
- Cy-Bus
- Cy-TBI
- Ida-Cy-Bus
- Ida-Cy-TBI
8 (5%)
29 (18%)
16 (10%)
108 (67%)
Stem cell source, no. (%)
- Bone marrow
- Peripheral blood
62 (39%)
99 (61%)
T cell depletion method, no. (%)
- Elutriation
- CD34 selection
- CD3/CD19 depletion
44 (27%)
85 (53%)
32 (20%)
aGVHD, no. (%)
- Grade 2-4
- Grade 3-4
57 (35%)
21 (13%)
cGVHD, no. (%)
- Limited
- Extensive
n = 142
16 (10%)
25 (16%)
Invasive fungal disease day 100, no (%)
- Candidaemia
- Invasive mold disease*
- Probable/proven
16 (10%)
12 (7.5%)
8 (5%)
*EORTC/MSG consensus 25. 
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Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; 
ALL, acute lymphatic leukemia; CML, chronic myeloid leukemia; MPS, 
myeloproliferative syndrome; NHL, non-Hodgkin lymphoma; CLL, chronic 
lymphatic leukemia; Cy, Cyclophosphamide; Bus, busulfan; Ida, idarubicin; TBI, 
total body irradiation; GVHD, graft-versus-host disease
patients were given a stem cell graft containing a median of 3.4 x 106 CD34+ cells/
kg (range 0.8-11.6; bone marrow or peripheral blood stem cells) and a median 
of 0.5 x 106 CD3+ T cells/kg (range 0.3-0.8) achieved by dosed T cell ad back. 
GVHD prophylaxis consisted of cyclosporine A (CsA) only. Anti-microbial prophy-
laxis consisted of 500 mg ciprofloxacin given twice daily and 500 mg valaciclovir 
given three times daily. Fluconazole was only given at a dose 200 mg/d orally to 
patients who were considered colonized by Candida albicans. No mold-active 
prophylaxis was given. 
Definition of outcome variables
aGVHD was graded according to the criteria by Przepiorka et al. 26 and cGVHD 
were classified according to the revised Seattle criteria of Lee et al. 4. IFD were 
scored according to the EORTC/MSG consensus guidelines, but only probable and 
proven cases were included in the analysis 25. Blood cultures were considered 
positive if a microorganism was recovered from one or more bottles, with the 
exception of coagulase-negative staphylococci, for which two separate positive 
blood cultures with the same strain were required 27. Early gram-positive bacte-
raemia was defined as bacteraemia with streptococci or staphylococci occurring 
between the start of conditioning until engraftment. TRM, disease-free survival 
(DFS), and overall survival (OS) were defined according to standard criteria. 
SNP genotyping using the KASPar system
Genotyping was performed for SNPs rs11209026 (Arg381Gln) and rs11805303, 
which are polymorphisms in the IL-23R gene and in linkage disequilibrium with 
each other 28. In addition, a tagSNP for CCR6, rs2301436, was genotyped. This 
SNP is located in the FGFR1OP gene, adjacent to CCR6, and has been associated 
with Crohn’s disease 23. SNP rs3093023 is located within the CCR6 gene and has 
been associated with rheumatoid arthritis 22.The HLA-matched HSCT donor-recip-
ient pairs were genotyped by specific KASPar assays (KBioscience, Hoddesdon, 
United Kingdom), which are fluorescence-based competitive allele-specific PCR 
using non-labeled primers. Details of the method used can be found at http://
www.kbioscience.co.uk. Primer sequences are listed in Table 2.
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Statistical analysis
Association between polymorphisms in recipient and donor at the one hand 
and occurrence of aGVHD, cGVHD, relapse, and IFD before day 100 after HSCT 
at the other hand were tested using the chi-square test and Fisher exact test 
if appropriate and univariate logistic regression analysis. To control for possible 
confounders as, for example, aGVHD and gender combination we used multivari-
ate logistic regression analyses.
Treatment related mortality, overall survival and time occurrence of IFD were 
analyzed using Kaplan Meier curves and the logrank test. All statistical analyses 
were performed using the cmprsk package of open source language R version 
2.6.2 (www.r-project.org, R Foundation, Vienna, Austria). A P value <0.05 was 
considered to indicate statistical significance.
Table 2. Primer sequences for KASPar genotyping assays.
SNP Gene Allele Forward primer 
(5’ to 3’)
Reversed primer 
(5’ to 3’)
rs11209026 IL-23R
a
gaaggtgaccaagttcatg
ctttgattgggatattaaca
gatcattcc
gtctaaatcagaaaacaga
aattctgcaaa
g
gaaggtcggagtcaacgg
attgggatatttaacagat
cattccg
rs11805303 IL-23R
c
gaaggtgaccaagttcatg
cttgcaaacagagaactgt
ttcctc
gtcggagctttgtctatttag
caactaat
t
gaaggtcggagtcaacgg
attgcttgcaaacagagaa
actgtttcctt
rs2301436
 tagSNP 
CCR6
t
gaaggtgaccaagttcatg
ctctgggtaatggaaaagg
gcttct
tctgtttgatataaactaaat
tgacctctt
c
gaaggtcggagtcaacgga
ttctgggtaatggaaaagg
gcttcc
rs3093023 CCR6
a
tattgaaacttcctcaaattt
aaaatcacat
tttatgcacctcacagtgtct
atgcaaat
g
attgaaacttcctcaaattt
aaaatcacac
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Results
SNP genotype frequencies 
The genotype frequency for both patient and donor of the polymorphisms 
rs11209026, rs11805303, rs2301436 and SNP rs3093023 are presented in Table 
3. For the IL-23R SNP rs11209026 (i.e. Arg381Gln) there was virtually no dif-
ference observed between the GA or GG genotype frequency between donors 
and patients. A homogenous AA gene variant for rs11209026 was not observed 
for any of the donors or patients. Genotype frequencies for the IL-23R SNP 
rs11805303 as well as for the CCR6 tagSNP rs2301436 showed equal distribution 
among donors and patients. 
Table 3. SNP genotype frequencies in patients and donor.
Variable Number evaluable n (%)
Patient Donor Patient Donor
rs11209026 (IL-23R)
GG
GA
160 158 140 (87.5%)
20 (12.5%)
140 (88.5%)
18 (11.5%)
rs11805303 (IL-23R)
CC
CT
TT
160 159
79 (49.5%)
59 (37%)
22 (13.5%)
79 (50%)
63 (39.5%)
17 (10.5%)
rs2301436 (tagSNP CCR6) 
AA
AG
GG
159 156
32 (20%)
79 (50%)
48 (30%)
29 (18.5%)
81 (52%)
46 (29.5%)
rs3093023 (CCR6) 
AA
AG
GG
153 153
24 (16%)
72 (47%)
57 (37%)
30 (20%)
68 (44%)
55 (36%)
SNPs in IL-23R and CCR6 are not associated with the incidence of 
aGVHD 
The cumulative incidence of aGVHD grade 2-4 was 35% (57/161), with grade 
3-4 occurring in 13% (21/161) (Table 1). Both polymorphisms in the IL-23R 
gene, rs11209026 and rs11805303, as well as the CCR6 SNPs rs2301436 and 
rs3093023, were not associated with the incidence of aGVHD (data not shown). 
Importantly, in contrast to previous studies 17, patients who received a transplant 
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from a donor with a GA genotype at the IL-23R SNP rs11209026 (Arg381Gln) did 
not experience less aGVHD.  
Association between the CCR6 polymorphisms and cGVHD
Of the 142 patients at risk for cGVHD, 10% developed limited and 26% extensive 
cGVHD (Table 1). In univariate analysis, the donor genotype of the CCR6 tag-
SNP rs2301436 and SNP rs3093023 were was significantly associated with the 
occurrence of cGVHD (Table 4). The other significant variable included previous 
aGVHD. For tagSNP rs2301436 the cumulative incidence of cGVHD was 10% for 
the GG genotype versus 38% and 33% for the AG and AA genotype, respectively 
(P=0.004) (Figure 1A and Table 4). In addition, the recipient genotype at tagSNP 
rs2301436 was also associated with cGVHD in univariate analysis, with an inci-
dence of 39% for the heterozygous AG genotype versus 17% and 20% for the 
Figure 1. Influence of genotype of rs2301436 on the incidence 
of cGVHD. 
(A) Recipients receiving a stem cell graft from a homozygous donor for 
rs2301436 (i.e. genotyped as GG), showed a significant lower incidence of 
cGVHD (P =0.004, univariate analysis; P =0.002, multivariate analysis). (B) 
Recipients genotyped as AG showed a higher incidence of cGVHD (P =0.007, 
univariate analysis; P =0.06, multivariate analysis). (C) Recipients receiving 
a stem cell graft from a homozygous donor for rs3093023 (i.e. genotyped 
as GG), showed a significant lower incidence of cGVHD (P =0.01, univariate 
analysis; P =0.005, multivariate analysis). (D) Recipients genotyped as AG 
showed a higher incidence of cGVHD (P =0.006, univariate analysis; P =0.01, 
multivariate analysis).
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Table 4. Influence of clinical factors on cGVHD, relapse, IFD at day 100: univariate 
and multivariate analysis. 
Outcome 
parameter
Variable Univeriate Multiveriate
cGVHD
Donor 
rs2301436 
GG vs. AA/AG
0.19 
(0.06-0.58)
0.004
 
0.16 
(0.05-0.51)
0.002
Recipient 
rs2301436 
AG vs. AA/GG 
2,86 
(1.32-6.16)
0.007 2.23 
(0.97-5.42)
0.06
Donor 
rs3093023 
GG vs. AA/AG
0.31 
(2.12-0.76)
0.02 0.24 
(0.09-0.65)
0.005
Recipient 
rs3093023 
AG vs. AA/GG
2.92 
(1.37-6.49)
0.02 3.02
(0.09-0.65)
0.01
aGVHD 4.5 
(2.07-9.77)
0.0001 4.69 
(2.00-10.95)
0.0004
Gender com-
bination
1.58 
(0.70-3.52)
0.27 1.54 
(0.60-3.93)
0.37
Relapse
Recipient 
rs2301436 AA 
vs. AG/GG
2.21 
(1.00-4.88)
0.05 1.88 
(0.74-4.76)
0.18
cGVHD 0.38 
(0.16-0.87)
0.02 0.26 
(0.10-0.68)
0.006
Prophylactic 
DLI
0.64 
(0.30-1.35)
0.24 0.34 
(0.14-0.86)
0.02
Diagnosis 
(CML vs. 
other)
4.97 
(2.5-12.07)
0.0004 4.86 
(1.73-13.62)
0.003
Conditioning 
Ida vs. Non-
Ida
0.49 
(0.24-1.04)
0.06 0.49 
(0.20-1.23)
0.13
IFD at day 
100
Donor 
rs2301436 
GG vs. AA/AG
2.60 
(1.10-6.13)
0.03 3.59 (1.41-
11.25)
0.008
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IFD at day 
100
Donor 
rs3093023 
GG vs. AA/AG
2.18 
(0.88-5.40)
0.09 2.15 
(0.89-5.36)
0.01
aGVHD 2.08 
(0.86-5.01)
0.10 2.41 
(0.89-6.53
0.08
Conditioning 
Ida vs. Non-
Ida
3.17 
(0.90-11.24)
0.07 3.32 
(0.86-12.78)
0.08
Dectin-1  
Y238X recipi-
ent vs. wt
0.76 
(0.16-3.70)
0.73 0.46 
(0.08-2.64)
0.38
Abbreviations: IFD, Invasive fungal disease;CML, chronic myeloid leukemia; Ida, 
idarubicin
homozygous AA and GG genotypes, respectively  (P =0.007) (Figure 1A and Table
4). For SNP rs3093023 the cumulative incidence of cGVHD was 15% for the GG 
genotype versus 39% and 32% for the AG and AA genotype, respectively (P=0.02) 
(Table 4). Also the recipient genotype at SNP rs3093023 was associated with 
cGVHD in univariate analysis, with an incidence of 41% for the heterozygous AG 
genotype versus 19% for both the homozygous AA and GG genotypes, respec-
tively (P =0.02) (Figure 1B and Table 4). Although we have found in both SNPs 
an association between the heterozygous genotype AG in recipients and cGVHD, 
these association did not seem very plausible given that comparison of the A 
allele versus G allele frequencies revealed no risk allele. No significant associa-
tions were found between the IL-23R SNPs rs11209026 and rs11805303 with the 
incidence of cGVHD (data not shown). In multivariate analysis, besides aGVHD, 
the donor genotype at rs2301436 and rs3093023 remained significantly asso-
ciated with the incidence of cGVHD. Interestingly, the GG genotype versus AA 
and AG genotypes in donors showed a protective effect with an OR of 0.16 (95% 
CI: 0.05-0.51, P =0.002) for rs2301436 as was also observed for rs3093023 (OR 
of 0.24; 95% Cl: 0.09-0.65, P = 0.005) (Table 4). In contrast, the influence of fe-
male to male SCT proved not to be significant in multivariate analysis (P=0.37). 
These data indicate that the GG donor genotype at tagSNP rs2301436 and SNP 
rs3093023 in the CCR6 region is protective for cGVHD.
TRM, relapse and OS were not significantly influenced by the poly-
morphisms studied
The median follow-up was 68 months (range 8-157 months) for surviving patients 
and 8 months (range 0-90 months) for the patients who died. Relapse includes 
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molecular, genetic, and haematological relapse, occurring in 54 out of 154 evalu-
able patients (35%). Known risk factors for relapse were significant in our mul-
tivariate analysis, with the diagnosis of CML, absence of cGVHD, and not having 
received prophylactic DLI increasing the risk of relapse (Table 4). Recipient geno-
type at CCR6 tagSNP rs2301436 was associated with the incidence of relapse; AA 
50%, AG 27%, and GG 38% (P =0.05 for AA versus AG/GG) (Table 4). However, 
in multivariate analysis this proved no longer significant. No effect effects were 
observed for any of the other tested SNPs.
Relapse free survival and overall survival at 5 years were 37.5% and 55%, respec-
tively, and 1-year treatment related mortality was 21%. None of the investigated 
SNP showed any association with these outcome parameters. 
Donor GG genotype at rs2301436 influences the occurrence of IFD
The incidence of candidemia and invasive mold infections at 100 days was 10% 
and 7.5%, respectively (Table 1). The GG genotype at rs2301436 in donors was 
associated with a higher incidence of IFD (32%) opposed to AA (12%) and AG 
(16%) (P =0.03 GG vs. AA/AG, Table 4 and Figure 2). In multivariate analysis donor 
rs2301436 genotype was the only significant risk factor, although the presence 
of aGVHD and conditioning regimen containing idarubicin both showed a trend 
towards more IFD (Table 4). Donor rs3093024 GG genotype was accompanied 
by an increased, but not significant, incidence of IFD (24% vs. 15% (AA) and 12% 
(AG), P =0.22). In a previous study, we determined the gene status of the Dectin-1 
polymorphism Y238X, for which it is known that it influences candida colonisa-
tion and possibly invasive aspergillosis in SCT recipients 29-31.  However,  no  asso-
 Figure 2 Cumulative incidence of IFD at day 100.
Donor GG genotype at CCR6 tagSNP rs2301436 was associated with a higher 
incidence of IFD (dashed line) opposed to AA and AG (black line) (P =0.03, 
log-rank test).  
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ciation was found between the Dectin-1 genotype and IFD at day 100. These 
data suggest that the GG genotype at CCR6 tagSNP rs2301436 influences post 
transplant immunity against fungal infections. Also the influence on the impact 
of Gram-positive bacteremia was examined for all 4 tested SNPs, but no associa-
tions were found. Data on CMV and EBV reactivation were incomplete and insuf-
ficient to perform proper statistical analysis, although EBV reactivation seemed 
not influenced by any of the SNPs.
Discussion
The role of polymorphisms in non-HLA genes in the outcome of allogeneic SCT 
is a subject that has received much attention in the last few years. In particular 
focus here lies on SNP located in genes involved in the immune system. How-
ever, with few exceptions, a general problem with genetic association studies has 
been that documented associations are very much context dependent and as a 
result often difficult to confirm and reproduce. This also seems to apply to the 
rs11209026 IL-23R polymorphism, as a large study failed to confirm an impact 
on GVHD in the particular setting of SCT from unrelated donors 32. Also in our 
current study, we were not able to reproduce the repeatedly described protec-
tion against aGVHD of the donor GA genotype at the SNP rs11209026 17-19. This 
GA genotype, resulting in Arg381Gln, is believed to perturb the IL-23 receptor 
function reducing allo-reactive T cell responses that mediate aGVHD. We believe 
that the reason we could not confirm this genetic association is mainly due to 
the practice of ex vivo T cell depletion in all of our transplants, this opposed to 
Elmaagacli et al. who did not perform any T cell depletion 17. The allele frequency 
was however comparable between the two cohorts (A allele frequency ≈ 6%), 
but the incidence of GVHD was lower in our study, which is directly related to 
the use of T cell depleted stem cell grafts. T cell depletion most likely results in 
a delayed T cell recovery which might influence the pathogenesis of aGVHD. By 
altering the kinetics and reducing the impact of T cell function, the influence of 
genetic variations such as those in the IL-23/Th17 pathway may be changed as 
well. Context dependency is a recurring theme in studies on genetic associations 
and discrepancies are often found, emphasizing that one should be cautious gen-
eralizing results from previous association studies.
Studying a second gene prominent in the IL-23/Th17 pathway, the chemokine 
receptor CCR6, we found significant associations between donor genotype at 
rs2301436 and rs3093023 and the occurrence of cGVHD. In case of rs2301436, 
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the incidence of IFD was significantly increased, as for rs3093024 only a trend 
towards a higher incidence was seen. The GG genotype of rs2301436 was pro-
tective for cGVHD, but conferred a high risk for developing IFD. SNP rs2301436 
is regarded as a tagSNP for the CCR6 gene, but the SNP itself lies within the 
FGFR10P gene 22. Functional consequences of the SNP itself, nor that of the CRR6 
phenotype corresponding with the tagSNP, are yet completely known. However, 
recently the A allele of rs2301436 has been shown to associate with a modestly 
higher risk for both Crohn’s disease and rheumatoid arthritis, with a protective 
effect attributed to the G allele 23. Kochi et al. show that two different polymor-
phisms, both located within the CCR6 gene and in linkage disequilibrium with 
tagSNP rs2301436, regulate the expression of CCR6 22. We have tested the impact 
of one of these polymorphisms, SNP rs3093023, on the clinical outcome post 
allogeneic SCT and also observed a protective effect of the G allele. Although 
for these specific CCR6 associated polymorphisms no direct functional conse-
quences are known, of other polymorphisms in strong linkage disequilibrium 
with rs3093023, functional studies have been performed. These studies show 
that a triallelic dinucleotide polymorphism correlated with CCR6 expression lev-
els as well as with the presence of IL-17 in rheumatoid arthritis patients 22.  In the 
absence of data on any functional consequences due to the genotype of tagSNP 
rs2301436 or SNP rs3093023 regarding CCR6, we propose two general hypoth-
eses which are not mutually exclusive. 
One hypothesis could be that the genotype GG at CCR6 SNPs rs2301436 and 
rs3093023 might represent the normal CCR6 variant opposed to what might be 
the dysfunctional A allele. Kochi et al. describe that, in activated cells, the expres-
sion levels of CCR6 increase with the number of alleles (T) 22.  Normal levels of 
CCR6 result in normal functioning APC and therewith contribute to intact muco-
sal immune homeostasis 33. Since distorted immune homeostasis predisposes 
to GVHD 34, the GG genotype could diminish the risk to excessive inflammation. 
In addition, normal CCR6-mediated Th17 homing might result in impaired Th1 
responses, with decreased allo-reactivity and tissue damage protecting subjects 
from GVHD 8, and decreased Th1-mediated antifungal defenses with subse-
quently more infections 35;36. This hypothesis relies on the other hand strongly on 
the assumption that Th1 cells are more important for the onset of cGVHD than 
Th17 cells would be. 
An alternative hypothesis could be that genotype GG at the CCR6 SNPs might 
correspond to low levels of the CCR6 protein, impairing homing of APC and Th17 
cells to GVHD target tissues and infection sites, as well as to T cell priming sites 37. 
Reduced APC function results in reduced allo-reactive T cell responses and GVHD, 
but on the other hand an increased risk of fungal infections due to less effective 
phagocyte recruitment 38.
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Alternatively, reduced Th17 homing might reduce GVHD as also in humans a role 
for Th17 has been suggested 39. Additionally, impaired Th17 responses might per-
turb host antifungal defenses, increasing the risk for IFD 40. This hypothesis relies 
however strongly on the assumption of an important, but not yet confirmed, role 
for Th17 in human SCT, cGVHD and IFD. 
Our study is the first to show an association with the donor-genotype of the 
CCR6 tagSNP rs2301436 and the occurrence of cGVHD and IFD as well as an asso-
ciation with the donor-genotype of the CCR6 SNP rs3093023 and we think that 
these findings provide new clues for further research. We conclude that patients 
undergoing allogeneic SCT might benefit from typing for this particular SNPs 
when looking for a suitable stem cell donor, though further research on CCR6 
gene variation is necessary.
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Abstract
Nonmyeloablative allogeneic stem cell transplantation (SCT) can induce remis-
sion in patients with renal cell carcinoma (RCC), but this graft-versus-tumor 
(GVT) effect is often accompanied by graft-versus-host disease (GVHD). Here, 
we evaluated minor histocompatibility antigen (MiHA)-specific T cell responses 
in two patients with metastatic RCC who were treated with reduced-intensity 
conditioning SCT followed by donor lymphocyte infusion (DLI). One patient had 
stable disease and emergence of SMCY.A2-specific CD8+  T cells was observed 
after DLI with the potential of targeting SMCY-expressing RCC tumor cells. The 
second patient experienced partial regression of lung metastases from whom we 
isolated a MiHA-specific CTL clone with the capability of targeting RCC cell lines. 
Whole genome association scanning revealed that this CTL recognizes a novel 
HLA-B7-restricted MiHA, designated ZAPHIR, resulting from a polymorphism in 
the splice donor site of the ZNF419 gene. Tetramer analysis showed that emer-
gence of ZAPHIR-specific CD8+ T cells in peripheral blood occurred in the absence 
of GVHD. Furthermore, the expression of ZAPHIR in solid tumor cell lines indi-
cates the involvement of ZAPHIR-specific CD8+ T cell responses in selective GVT 
immunity. These findings illustrate that the ZNF419-encoded MiHA ZAPHIR is an 
attractive target for specific immunotherapy after allogeneic SCT. 
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Introduction
Allogeneic stem cell transplantation (SCT) has become the treatment of choice 
for patients with various hematological malignancies and some studies have also 
shown that metastatic renal cell carcinoma (RCC) does respond to this therapy 1. 
Several studies have explored allogeneic SCT after nonmyeloablative or reduced 
intensity conditioning (RIC) with or without donor lymphocyte infusions (DLI) 
as curative treatment for metastatic RCC, and objective response rates varied 
from 0% to 53% 1-6. However, substantial transplantation-related mortality and 
toxicity due to graft-versus-host-disease (GVHD) has been observed. Therefore, 
further development of allogeneic SCT for solid tumors demands a more spe-
cific approach to selectively boost graft-versus-tumor (GVT) reactivity without 
enhancement of GVHD.
Minor histocompatibility antigens (MiHA) are the target antigens of the GVT 
response, and expansion of MiHA-specific cytotoxic T lymphocytes (CTL) usu-
ally precedes clinical remission of the malignancy in patients treated with DLI 
7-9. However, alloreactive CTL responses induced upon DLI generally lack tumor 
specificity and are often accompanied by GVHD. Therefore, it would be highly 
beneficial to direct T cell immunity towards MiHA that are selectively expressed 
on malignant cells. Only a few tissue-restricted MiHA have been described that 
are aberrantly expressed on solid tumors, including HA-1, ECGF-1, BCL2A1, 
LRH-1 and C19orf48 10-14. In addition to a MiHA, an immunogenic antigen has 
been described expressed on metastatic RCC, HERV-E which is derived from a 
human endogenous retrovirus 15. However, further characterization of the target 
antigens of alloreactive T cells on RCC tumor cells is of great importance for the 
development of specific post-transplant immunotherapy for metastatic RCC.
Here, we characterized MiHA-specific T cell responses in two patients with meta-
static RCC treated with partial T cell-depleted RIC-SCT followed by DLI. Presence 
of MiHA-specific CTL targeting RCC tumor cells in vitro could be demonstrated 
in both patients who experienced partial regression or stable disease follow-
ing RIC-SCT and DLI without clinical evidence of GVHD. In one patient the T cell 
response was directed against the HLA-A2-restricted SCMY peptide FIDSYICQV, 
and in the other patient a MiHA-specific CTL clone emerged with the capability of 
targeting RCC cell lines. We found that this CTL recognizes an HLA-B7-restricted 
MiHA resulting from a polymorphism in the splice donor site within the ZNF419 
gene. This novel MiHA, designated ZNF419 alternatively spliced polymorphic his-
tocompatibility antigen in RCC (ZAPHIR), is co-expressed by RCC and transformed 
B cells, but is not presented by non-hematopoietic fibroblasts. Furthermore, 
ZAPHIR-specific CD8+ T cells were detectable in peripheral blood post-transplant 
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using tetramer analysis. These findings exemplify that ZAPHIR represents a new 
target antigen for the development of adjuvant immunotherapy for RCC and 
hematological malignancies after allogeneic SCT. 
Materials and Methods
Patient eligibility
From December 2002 till August 2003, four consecutive patients with metastatic 
RCC have been treated in our transplantation program. The eligibility criteria for 
patients included histological proven, clinically progressive metastatic RCC, fail-
ure on earlier cytokine based systemic therapy and no other curative treatment 
available. This study was approved by the institutional review board of RUNMC, 
and all patients gave written informed consent. 
Conditioning regimen, GVHD prophylaxis and DLI
Patients received partial T cell-depleted RIC-SCT. The conditioning regimen con-
sisted of total lymph node irradiation on each of three consecutive days followed 
by cyclophosphamide 50 mg/kg body weight intravenously on each of four con-
secutive days (total dose 200 mg/kg bodyweight). Inguinal and femoral lymph 
node regions were also irradiated. A total dose of 12 Gy was delivered in 2 Gy 
fractions, twice daily, on three consecutive days. 
Donors were HLA-identical siblings. Following T cell depletion, CD3+ T cells were 
added back to generate a stem cell graft containing a fixed number of 0.5 x 106 
T cells/kg body weight of recipient. All patients received CsA 3 mg/kg/day by 
continuous intravenous infusion from days -1 to +14. Thereafter CsA dose was 
reduced to 2 mg/kg/day and continued until day 21, when CsA was tapered off 
for 8-10 weeks. 
Patients underwent CT-scan of abdomen and chest before, and every 3 months 
after RIC-SCT to assess disease response. Patients without acute GVHD grade 
>II, without chronic GVHD and with persistent disease received DLI four weeks 
after discontinuation of immunosuppression. If no GVHD occurred and residual 
disease persisted, a second DLI was administered two months later. The first DLI 
dose consisted of 0.1 x108 T cells/kg bodyweight of the recipient, and the second 
DLI dose was 0.7 x 108 T cells/kg.
Cell isolation and culture 
CD8+ CTL lines H and B were isolated from PBMC obtained one and three months 
after DLI-1, respectively, by weekly stimulation with PBMC obtained before 
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SCT in Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen, Carlsbad, CA) 
supplemented with 10% human serum (HS; Sanquin blood bank, Nijmegen, the 
Netherlands). After initial stimulation, CTL line H, CTL line B, the HLA-B7 alloreac-
tive CTL Kor18 and the HLA-A2 alloreactive CTL 1E2 (0.5*106) were cultured in 
IMDM/10% HS containing irradiated (80 Gy) recipient EBV-LCL (0.5*106), irradi-
ated (60 Gy) allogeneic PBMC (0.5*106) from two donors, 100 IU/ml IL-2 (Chiron, 
Emeryville, CA) and 1 μg/ml PHA-M (Boehringer, Alkmaar, the Netherlands). All 
cell lines and primary cells were cultured in IMDM/10% fetal calf serum (FCS; 
Integro, Zaandam, The Netherlands). 
Fibroblasts were cultured from BM aspirates obtained from healthy stem cell 
donors. BM was resuspended in 20 ml IMDM/20% FCS and incubated overnight 
at 37C in tissue culture flasks. The non-adherent fraction was removed and fibro-
blasts were further cultured in IMDM/20% FCS to passage 3 before analysis. T 
cell blasts were generated by stimulating PBMC in IMDM/10% HS with 20 µg/
ml PHA-M for 3 days. Thereafter, PHA-activated T cells were washed and further 
cultured with 100 IU/ml IL-2 for 2 additional days.
IFNγ secretion assay 
IFNγ producing CTLs were detected and isolated using the IFNγ secretion assay 
(Miltenyi Biotec). Briefly, 1x106 CTLs were incubated with 1x106 irradiated (30 Gy) 
recipient EBV-LCL in a total volume of 2 ml IMDM/10% HS. After 16 hours of incu-
bation at 37°C, cells were harvested, washed with PBS/0.5% FCS and 5 mM EDTA, 
and labeled at a concentration of 108 cells/ml with 50 μg/ml Ab-Ab conjugates 
directed against CD45 and IFNγ for 10 minutes on ice. 
Subsequently, cells were diluted with IMDM/10% FCS at 1x105 cells/ml and 
allowed to secrete IFNγ for 45 minutes at 37°C. After the cytokine-capturing 
period, cells were collected, resuspended at a concentration of 108 cells/ml in 
PBS/0.5% FCS/5 mM EDTA, and stained with 5 μg/ml PE–conjugated anti-IFNγ 
mAb and FITC-conjugated CD8 mAb for 20 minutes at 4°C. Finally, cells were ana-
lyzed and sorted using an Epics Elite flow cytometer (Beckman Coulter).
Flow cytometry
PE- and APC-labeled SMCY.A2 tetramers containing peptide FIDSYICQV and 
ZAPHIR.B7 tetramers containing peptide IPRDSWWVE were produced as 
described previously 16. PE-labeled tetramer for the HLA-A2-restricted EBV pep-
tide GLCTLVAML were purchased from Beckman Coulter. PBMC or CTL lines were 
incubated with 20 μg/ml tetramer for 15 min at room temperature. After wash-
ing with PBS/0.5% bovine serum albumin (BSA; Sigma,St Louis, MO, USA), cells 
were labeled with AlexaFluor700-conjugated anti-CD8 (Invitrogen) in combina-
tion with FITC-conjugated CD4, CD14, CD16 and CD19 (Beckman Coulter) for 30 
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min at 4°C. 
Finally, cells were washed and resuspended in PBS/0.5% BSA containing 0.2 μM 
Sytox Blue (Invitrogen) marking dead cells and analyzed using the Cyan flow 
cytometer (Beckman Coulter). Tetramer staining using both APC and PE showed 
double positive events, allowing optimal discrimination between background 
staining and positive cells. All FITC-positive cells were gated into a dump channel 
and played no role in further analysis. 
Retroviral transduction of HLA-B*0702 in cell lines and CTL stimula-
tion assay
LZRS-HLA-B*0702-IRES-EGFP vector was used to generate a stable producer cell 
line. Retroviral transduction was performed using non-tissue culture-treated 
35-mm2 dishes (Becton Dickinson) coated with 10 μg/ml retronectin (Takara Bio-
medicals, Shiga, Japan). In brief, 106 target cells were resuspended in 2 ml virus 
supernatant and transferred to retronectin-coated dishes. After 24 h of incuba-
tion, cells were collected and incubated with fresh virus supernatant and used 
in CTL stimulation assays 17. Release of IFNγ was determined by ELISA (Pierce 
Endogen, Rockford, IL). 
Flow cytometry-based cytotoxicity studies
Flow cytometry-based cytotoxicity assays were performed as previously 
described 18. HLA-B7+ cell lines were labeled with 2.5 μM carboxyfluorescein 
diacetate succimidyl ester (CFSE; Molecular Probes Europe). Target cells (1 × 104) 
were co-cultured with unlabelled effector cells (3 × 104) at an E:T ratio of 3:1 in 
a total volume of 200 μl IMDM/10% FCS containing 25 U/ml IL-2 in 96-wells flat-
bottom plates. After 1-3 days of co-culture, cells were harvested and 7-amino-
actinomycin D (7AAD; Sigma-Aldrich, St Louis, MO) was added. Numbers of viable 
target cells were quantified by flow cytometry.
Whole Genome Association scanning (WGAS)
A panel of 87 HLA-B*0702 expressing EBV-LCL was selected to perform WGAs. 
To test recognition of the EBV-LCL panel by the T cell clone, triplicate samples 
of 6x104 EBV-LCL were thawed, washed and cultured for 2 days, and 5x103 MiHA 
specific T cells were added to each well. After 24 hours, culture supernatant was 
used for IFNγ ELISA. Of each EBV-LCL, PCR-free whole genome amplification was 
performed and analyzed by Illumina Human1M-duo arrays containing probes for 
1.1 million SNPs (Illumina, San Diego, CA) 19. EBV-LCL panel was divided into MiHA-
pos and MiHAneg groups using 5 times the level of IFNγ production in the absence 
of EBV-LCL as a threshold for recognition. WGAs was performed by combining T 
cell recognition with SNP-genotyping data. The level of matching between both 
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patterns was calculated according to Fisher’s exact test.
Genotyping using KASPar system
Genotyping of the HLA-B7-matched SCT donor-recipient pairs was conducted by 
KASPar (KBioscience, Herts, UK), a fluorescence-based competitive allele spe-
cific PCR which utilizes non-labeled primers. Details of the process and primer 
sequence of SNP rs2074071 can be obtained from KBioscience.
Microarray gene expression analysis
Total RNA was isolated from various (malignant) hematopoietic and non-
hematopoietic cell samples using small and micro scale RNAqueous isolation 
kits (Ambion, Inc., Austin, TX). Malignant hematopoietic cell samples included 
CML, AML and ALL cells isolated by flow cytometry based on expression of CD34, 
CD33, and CD19/CD34, respectively. Non-malignant hematopoietic cells included 
total PBMC, and B-cells, T-cells and monocytes isolated from total PBMC by flow 
cytometry based on expression of CD19, CD3 and CD14, respectively. In addition, 
hematopoietic stem cells were isolated from G-CSF-mobilized peripheral blood 
by flow cytometry based on expression of CD34. Non-hematopoietic cell sam-
ples included cultured skin-derived fibroblasts, keratinocytes and PTEC (kindly 
provided by Dr. C. van Kooten, Leiden, Netherlands). Finally, total RNA was iso-
lated from EBV-B cells, PHA-T blasts and RCC cell lines. (kindly provided by Dr. 
E.M.E. Verdegaal, Leiden, Netherlands). 
RNA samples were amplified for microarray gene expression analysis using the 
Illumina TotalPrep RNA amplification kit (Ambion). Briefly, total RNA was treated 
with DNase I using the TURBO DNA-free kit (Ambion), and converted to cDNA 
by reverse transcription. After purification of cDNA, cRNA was synthesized by in 
vitro transcription. cRNA samples were prepared following the whole-genome 
gene expression direct hybridization assay (Illumina, Inc., San Diego, CA), and 
resuspended cRNA samples were dispensed onto Human HT-12 v3 Expression 
BeadChips (Illumina). Hybridization was performed in the Illumina hybridization 
oven for 17 hours at 58°C. Microarray gene expression data were analyzed using 
Rosetta Resolver 7.2 gene expression data analysis system.
Construction of full-length and truncated ZNF419 constructs.
The full-length ZNF419 transcript in pCMV6-XL was obtained by Origene, Rock-
ville, MD (sc 316397). The different splice variants of the ZNF419 transcript con-
taining exon 1 to 5 and the exon 4/intron 4 boundary were generated by RT-PCR of 
the MiHA+ recipient and MiHA- donor EBV-LCL. The following primers were used 
to amplify ZNF419 transcript variants: ZNF419-F 5’-AAAGGTACCTCTACTCACAG-
GCTCCGATGG-3’ and ZNF419-R 5’-AAACCTAGGGAGGTTGAAACGCTGGCTAAAG-3’. 
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These primers contained BamHI and KPNI digestion sites. PCR products were puri-
fied from 1.5% agarose gel using the Qiagen gel extraction kit, and cloned into 
vector pcDNA3.1(+) (Invitrogen) using the BamHI and KPNI digestions. Constructs 
were verified by sequencing, and used for transfection into 293T-HLA-B*0702/
ICAM/CD80 cells. In brief, 3*104 293T-HLA-B*0702/ICAM/CD80 cells were plated 
into poly-D-lysine coated 96-wells flat bottom wells (Becton Dickinson, Franklin 
Lakes, NY), cultured overnight at 37°C, and then transfected with 200 ng plasmid 
DNA using lipofectamin reagent (Invitrogen). Transfected cells were cultured for 
2 additional days and used in CTL stimulation assays.
Epitope prediction and epitope reconstitution assay. 
HLA-B7 binding peptides were predicted using the NetMHC 3.2 server (http://
www.cbs.dtu.dk/services/NetMHC/). Peptides were synthesized by Proimmune 
and dissolved in DMSO. Peptide stock solutions were diluted in IMDM to a con-
centration of 1 mM. In peptide recognition assays, target cells were preincubated 
with peptide for 1 hour in a volume of 1 ml prior to the addition of CTL.
Results
Assessing for alloreactive MiHA-specific CD8+ CTL after transplanta-
tion of metastatic RCC patients
Four patients with progressive metastatic RCC after treatment with at least one 
line of therapy were treated with RIC-SCT from an HLA identical sibling donor 
(Table 1). These patients had undergone tumor nefrectomy at a median of 4.9 
years (range 2.8-11.1 years) before transplantation. After RIC-SCT, all patients 
reached eventually complete donor chimerism in the T cell fraction. The first 
tumor evaluation in UPN677 at three months after RIC-SCT showed stable dis-
ease, paralleled by expansion of CD8+ T cells during tapering of cyclosporine A 
(CsA). One month later this patient developed encephalopathy attributed to 
EBV-reactivation. Following DLI, a second expansion of CD8+ T cells as well as 
circulating EBV-specific CD8+ T cells was detected up to 11 weeks using tetramers 
against the GLCTLVAML epitope. At seven months after RIC-SCT a second DLI was 
administered and the tumor in the abdomen remained stable without occur-
rence of GVHD (Figure 1A). Evaluation of disease response in UPN686 3 months 
after RIC-SCT showed partial regression of pulmonary metastases that coincided 
with expansion of CD8+ T cells during tapering of CsA and before the first DLI. 
This patient received DLI at 3 months after RIC-SCT inducing a second CD8+ T cell 
expansion and conversion to complete donor T cell chimerism (Figure 1B). Three
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Figure 1. Longitudinal follow-up of CD8+ T cells in peripheral 
blood from metastatic RCC patients UPN677 and UPN686 in 
relation to clinical outcome.
(A) UPN677: percentages of recipient T cells (right y axis) are compared with 
CD8+ T cell count ×106 per liter peripheral blood (left y axis). Administration 
of SCT and DLI 1-2 are indicated by   and   , respectively. Treatment interval 
with CsA is shown by the dotted line. Time points of confirmed EBV infection, 
occurrence of EBV-specific T cells (depicted as % from total CD8+ T cell popu-
lation) and death are indicated. (B) UPN686: for legend see (A). Time points 
of confirmed candidemia and death are indicated.
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months later (i.e. 6 months after RIC-SCT) CT-scan evaluation showed stable dis-
ease. Unfortunately, this patient died from invasive fungal infection 9 months 
after RIC-SCT. Post-mortal examination showed multiple histological-confirmed 
fungal lesions and two pulmonary metastasis were found, but no signs of GVHD. 
Collectively, the chimerism kinetics and expansions of CD8+ T cells in UPN677 
and UPN686 indicated T cell alloreactivity, but episodes with infections may have 
interfered. To investigate whether MiHA-specific CD8+ T cells targeting RCC tumor 
cells could be isolated from these two patients post DLI-1, IFNγ+ CD8+ T cells 
(≈2%) were sorted and weekly restimulated with irradiated recipient peripheral 
blood mononuclear cells (PBMC) obtained pre-SCT. The resulting CD8+ T cell lines, 
termed CTL line H (UPN677) and CTL line B (UPN686), displayed significant IFNγ 
production against recipient EBV-LCL, but not towards donor EBV-LCL, indicating 
the recognition of a disparate MiHA (supplemental Figure 1). These data indicate 
that MiHA-specific CD8+ T cells were present in vivo in RCC patients UPN677 and 
UPN686 following allogeneic RIC-SCT and DLI. 
Emergence of SMCY-specific CTLs in a RCC patient after DLI
Next, we revealed TCR-Vb1+CD8+ cells to be the dominant T cell population in 
CTL line H using TCR-Vb PCR and flow cytometry (data not shown). Functional 
analysis showed that specific IFNγ production by CTL line H was substantially 
inhibited by anti-HLA class I and anti-HLA-A2 antibodies, but not by antibod-
ies against anti-HLA-B/C and anti-HLA class II (Figure 2A). Furthermore, testing 
EBV-LCL from unrelated HLA-A2+ individuals revealed that 3 out of 9 individuals 
were recognized, which were all of male origin (Figure 2B). These observations 
suggested that the dominant TCR-Vb1+CD8+ T cells in CTL line H recognize an 
HLA-A2-restricted HY antigen. Therefore, we stained CTL line H with PE- and 
APC-conjugated tetramers for HLA-A2-restricted SMCY.A2 epitope FIDSYICQV 
and found around 12.5% tetramer+ CD8+ T cells (Figure 2C). These SMCY.A2 tet-
ramer+ T cells confirmed to be TCR-Vb1+ by flow cytometry (data not shown). A 
greater than 95% pure population of SMCY.A2 tetramer+ CTLs was isolated by 
flow cytometry allowing further characterization of its cytotoxic potential (Figure 
2C). Flow cytometry-based cytotoxicity assays revealed that the TCR-Vb1+ SMCY.
A2 CTL induced high levels of cytotoxicity against HLA-A2+ peptide-loaded SMCY- 
donor EBV-LCL as well as SMCY+ recipient EBV-LCL (Figure 2D). Tetramer analysis 
showed that SMCY.A2-specific CD8+ T cells became detectable in vivo in the post-
DLI setting, constituting 3.6%, 2.1% and 2.4% of the CD3+CD8+ T cell population 
collected at week +24, +28 and +31, respectively (Figure 2E). Collectively, these 
data show that SMCY.A2 CD8+ T cells expanded in RCC patient UPN677 after DLI 
with the potential of targeting SMCY-expressing RCC tumor cells in the absence 
of GVHD.
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Figure 2. CD8+ T cells reactive with the SMCY.A2 peptide devel-
oped after DLI in RCC patient UPN677.
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(A) HLA-restriction was determined by the production of IFNγ released by 
CTL line H upon stimulation with recipient EBV-LCL in the presence of HLA 
blocking antibodies. Data are displayed as mean IFNγ release ± SD of tripli-
cate wells. (B) Production of IFNγ by CTL line H stimulated with EBV-LCL of 9 
HLA-A2+ unrelated individuals, showing recognition of 3 out of 9 EBV-LCL of 
male origin. (C) Flow cytometry analysis of CD8+ CTL line H simultaneously 
stained PE- and APC-conjugated SMCY.A2 tetramer, CD8 AlexaFluor 700, 
CD4, CD14, CD16 and CD19 FITC and Sytox Blue. CD8+ T cells were gated on 
FITC- and Sytox Blue- cells. The percentage of SMCY.A2 tetramer-binding cells 
among viable CD8+ T cells was 12.6%. These SMCY.A2 tetramer+ CD8 T cells 
were sorted and expanded resulting in a >95% pure population. (D) Survival 
of the recipient and donor EBV-LCL, and donor EBV-LCL pulsed with peptide 
FIDSYICQV was determined in a flow cytometry-based cytotoxicity assay after 
incubation with SMCY.A2-specific CTL from patient UPN677 (    )  allo-HLA-A2 
CTL (   ; positive control) or medium only (•) at an E:T ratio of 3:1 in the pres-
ence of 25 U/ml IL-2.  Data are depicted as mean ±SD of triplicate wells. (E) 
Detection of SMCY.A2-specific CD8+ T cells in peripheral blood of RCC patient 
UPN677. PBMC collected 24, 28 and 31 weeks post DLI-1 were simultaneously 
stained with PE- and APC-conjugated SMCY.A2 tetramer, CD8 AlexaFluor 700, 
CD4, CD14, CD16 and CD19 FITC and Sytox Blue. Subsequently, cell popula-
tions were analyzed by flow cytometry. Cells were gated on CD8+FITC-Sytox 
Blue- lymphocytes, and the percentage of tetramer-binding cells among CD8+ 
T cells is depicted.  
Identification of a novel HLA-B7-restricted MiHA resulting from a 
polymorphism in the splice donor site of ZNF419
TCR receptor analysis using PCR and flow cytometry showed a predominant TCR-
Vb4+CD8+ population in CTL line B,  which were sorted and cultured resulting 
in a pure population (data not shown). This TCR-Vb4+CD8+ CTL, designated CTL 
B1, mediated specific IFNγ production against recipient EBV-LCL, but not towards 
donor EBV-LCL (Figure 3A). Release of IFNγ could be completely inhibited by anti-
HLA class I and anti-HLA-B/C antibodies, but not by antibodies against anti-HLA-
A2 and anti-HLA class II (Figure 3A). Testing of EBV-LCL from unrelated individuals 
sharing expression of HLA-B7 with the recipient, and EBV-LCL from an HLA class 
I-mismatched individual that were transduced with HLA-B*0702, revealed that 
CTL B1 recognizes an HLA-B7-restricted MiHA (Figure 3B). 
Next, we investigated whether the MiHA recognized by CTL B1 was selectively 
expressed by hematopoietic cells. Therefore, EBV-LCL, PHA-stimulated T cells 
and non-hematopoietic fibroblasts from two MiHA+ HLA-B7+ healthy donors were 
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Figure 3. Cytotoxicity of HLA-B7-restricted CTL B1 against RCC 
and hematological tumor cell lines. 
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(A) HLA-restriction was determined by the production of IFNγ released 
by CTL B1 upon stimulation with recipient EBV-LCL in the presence of HLA 
blocking antibodies. (B) Production of IFNγ by CTL B1 stimulated with rt 
EBV-LCL, EBV-LCL of an unrelated individual (#2) sharing HLA-B7 with the 
recipient, and an EBV-LCL of an HLA class I-mismatched individual (#3) that 
was transduced with HLA-B*0702. (C) Production of IFNγ by CTL B1 and allo-
HLA-B7 CTL stimulated with MiHA+ EBV-LCL and PHA-stimulated T cells and 
bone marrow-derived fibroblasts. Fibroblasts were pretreated with 10 ng/ml 
TNFα and 200 U/ml IFNγ for 2 days before coculture with CTL B1 (E:T ratio 
10:1). (D) MiHA mediated cytotoxicity on the HLA-B7+ RCC cell lines SKRC33 
(rs2074071 genotype AA) and SKRC18 (rs2074071 genotype GG), the brain 
tumor cell line DAOY (rs2074071 genotype AG), and pharynx cell line FaDu 
(rs2074071 genotype GG), in flow cytometry-based cytotoxicity assays was 
determined after incubation with CTL B1 (  ), allo-HLA-B7 CTL (  ; positive 
control) or medium only (•) at an E:T ratio of 3:1 in the presence of 25 U/ml 
IL-2.  Data are depicted as mean ±SD of triplicate wells. 
used as target cells. CTL B1 produced IFNγ upon co-culture with EBV-LCL, whereas 
PHA-stimulated T cells and TNFα/IFNγ pre-treated bone marrow-derived fibro-
blasts were not recognized (Figure 3C). In contrast, all target cell types were 
significantly recognized by allo-HLA-B7 CTL, indicating their susceptibility to CTL-
mediated recognition (Figure 3C). To investigate whether the MiHA targeted by 
CTL B1 is expressed by RCC tumor cells, we performed flow cytometry-based 
cytotoxicity assay. We observed that CTL B1 significantly targets the HLA-B7+ RCC 
cell line SKRC33 and not SKRC18, showing MiHA mediated cytotoxicity (Figure 
3D). In addition to these RCC cell lines, CTL B1 also recognizes and kills other solid 
tumor cell lines such as the HLA-B7+ brain cancer cell line DAOY, but not pharynx 
cell line FaDu. Allo-HLA-B7-specific CTL efficiently lysed all solid tumor cell lines 
tested (Figure 3D). To map the chromosomal region containing the gene encod-
ing the MiHA recognized by CTL B1, we performed whole genome association 
scanning (WGAs). A total of 87 endogenous HLA-B7+ EBV-LCL were tested and 42 
were recognized by CTL B1 (Supplemental Figure 2A). Comparing CTL recognition 
with SNP genotypes showed a strong association for a cluster of 5 SNPs on chro-
mosome 19 (Supplemental Figure 2B). This genetic region included the ZNF419 
gene which is located at 19q13.43. There are 7 different splice variants of the 
ZNF419 gene (Supplemental Figure 3A-B), from which several are expressed by 
patient UPN686 and its related donor (Supplemental Figure 3C). To confirm that 
the MiHA is encoded by the ZNF419 gene, we cloned the different splice vari-
ants of the ZNF419 gene from both the donor and recipient EBV-LCL. The various 
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Figure 4. A SNP in the splice donor site between exon 4 and 5 of 
the ZNF419 gene determines CTL B1 recognition
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(A) IFNγ production by CTL B1 upon stimulation with 293T-HLA-B*0702/
ICAM/CD80 cells transfected with ZNF419 full length, cloned splice variant 
containing the exon4/exon5 boundary and the alternative ZNF419 splice 
variant containing intron 4. (B) Schematic representation of the ZNF419 
gene on chromosome 19q13.43. The nucleotide and deduced amino acid 
sequences of the alternatively and correctly spliced transcripts present in 
recipient and donor, respectively, are shown. Disparity between the recipient 
and donor ZNF419 protein sequence is due to a G to A polymorphism in de 
splice donor site of intron 4 leading to the ZAPHIR epitope (underlined). (C) 
ZAPHIR epitope reconstitution with synthetic peptides corresponding to 
HLA-B7 10-mer peptide IPRDSWWVEL, 9-mer peptide IPRDSWWVE, 8-mer 
peptide IPRDSWWV, HLA-B7 10-mer peptide IPRGSWWVEL and HLA-B7 
9-mer peptide IPRGEWHGA. Donor EBV-LCL was pulsed with 10 μM peptide 
and tested for recognition by CTL B1 in the presence of 25 U/ml IL-2. Data 
are displayed as mean ± SD of triplicate wells.  (D) Flow cytometry analysis 
of CTL B1 with tetramers containing the 8-, 9-, or 10-mer peptide. Cells were 
stained with PE- and ACP-conjugated tetramer, CD8 AlexaFluor 700, CD4 FITC 
and Sytox Blue. Cells were analyzed by flow cytometry by gating on CD8+CD4-
Sytox Blue- lymphocytes. The percentage of tetramer+ cells among CD8+ T 
cells is depicted.
 
constructs were transiently transfected into 293T-HLA-B*0702/ICAM/CD80 cells 
and tested for CTL B1 recognition. CTL B1 efficiently recognized cells transfected 
with a construct encoding an alternative ZNF419 isoform of the MiHA-positive 
recipient EBV-LCL (Figure 4A), whereas none of the ZNF419 isoforms cloned 
from the donor EBV-LCL stimulated IFNγ production by CTL B1 (data not shown). 
Sequence analysis revealed that the recognized ZNF419 isoform results from the 
A/G SNP rs2074071 located in the splice donor site involved in the joining of 
exon 4 to intron 4. As a result of the G to A substitution in the splice donor site, 
the alternative ZNF419 transcript of the recipient contains a disparate amino 
acid sequence compared with that of the donor. By analyzing this disparate 
sequence for HLA-B7 binding peptides using the NetMHC server, we identified 
the strong HLA-B7 binding peptide IPRDSWWVEL that is located over the exon4-
intron4 boundary (Figure 4B). We synthesized this 10-mer IPRDSWWVEL pep-
tide (encoded by rs2074071 A variant), the 9-mer IPRDSWWVE peptide and the 
8-mer IPRDSWWVEL peptide. We tested the HLA-B7 decamer peptide IPRGSW-
WVEL that would be encoded by the G genotype as well. In addition, we synthe-
sized the HLA-B7 9-mer peptide IPRGEWHGA that is located on the exon4-exon5 
boundary of the full length ZNF419 transcript. Their ability to stimulate IFNγ 
release by CTL B1 upon loading of synthetic peptide on donor EBV-LCL was tested 
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and only the IPRDSWWVEL epitope was recognized (Figure 4C). Flow cytometry 
analysis of CTL B1 showed that only the tetramer containing the 10-mer peptide 
was positive as opposed to tetramers containing the 8-, or 9-mer peptide (Figure 
4D). These data demonstrate that the 10-mer peptide IPRDSWWVEL is the natu-
rally presented epitope that is recognized by CTL B1. Based on these findings, we 
designated this novel MiHA as ZAPHIR for ZNF419 alternatively spliced polymor-
phic histocompatibility antigen in RCC, which is the result of a polymorphism in 
a splice donor site. Expression of ZNF419 in various (malignant) hematopoietic 
and non-hematopoietic cell samples was performed by microarray gene expres-
sion analysis. Analysis of primary hematopoietic tissues (Figure 5A) show that the 
overall expression of the gene is low, as is the case for hematopoietic malignan-
cies (Figure 5B). Although fibroblast, keratinocytes, proximal tubular epithelial 
cells (PTEC) and RCC show low expression levels as well, the keratinocytes show 
an upregulation of ZNF419 when cultured in the presence of IFNγ (Figure 5C).
Figure 5. ZNF419 microarray gene expression analysis of 
(malignant) hematopoietic and non-hematopoietic cells
(A) ZNF419 expression of various hematopoietic cell types isolated from 
PBMC. (B) ZNF419 expression of hematopoietic malignancies sorted for 
CD34, CD33, and CD19/CD34. (C) ZNF419 expression of normal tissues +/- 
IFNγ. Data are displayed as MFIx106. 0-10 = no expression, 10-100 = low 
expression, 100-1000 = intermediate expression, >1000 = high expression.
Detection of ZAPHIR-specific CD8+ T cells in vivo
Next, we determined the rate of ZAPHIR disparity in HLA-B7-matched SCT donor-
recipient pairs using a competitive allele-specific PCR.  In 98 donor-recipient 
pairs (including RCC patient UPN686), we identified 13 ZAPHIR-positive patients
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Figure 6. Detection of ZAPHIR-specific CD8+ T cells in peripheral 
blood of RCC patient UPN686 and CML patient UPN539.
(A) PBMC collected before DLI and 4, 9, and 20 weeks post DLI were stained 
with PE- and ACP-conjugated ZAPHIR/HLA-B7 tetramer, CD8 AlexaFluor 700, 
CD4, CD14, CD16 and CD19 FITC and Sytox Blue. Cells were analyzed by flow 
cytometry by gating on CD8+FITC-Sytox Blue- lymphocytes. The percentage 
of tetramer+ cells among CD8+ T cells is depicted. The remaining PBMCs were 
stimulated once with ZAPHIR peptide pulsed (10 μM) EBV-LCL of the donor 
and assayed on day 7 for ZAPHIR-tetramer+ CD8+ T cells.  (B) PBMC collected 
pre-DLI, 7 and 40 weeks post-DLI were stained and gated as described under 
(A). The remaining PBMCs were stimulated once with ZAPHIR peptide-pulsed 
(10 μM) EBV-LCL of the donor and assayed on day 7 for ZAPHIR-tetramer+ 
CD8+ T cells.  
Proefschrift Broen_2.indd   77 18-3-2012   15:42:08
78
CHAPTER 3
(i.e. 13.3%) that had received a transplant from a ZAPHIR-negative donor. To detect 
ZAPHIR-specific CD8+ T cells in these mismatched patients in vivo, we constructed 
an HLA-B7 tetramer using the 10-mer peptide IPRDSWWVEL. First, we analyzed 
PBMCs samples of RCC patient UPN686 from which the ZAPHIR-specific CTL B1 
was isolated. In addition, specific detection of ZAPHIR-tetramer+ CD8+ T cells was 
assessed after in vitro stimulation of PBMC samples with peptide-pulsed donor 
EBV-LCL. At fourteen weeks post-SCT (i.e. pre-DLI) <0.01% ZAPHIR-tetramer+ cells 
could be directly detected in the PBMC sample, but after stimulation the percent-
age increased to 0.26% within the total CD8+ T cell population (Figure 6A). Inter-
estingly, the percentage ZAPHIR-tetramer+ CD8+ T cells increased at 4 weeks after 
DLI to a level of 0.11%, and persisted at a low frequency (~0.01%) up to 20 weeks 
post-DLI. In vitro stimulation resulted in an increase of ZAPHIR-specific CD8+ T 
cells up to 1.37% for week 4, 0.46% for week 9, and 0.70% for week 20 post-DLI 
(Figure 6A). These data show that ZAPHIR-specific CD8+ T cells with the capability 
of targeting RCC metastases emerged in RCC patient UPN686 following SCT and 
DLI in the absence of GVHD. Specific detection of ZAPHIR-tetramer+ CD8+ T cells 
was also performed in the peripheral blood of 12 additional ZAPHIR-mismatched 
patients. In 1 of these 12 patients, chronic myeloid leukemia (CML) patient UPN 
539, 0.04% and 0.36% ZAPHIR-tetramer+ CD8+ T cells could be detected in the in 
vitro-stimulated T cell cultures obtained from PBMC samples at 7 and 40 weeks 
post-therapeutic DLI, while no (<0.01%) tetramer+ cells could be detected directly 
in the PBMC (Figure 6B). Furthermore, ZAPHIR-specific CTL could be cloned from 
PBMC collected 40 weeks post-therapeutic DLI (Supplemental Figure 4). These 
data indicate that ZAPHIR-specific CD8+ T cell responses can also be detected in 
transplanted CML patients. 
Discussion
MiHA are considered to play a dominant role in mediating GVT reactivity after 
HLA-identical allogeneic SCT for both hematological malignancies and solid 
tumors. Especially MiHA with a hematopoietic- or tumor-restricted distribution 
are promising targets to boost GVT reactivity without enhancing GVHD. For the 
development of tumor-specific immunotherapy it is important to enlarge the 
spectrum of molecularly identified MiHA that are selectively expressed. In this 
study, we characterized antigens targeted by allogeneic donor T cells in meta-
static RCC patients treated with partial T cell-depleted RIC-SCT followed by DLI. 
Using PBMCs collected from two patients, showing either stable disease or par-
tial response, we succeeded in expanding CD8+ CTLs with the capability of target-
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ing MiHA expressed by RCC cells. Interestingly, a TCR-Vb4+CD8+ CTL targeting a 
novel HLA-B7-restricted MiHA, designated ZAPHIR, was isolated from RCC patient 
UPN686 showing partial regression of lung metastases in the absence of GVHD. 
Flow cytometry-based cytotoxicity assays revealed that ZAPHIR-specific CTL B1 
mediated efficient lysis of HLA-B7+ RCC cell lines. In addition, ZAPHIR-specific 
CTL also mediated cytotoxicity against an HLA-B7+ brain tumor cell line. Further-
more, while EBV-LCL were recognized by ZAPHIR-specific CTL, PHA-stimulated T 
cells and cytokine-treated bone marrow (BM)-derived fibroblasts did no induce 
IFNγ production. These data indicate that the HLA-B7-restricted MiHA ZAPHIR 
is co-expressed by solid tumors and transformed B cells. Notably, emergence of 
ZAPHIR-specific CD8+ T cells in RCC patient UPN686 as well as CML patient UPN 
539 was observed in the absence of GVHD. Microarray gene expression analysis 
of several (malignant) hematopoietic cells and normal tissues show that expres-
sion of ZNF419 is low. This might explain the absence of an immune response, 
as is the case in vivo in non-malignant tissues, and therefore no GVHD could be 
observed. However, as the keratinocytes cocultured with IFNγ show that under 
inflammatory conditions ZNF419 is upregulated and could lead to an immune 
response. Since the tumor tissues are surrounded by an inflammatory environ-
ment, a GVT response mediated by MiHA-specific T cells could occur in vivo.
In order to identify the novel MiHA recognized by CTL B1, we used the WGAs 
method that was recently described by Van Bergen et al 19. This method makes 
use of the SNP-genotyping of unrelated HLA-B7+ individuals who were divided 
in a MiHA+ and MiHA- group and yielded a highly specific genomic location on 
chromosome 19q13.43. This led to the rapid identification of ZNF419 as the gene 
of interest showing WGAs to be a very suitable method for MiHA identification. 
Further analysis revealed that the novel ZAPHIR epitope is located on the exon4-
intron4 boundary which is the result of a G to A substitution in the splice donor 
site leading to an alternative spliced ZNF419 variant. The mechanism that MiHA 
immunogenicity can arise from alternative splicing due to a single intronic SNP, 
has been previously described for the MiHA ACC-6 20. 
In RCC patient UPN677, we demonstrated emergence of SMCY.A2-specific CD8+ 
T cells after DLI without the clinical manifestations of GVHD. Interestingly, Ham-
bach et al. showed that SMCY.A2-specific CTL are capable of efficiently target-
ing solid tumor cells in a three-dimensional micro tumor model 11. Therefore, 
our clinical findings suggest that emergence of SMCY.A2 CTL may have played a 
role in stabilization of the tumor growth after allogeneic SCT and DLI in patient 
UPN677. Interestingly, high numbers of SMCY.A2 CD8+ T cells up to 3.6% of the 
total CD8+ T cell population in patient UPN677 did not induce clinical signs of 
GVHD to either skin, liver or gut. Earlier studies have shown that SMCY is ubiq-
uitously expressed, and SMCY-specific CTL responses have been associated with 
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GVHD 7;15;21-23. However, GVHD is a multi-factorial disease process to which many 
factors contribute, and we speculate that lack of other inflammatory triggers 
prevented the development of acute GVHD (reviewed by Ferrara et al 24). Cur-
rently, the role of allogeneic RIC-SCT for the treatment of metastatic RCC patients 
is still unclear. New developments in treatment of metastatic RCC have signifi-
cantly changed the treatment strategies for these patients. However, the novel 
drugs that are currently used do not cure patients and the incidence of com-
plete remissions is low. Therefore, new strategies should continue to be explored 
and the discovery of antigenic targets of alloreactive T cells in transplanted RCC 
patients may allow the development of tumor-specific post-transplantation strat-
egies such as vaccination or adoptive T cell transfer. Two earlier studies have 
identified target antigens at the molecular level using CD8+ CTL isolated from 
patients with metastatic RCC treated with allogeneic SCT. Tykodi et al. identified 
an HLA-A*0201-restricted MiHA, which is encoded by the C19orf48 gene located 
on chromosome 19q13 14. In addition, recognition of the non-polymorphic RCC 
over-expressed human endogenous retrovirus type E (HERV-E) antigen by allore-
active T cells was described by Takahashi et al 15. Not only tumor-specific MiHA 
are interesting for these purposes, but also hematopoietic-restricted MiHA with 
aberrant expression in solid tumor cells may be useful for this strategy. Genotype 
frequency analysis in HLA-B7 allo-SCT couples revealed a disparity rate of 13.3%, 
making the ZAPHIR MiHA therapeutically relevant as is the case for the other, 
commonly mismatched MiHA HA-1, LRH-1 and BCL2A1 25-27. Adoptive transfer of 
a single dose of HA-1 CTLs was effective in eradicating disseminated solid tumors 
in a mouse model 11. Therefore, adoptive immunotherapy with ex vivo-generated 
CTLs directed against MiHA expressed by RCC might be an attractive adjuvant 
approach as has also been studied in patients with leukemia 28. Alternatively, 
patients could be vaccinated with peptides or DCs loaded with peptides or elec-
troporated with MiHA-encoding mRNA 29;30. 
In conclusion, this study describes T cell responses after partial T cell-depleted 
RIC-SCT followed by DLI in patients with metastatic RCC. Our transplant proce-
dure resulted in stable engraftment, manageable GVHD and T cell responses in 
two patients. SMCY-specific CD8+ T cells were identified in a patient with stable 
disease, and CD8+ T cells targeting the novel HLA-B7-restricted MiHA ZAPHIR 
in the second patient with a partial response. Although the role of allogeneic 
RIC-SCT in RCC may be limited in the near future, this study shows that the 
approach of partial T cell-depleted SCT followed by DLI induces MiHA-specific T 
cell responses potentially targeting RCC tumor cells. The significance for cellular 
immunotherapy of the novel MiHA ZAPHIR is demonstrated by the emergence 
of ZAPHIR-specific CTL after allo-SCT, and its ex vivo cytotoxic activity against RCC 
and transformed B cell lines. Furthermore, identification of the antigenic targets 
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of alloreactive T cells remains important for the further understanding of the GVT 
response in different malignancies and for development of strategies to selec-
tively target tumor cells after allogeneic SCT.
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Supplemental Figures
Figure S1. Generation of MiHA-reactive CD8+ CLT lines from patients 
with RCC after allogeneic RIC-SCT.
(A) Detection of IFNγ secreting CD8+ T cells in T cell lines generated from patient 
UPN677 and UPN686 after co-culture with EBV-LCL of the recipient.  Stimulated T 
cells were stained with PE-conjugated IFNγ detection reagent and FITC-conjugated 
anti-CD8 mAb, and analyzed by flow cytometry. (B) Production of IFNγ by CTL 
lines H and B upon stimulation with recipient (Rt) EBV-LCL, donor (Do) EBV-LCL or 
medium. Data are displayed as mean IFNγ release ± SD of triplicate wells. 
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Figure S2. WGAS using 87 HLA-B7 positive EBV-LCL revealed a 
cluster of 5 SNPs to associate on chromosome 19 cluster of SNP. 
(A) Detection of IFNγ-secretion by CTL B1, here depicted as OD450, upon 
stimulation with 87 HLA-B7+ EBV-LCL showed 42 EBV-LCL to be recognized. The 
threshold for recognition was set at 5 times the level of IFNγ production in the 
absence of EBV-LCL. (B) Detail of chromosome 19 showing all SNP that cluster 
according to Fisher’s exact test. No other SNP cluster was found at any other 
chromosome.  
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Figure S3. ZNF419 splice variant. 
(A-B) The full length transcript of ZNF419 (NM_001098491) consists of 5 exons 
which are spliced into an additional 6 splice variants (NM001098492 through 
NM _001098496 and NM_024691). Due to SNP rs2074074 in the splice donor site 
an additional transcript occurs in patient UPN686 which includes exon 4 (grey) 
leading to a stop-codon (*). (C) The different splice variants that were expressed 
by patient UPN686 and its related donor were amplified as a pool, using the 
primerset as depicted (→) and cloned into pcDNA3.1(+).
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Figure S4. Generation of ZAPHIR-reactive CD8+ CTL Lines from CML 
patient UPN539 40 weeks post DLI. 
(A) PBMC collected 40 weeks post DLI were sorted for TET+CD8+ T cells (inside 
square) and cloned into single cells. (B) Production of IFNγ by ZAPHIR-specific CTL 
clones with ZAPHIR-peptide pulsed donor EBV-LCL, donor EBV-LCL or medium. 
Data are displayed as mean IFNγ release ± SD of triplicate wells. 
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donor lymphocytes and recipient DCs
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Abstract
Recently, we demonstrated that reduced intensity conditioning (RIC) followed by 
partial T cell-depleted allogeneic stem cell transplantation (SCT) creates a plat-
form for inducing the graft-versus-myeloma (GVM) effect by adjuvant immuno-
therapy. Here, we evaluated minor histocompatibility antigen (MiHA)-specific T 
cell responses in a multiple myeloma (MM) patient who was treated with RIC-SCT 
followed by donor lymphocyte infusion (DLI) and subsequent recipient dendritic 
cell (DC) vaccination. We isolated a MiHA-specific cytotoxic T cell clone (CTL) 
clone with the capability of targeting MM tumor cells from this patient experi-
encing long-term complete remission. This CTL recognizes an HLA-A3-restricted 
MiHA and mediates killing of both primary MM cells and the MM cell line U266, 
while bone marrow (BM)-derived fibroblasts are not recognized. CTL-specific T 
cell receptor (TCR) transcripts could be detected by quantitative PCR analysis in 
both peripheral blood and BM during tumor remission. Interestingly, a strong 
increase of CTL-specific TCR transcripts at the BM tumor site was observed fol-
lowing DLI and recipient DC vaccination, while the TCR signal in peripheral blood 
decreased. These findings illustrate that the approach of partial T cell-depleted 
RIC-SCT followed by post-transplantation immunotherapy induces MiHA-specific 
T cell responses targeting MM tumor cells.
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Introduction
Allogeneic stem cell transplantation (SCT) has the potential to cure patients 
with multiple myeloma (MM) due to the graft-versus-myeloma (GVM) effect 1;2. 
This GVM effect can be mediated by alloreactive donor T cells targeting minor 
histocompatibility antigens (MiHA) expressed on myeloma tumor cells in the 
bone marrow. Previously, we have established the potential of partial T cell-
depleted allogeneic SCT followed by pre-emptive donor lymphocyte infusion 
(DLI) to induce GVM immunity with limited risk of inducing graft-versus-host 
disease (GVHD). These studies showed that long-term complete remission (CR) 
can be induced in about one third of MM patients 3. To further improve these 
results we have explored the possibility to boost GVM immunity, without the 
toxicity and morbidity due to GVHD, by means of recipient dendritic cell (DC) 
vaccination post-DLI. Although we showed that mature recipient-derived DC 
could be generated, and that vaccination resulted in limited toxicity, no obvious 
direct effects on tumor load could be demonstrated 4. 
In the setting of using unloaded recipient-derived DC vaccines, we aimed at 
the induction of alloreactive donor T cell responses against both known and 
unknown MiHA on myeloma tumor cells of the recipient. Previously, it has 
been reported that MiHA-specific cytotoxic T lymphocytes (CTL) isolated from 
transplanted MM patients are able to target MiHA, like HA-1 5, ADIR 6 and ECGF 
7, that are co-expressed by MM tumor cells and monocyte-derived DCs. In this 
case report, we investigated MiHA-specific-CD8+ T cell responses in a MM patient 
who successfully obtained long-term clinical remission (CR) in the absence of 
GVHD after treatment with RIC-SCT followed by DLI and recipient DC vaccination. 
Following DC vaccination, primary T cell responses were elicited against keyhole 
limpet hemocyanin (KLH) that was used as control antigen and for providing T 
helper responses. Although no CD8+ T cells were found against known MiHA, an 
HLA-A3 restricted CTL directed against an unknown MiHA could be isolated from 
the bone marrow (BM). This MiHA-specific CTL clone recognized both primary 
MM cells as well as MM cell lines, while healthy BM-derived fibroblasts were not. 
In addition, we found a strong increase in the CTL-specific TCR signal in the BM 
during post-transplant immunotherapy, while the TCR signal in peripheral blood 
decreased. These findings suggest that post-transplant immunotherapy results in 
boosting or increased trafficking of MiHA-specific CTL to the BM.
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Materials and Methods
Transplantation procedure
Prior to transplantation a conditioning regimen consisting of 1200 mg/m2 
cyclophosphamide (Cy) was given intravenously in combination with 30 mg/m2 
fludarabine (Flu) on each of four consecutive days (days -5, -4, -3, -2 before SCT). 
Partial T cell depletion was performed using anti-CD3 and anti-CD19 immuno-
magnetic beads (Miltenyi Biotec, Bergisch Gladbach, Germany) and 0.5x106 CD3+ 
T cells/kg body weight were given within the graft. Subsequent pre-emptive DLIs 
were given at week 34 post-SCT (1x106 CD3+ T cells/kg) and at week 44 post-
SCT (5x106 CD3+ T cells/kg). Furthermore, patient UPN8458 received additional 
immunotherapy in the form of autologous KLH-pulsed DC vaccination starting at 
week 65 post-SCT. DC vaccines were produced as described previously 4. Vaccina-
tion was performed three times at 2-week intervals. The DC dose was injected 
intravenously (7x106) and intradermally (3x106) in the upper leg near the inguinal 
lymph node region. At specific time points BM aspirates and peripheral blood 
mononuclear cells (PBMC) were collected to evaluate responses. The study was 
approved by the Local Ethics Committee of Radboud University Nijmegen Medi-
cal Centre. 
Cell isolation and culture 
CD8+ CTL clones 44 and 298 were isolated from BM mononuclear cells obtained 
9 weeks post DLI-2. For this, BM mononuclear cells were single cell sorted for 
CD8+/HLA-DR+/CD4-/CD14-/CD16-/CD19-cells by flow cytometry (Elite, Beckman 
Coulter) and cultured in Iscove’s modified Dulbecco’s medium (IMDM; Invitrogen, 
Carlsbad, CA) supplemented with 10% human serum (HS; Sanquin blood bank, 
Nijmegen, the Netherlands). These single cell cultures were weekly stimulated 
with irradiated (80 Gy) recipient EBV-LCL (1x104), irradiated (60 Gy) allogeneic 
PBMC (0.5x106) from two donors, 100 IU/ml IL-2 (Chiron, Emeryville, CA) and 1 
μg/ml PHA-M (Boehringer, Alkmaar, the Netherlands). CTL cultures consisting of 
more than 0.5x106 cells were maintained and subsequently cultured with irradi-
ated recipient EBV-LCL (0.5x106), allogeneic PBMC (0.5x106) from two donors, 
100 IU/ml IL-2 and 1 μg/ml PHA-M. All cell lines were cultured in IMDM/10% 
FCS. Fibroblasts were cultured from BM aspirates obtained from healthy stem 
cell donors. For this, BM was resuspended in 20 ml IMDM/20% FCS and incu-
bated overnight at 37 °C in tissue culture flasks. The non-adherent fraction was 
removed and fibroblasts were further cultured in IMDM/20% FCS to passage 3 
before analysis. Monocytes were isolated from PBMCs via plastic adherence in 
tissue-culture flasks (Greiner Bio-One). Immature DC were generated by cultur-
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ing adherent monocytes in X-VIVO-15 medium (Lonza) supplemented with 2% 
HS, 500 U/ml IL-4 (Immunotools), and 800 U/ml GM-CSF (Immunotools). Matura-
tion of DCs was induced at day 6 by culturing 0.5×106 immature DC/ml in 6-well 
plates (Costar; Corning) in X-VIVO-15/2% HS containing 500 U/ml IL-4, 800 U/ml 
GM-CSF, 5 ng/ml IL-1ß, 15 ng/ml IL-6, 20 ng/ml TNF-α (all Immunotools), and 1 
μg/ml PGE2 (Pharmacia & Upjohn). At day 8, mature DCs were harvested and 
used in CTL stimulation assays. 
Flow cytometry-based cytotoxicity studies
Flow cytometry-based cytotoxicity assays were performed as previously described 
8;9. Briefly, HLA-A3+ cell lines were labeled with 2.5 μM carboxyfluorescein diace-
tate succimidyl ester (CFSE; Molecular Probes Europe). Target cells (1×104) were 
co-cultured with unlabelled effector cells (3×104) at an E:T ratio of 3:1 in a total 
volume of 200 μl IMDM/10% FCS containing 25 U/ml IL-2 in 96-wells flat-bottom 
plates. After 1-3 days of co-culture, cells were harvested and 7-amino-actinomy-
cin D (7AAD; Sigma-Aldrich, St Louis, MO) was added. Numbers of viable target 
cells were quantified by Coulter FC500 flow cytometer (Beckman Coulter). 
Real-time quantitative PCR analysis 
Total RNA was isolated from cells by the Trizol method (Invitrogen) or the Zymo 
RNA isolation kit II (Zymo Research Corporation, Orange, CA). First strand cDNA 
was prepared from total RNA (2 μg) using an oligo-dT primer, random hexamers 
and Mo-MuLV reverse transcriptase (Invitrogen). For the T cell receptor (TCR) 
of CD8+ CTL clone 44 gene-specific primers sets were designed at the 5’ and 
3’ end of the hypervariable domain. The following primers were used: TCR-F 
5’-gctgctcagtgatcggttctc-3’, TCR-R 5’-gccaaaatactgcgtataatctgc-3’. In addition, 
primers were used specific for CD8: CD8-F 5’-ccctgagcaactccatcatgt-3’, CD8-R 
5’gtgggcttcgctggca-3’. One µl of cDNA was amplified in a 25 µl SYBR Green PCR 
mastermix (Applied Biosystems) containing 150 nM of each primer. The porpho-
bilinogen deaminase (Pbgd) gene was used to normalize the expression of each 
candidate gene. The following primers were used for Pbgd real-time PCR: Pbgd-F 
5’-ggcaatgcggctgcaa-3’, Pbgd-R 5’-gggtacccacgcgaatcac-3’. The reaction mixture 
for the Pbgd-PCR was amplified in a 25 µl SYBR Green PCR mastermix (Applied 
Biosystems) containing 150 nM of each primer in a total volume of 25 µl. PCR 
amplification was performed using an ABI Prism 7700 (Applied Biosystems) with 
the following PCR conditions: enzyme activation for 10 min at 95°C, followed by 
45 cycles of 95°C for 15 s and 62°C of 1 min. Subsequently, the threshold cycle 
(Ct) was determined by software analysis. The expression of candidate genes was 
calculated using BMMC or PBMC collected at time of first DLI (i.e. 34 weeks post-
SCT),  as calibrator with the following formula: (2-(∆∆Ct))*100 10. 
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Results
Case description
In 2006, we transplanted a 39 year-old male (UPN8458) for symptomatic MM 
with a partially T cell-depleted peripheral stem cell graft from his HLA-identical 
sister (A2, A3, B7, B35). At diagnosis this patient presented with an M-protein 
of 52.7 g/l IgG kappa. Treatment was started in the current HOVON50 protocol 
consisting of 3xVAD, CAD and stem cell collection followed by autologous SCT 
after high dose Melphalan4.  Five months later the autologous SCT was followed 
by a reduced intensity conditioning (RIC) allogeneic SCT. At time of allogeneic 
SCT the patient was in partial remission with an persistent M-protein of 16.9 g/l. 
Post transplant, the patient did not develop any acute GVHD and received two- 
preemptive DLIs after discontinuation of CsA. At 25 weeks post-SCT complete
Figure 1. Longitudinal follow-up of recipient cells and M-protein 
in peripheral blood of MM patient UPN8458 in relation post-
transplantation immunotherapy. 
The left Y-axis shows disease load as measured by M-protein (g/l). The right 
Y-axis shows percentages of recipient cells. Administration of an autologous 
and allogeneic SCT, DLI 1-2 and DC vaccination 1-3 are indicated. Treatment 
interval with CsA is shown by the dotted line. Arrow indicates the time point 
of isolation of CTL clones 44 and 298. 
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donor chimerism was achieved (Figure 1). 
Tumor evaluation by measuring M-protein in UPN8458 showed undetectable 
levels from week 9 post DLI-2 and the patient reached CR, which remains up 
to 63 months post-SCT. A patient-specific IgH-PCR was developed and this PCR 
became negative after DLI, indicating molecular remission (data not shown). 
As part of the post-transplantation immunotherapy, DC vaccinations generated 
from a cryopreserved recipient apheresis product were administered 4 (Figure 
1). While local induration at the intradermal site of injection and fever were 
observed, no GVHD occurred. After the immunizations, KLH-specific T cells were 
induced but no antibodies against KLH could be detected. No MiHA-specific T 
cells were found against known MiHA that were mismatched between donor and 
recipient on DNA level (i.e. SMCY.A2, SMCY.B7 and ZAPHIR.B7) (data not shown) 
11-13. 
Isolation of an alloreactive MiHA-specific CD8+ CTL from the MM 
tumor site
To investigate whether MiHA-specific CD8+ T cells targeting MM cells could be 
isolated from the BM of patient UPN8458 at the moment a strong decline of 
M-protein level was observed (i.e. 9 weeks post DLI-2), HLA-DR+ CD8+ T cells were 
sorted as single cells and clonally expanded. 
Functional analysis of outgrowing clones revealed that two CD8+ T cell clones, 
designated CTL clone 44 and CTL clone 298, displayed specific IFNγ production 
against recipient EBV-LCL, but not towards donor EBV-LCL, indicating the recogni-
tion of a disparate MiHA (Figure 2A).
Next, HLA restriction of these CTL clones was determined by using blocking anti-
bodies. Release of IFNγ was completely abolished by anti-HLA class I antibod-
ies, but not by antibodies against anti-HLA-A2 or anti-HLA-B/C (Figure 2B). This 
indicated that CTL clone 44 and 298 were restricted for HLA-A3 since the HLA 
type of patient UPN8458 was A2, A3, B7, B35. Testing of EBV-LCL from unrelated 
individuals sharing expression of HLA-A3 with the recipient indeed revealed that 
both CTL clone 44 as well as CTL clone 298 recognizes 5 out of 7 tested EBV-LCL, 
confirming restriction of the MiHA-specific T cells for HLA-A3 (Figure 2C). 
Since no differences were observed in recognition pattern of CTL clone 44 com-
pared to clone 298, further experiments were performed using CTL clone 44 only. 
These data indicate that MiHA-specific CD8+ T cells against an unknown HLA-
A3-presented MiHA were present in vivo in MM patient UPN8458 following allo-
geneic RIC-SCT and DLI. 
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Figure 2. Characterization of CD8+ T cell clones 44 and 298 
isolated from MM patient UPN8458. 
(A) Single cell sorted HLA-DR+ CD8+ T cells from BM post DLI-2 were expanded 
using allogeneic stimulator cells. The resulting CD8+ T cell clones, termed CTL 
clone 44 and CTL clone 298, displayed significant IFNγ production against 
recipient EBV-LCL, but not towards donor EBV-LCL. (B) HLA-restriction was 
determined by measuring production of IFNγ released by CTL clone 44 (right 
panel) or CTL clone 298 (left panel) upon stimulation with recipient EBV-LCL 
in the presence of HLA blocking antibodies. (C) Production of IFNγ by CTL 
clone 44 (right panel) and CTL clone 298 (left panel) stimulated with HLA-A3+ 
unrelated EBV-LCL. The cut off point for positivity was set at the mean + 3x 
SD level of IFNγ production. All tests were performed at an E:T ratio of 1:3 in 
the presence of 25 U/ml IL-2.  Data are displayed as mean IFNγ release ± SD 
of triplicate wells.
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CTL clone 44 recognizes an HLA-A3-restricted MiHA expressed on 
transformed B cell lines and monocyte-derived DC, but not fibroblast 
cell lines
Next, we investigated whether the HLA-A3-restricted MiHA recognized by CTL 
clone 44 was expressed by hematopoietic tumor cell lines, primary MM tumor 
cells or healthy fibroblasts. Interestingly, CTL clone 44 significantly recognizes 
the U266 myeloma cell line and the RAJI Burkitt’s lymphoma cell line (Figure 
3A). In contrast, the HLA-A3+ Jurkat T acute lymphoblastic leukemia cell line and 
Monomac6 monocytic cell line were not recognized. In addition, flow cytometry-
based cytotoxicity assay were performed to determine whether CTL clone 44 not 
only produced IFNγ upon recognition, but also mediates killing of the recognized 
B cell lines. We observed that CTL clone 44 significantly targets the recipient 
EBV-LCL, but not the donor EBV-LCL (Figure 3B). Furthermore, in agreement with 
stimulating IFNγ production, the HLA-A3+ cell lines U266 and RAJI were lysed effi-
ciently by CTL clone 44 (Figure 3C). Moreover, CTL clone 44 was cytotoxic towards 
primary HLA-A3+CD38+CD138+CD45- MM cells (Figure 3D).
In addition, we tested cytotoxicity of CTL clone 44 towards healthy fibroblasts. 
Therefore, EBV-LCL and BM-derived fibroblasts from MiHA+ HLA-A3+ healthy 
donors were used as target cells. CTL clone 44 produced IFNγ upon co-culture 
with EBV-LCL, whereas TNFα/IFNγ pre-treated BM-derived fibroblasts were not 
recognized (Figure 3E).
Collectively, these findings show that CTL clone 44 isolated from MM patient 
UPN8458 targets myeloma tumor cells, whereas BM-derived fibroblasts are not 
recognized. 
Detection of MiHA-specific CD8+ T cells in vivo by quantitative PCR 
We have established that MiHA-specific CTL clone 44 can target MM cells in vitro, 
however to execute this function in vivo, the CTL has be present at the BM tumor 
site. Therefore, we performed quantitative PCR analysis of the TCR specific for CTL 
clone 44 on PBMC and BM mononuclear cells collected from patient UPN8458 at 
several time points during post-transplant immunotherapy. First, TCR-Vβ-region 
PCR analysis was performed revealing expression of TCR-Vβ24+ by CD8+ CTL clone 
44 (data not shown). Next, sequencing of the CTL-specific TCR-Vβ24 transcript 
was performed after amplification of the TCR using a forward primer specific for 
Vβ24 and a reverse primer specific for the constant region. A rearranged region, 
unique for the TCR-Vβ24 chain of CTL clone 44, flanked by the V and J domain 
(no D domain present) on both sides, was identified that was used to develop 
primers for a TCR clone-specific quantitative PCR. Finally, CD8 and CTL clone 44 
specific-TCR gene expression in PB and BM was determined by real-time quan-
titative PCR and normalized for the housekeeping gene Pbgd. Data is expressed 
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Figure 3. Cytotoxicity of HLA-A3-restricted CTL clone 44 against 
B cell tumor cell lines and primary MM. 
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(A) CTL clone 44 was cocultured with endogenous HLA-A3+ hematopoietic 
tumor cell lines. IFNγ production was observed upon coculture with the MM 
cell line U266 and the Burkitt cell line RAJI. Test was performed at an E:T 
ratio of 1:3 in the presence of 25 U/ml IL-2. Data are displayed as mean IFNγ 
release ± SD of triplicate wells. (B)  Survival of the Rt and Do EBV-LCL in flow 
cytometry-based cytotoxicity assays was determined after incubation with 
CTL clone 44 (  ) or medium only (  ) at an E:T ratio of 3:1 in the presence of 
25 U/ml IL-2. (C)  Survival of MM cell line U266 and Burkitt lymphoma cell 
line RAJI in flow cytometry-based cytotoxicity assays was det ermined after 
incubation with CTL clone 44 (  ) or medium only (  ) at an E:T ratio of 3:1 in 
the presence of 25 U/ml IL-2.  (D) Primary HLA-A3+ MM cells were cocul-
tured with clone 44 at effector to target (E:T) ratios as indicated. MM cells 
were gated on CD38+CD138+CD45- and viable cells were counted. Data are 
depicted as mean ±SD of triplicate wells. (E) Production of IFNγ by CTL clone 
44 stimulated with MiHA+ EBV-LCL and BM-derived fibroblasts. Fibroblasts 
were pretreated with 10 ng/ml TNFα and 200 U/ml IFNγ for 2 days before 
coculture with CTL clone 44. The cut off point for positivity was set at the 
mean + 3x SD level of IFNγ production.  Test was performed at an E:T ratio of 
1:3 in the presence of 25 U/ml IL-2.  Data are displayed as mean IFNγ release 
± SD of triplicate wells. 
as the level of CTL clone 44 specific-TCR gene expression corrected for the total 
amount of CD8 expression (Figure 4). CTL clone 44 TCR transcripts were found 
in both PB and BM already at the time of the first DLI. Interestingly, an increase 
of the TCR signal was observed in the BM 9 weeks post DLI-2 as well as 3 weeks 
after the third recipient 
DC vaccination. In contrast, a decrease of the CTL clone 44 specific TCR signal was 
found in PB. These data suggest either increased migration or direct boosting of 
CTL clone 44 in the BM tumor site by the post-transplantation immunotherapy.
Discussion
MiHA are considered to play a dominant role in mediating GVT reactivity after 
HLA-identical allogeneic SCT for hematological malignancies 14-16. Recently, we 
demonstrated that partial T cell-depleted allogeneic RIC-SCT creates a platform 
for inducing GVT immunity by post-transplant immunotherapy in patients suf-
fering from MM. Escalating dose DLI could be given to most patients (63%) and 
vaccination with KLH-loaded recipient DCs was explored in six patients 4. After
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Figure  4. Longitudinal follow-up of MiHA-specific CD8+ T cells in 
peripheral blood and BM from MM patient UPN8458 in relation 
to post-transplantation immunotherapy. 
M protein representing MM tumor load (g/l) (left y axis) and post-transplan-
tation immunotherapy intervention are compared with CTL clone 44 specific-
TCR/total CD8 ratio both expressed as 2-(∆∆Ct) calibrated for BM or PBMC 
collected at 34 weeks post allogeneic SCT (right y axis). Administration of 
autologous and allogeneic SCT, DLI 1-2 and DC vaccination 1-3 are indicated. 
Treatment interval with CsA is shown by the dotted line. 
vaccination, potent primary T cell responses against KLH could be detected, but 
we did not observe MiHA-specific T cell responses against known MiHA. In this 
case study, we aimed at isolating novel MiHA-specific T cells involved in the GVM 
response in patient UPN8458, who obtained long-term clinical and molecular 
remission after RIC-SCT, DLI and DC vaccination in the absence of GVHD. Func-
tional cloning of HLA-DR+CD8+ T cells obtained from BM at time of tumor remis-
sion resulted in the isolation of an HLA-A3-restricted CD8+ CTL clone, designated 
clone 44, recognizing an unknown MiHA. This CTL clone mediated IFNγ produc-
tion and cytotoxicity towards both primary MM cells and the MM cell line U266. 
Interestingly, MiHA-specific CTL clone 44 did not target BM-derived fibroblasts 
derived from MiHA+ healthy donors. 
Previously, MiHA-specific T cells have been isolated from relapsed MM patients 
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post-DLI. These MiHA-specific T cells recognized patient MM cells and character-
ization of these T cell clones isolated from peripheral blood ultimately led to the 
molecular identification of the MiHAs ADIR 6 and ECGF 7. In this case report, the 
HLA-A3-restricted CTL clone 44 from our patient UPN8458 was isolated from BM, 
the site were the tumor resides. Quantitative analysis of CTL clone 44-specific 
TCR transcripts revealed the presence of CTL clone 44 in both peripheral blood 
and BM. Interestingly, a strong increase of the CTL at the BM tumor site was 
observed following DLI and DC vaccination. Notably, we could further show that 
during post-transplantation immunotherapy the amount of these MiHA-specific 
T cells increased in the BM, while in blood levels became undetectable. Previ-
ously, it has been described that high avidity leukemia-reactive T cells reside pref-
erentially in the BM in contrast to other specific T cell populations that are evenly 
distributed between BM and peripheral blood 17. Although we, at this stage, have 
no information or possibilities to explore the avidity of CTL clone 44, we showed 
that this population does reside almost exclusively in the BM confirming previ-
ous studies. CD8+ T cells homing to the BM have a specific chemokine receptor 
profile, distinct from T cells homing to secondary lymphoid organs 18. Further 
research mapping the chemokine receptor profiles of MM-reactive T cells iso-
lated from blood and BM over time would provide new insights into the role of 
DC vaccination. An important question to address is whether the observed accu-
mulation of CTL clone 44 is due to increased proliferation or increased trafficking 
towards the tumor site? 
We have shown that RIC-therapy followed by partial T cell-depleted allogeneic 
SCT creates a platform for boosting the GVM effect by post-transplantation 
immunotherapy 4. Patient UPN8458 was treated by both DLI and unloaded recip-
ient-derived DC vaccines. Although the initial priming of MiHA-specific T cells 
is most probably done by recipient DC, which can still be present following RIC, 
donor-derived DC may drive further expansion of the T cell compartment due 
to crosspresentation (reviewed in 19). Here, we showed that recipient-derived 
Mo-DC vaccination might have been involved in increased T cell responses in the 
bone marrow, although this is not yet robustly demonstrated in this case study. 
Therefore, the use of donor-derived DC loaded with MiHA peptide should be 
explored more extensively in the future. This approach circumvents the obstacle 
of cryoperseveration and has previously proved to be safe as posttransplantation 
therapy 20-22.
In conclusion, this case report describes an interesting MiHA-specific T cell 
response in a MM patient who was successfully treated with partial T cell-
depleted RIC-SCT followed by DLI and DC vaccination. During post-transplanta-
tion immunotherapy measurable M-protein disappeared in the patient resulting 
in long-term CR. This study shows that the approach of partial T cell-depleted SCT 
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followed by DLI and DC vaccination induces MiHA-specific T cell responses tar-
geting MM tumor cells. Furthermore, our findings suggest that DLI and possibly 
DC vaccination results in boosting or increased trafficking of MiHA-specific CTL 
to the BM. Identification of the antigenic targets of alloreactive T cells remains 
important for the further understanding of the GVT response in different malig-
nancies and for development of strategies to selectively target tumor cells after 
allogeneic SCT.
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Abstract
Allogeneic stem cell transplantation (SCT) is a potentially curative treatment 
for patients with hematologic malignancies. Its therapeutic effect is largely 
dependent on recognition of minor histocompatibility antigens (MiHA) by donor-
derived CD8+ T cells. Therefore, monitoring of multiple MiHA-specific CD8+ T cell 
responses may prove to be valuable for evaluating the efficacy of allogeneic SCT. 
In this study, we investigated the use of the combinatorial encoding MHC multi-
mer technique to simultaneously detect MiHA-specific CD8+ T cells in peripheral 
blood of SCT recipients. Feasibility of this approach was demonstrated by apply-
ing dual-color encoding MHC multimers for a set of 10 known MiHA. Interestingly, 
single staining using a fluorochrome- and Qdot-based five-color combination 
showed comparable results to dual-color staining for most MiHA-specific CD8+ T 
cell responses. In addition, we determined the potential value of combinatorial 
encoding MHC multimers in MiHA identification. Therefore, a set of 75 candidate 
MiHA peptides was predicted from polymorphic genes with a hematopoietic 
expression profile and further selected for high and intermediate binding affinity 
for HLA-A2. Screening of a large cohort of SCT recipients resulted in the detec-
tion of dual-color encoded CD8+ T cells following MHC multimer-based T cell 
enrichment and short ex vivo expansion. Interestingly, candidate MiHA-specific 
CD8+ T cell responses for LAG3 and TLR10 derived polymorphic peptides could be 
confirmed by genotyping of the respective SNPs. These findings demonstrate the 
potency of the combinatorial MHC multimer approach in the monitoring of CD8+ 
T cell responses to known and potential MiHA in limited amounts of peripheral 
blood from allogeneic SCT recipients.
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Introduction
In HLA-identical allogeneic stem cell transplantation (SCT), alloreactive CD8+ T 
cells specific for minor histocompatibility antigens (MiHA) play a pivotal role in 
graft rejection, graft-versus-host disease (GVHD) and the curative graft-versus-
tumor (GVT) response. Several MiHA have been molecularly defined with the 
potential to induce a GVT response without inducing GVHD, such as HA-1 1-4, 
LRH-1 5 and ACC-1 6. 
Although MiHA can be regarded as the most dominant antigens in GVT immu-
nity, the CD8+ T cell response rate towards these antigens has not been followed 
extensively in transplanted patients. Furthermore, most analysis focused on the 
detection of CD8+ T cell responses to single MiHA epitopes using conventional 
techniques such as single-tetramer staining or the ELISPOT assay.Fluorescent 
labeled peptide-major histocompatibility antigen (MHC) complexes, known as 
MHC multimers, are excellent reagents to monitor MiHA-specific T cell responses 
after SCT and donor lymphocyte infusion (DLI) in peripheral blood of transplanted 
patients. Especially, the recently developed combinatorial encoding technique 
using dual-color encoded MHC multimers is a very attractive approach to accu-
rately detect multiple MiHA-specific T cells in one sample 7. The principle of this 
method relies on the flow cytometric detection of a single T cell population that 
is stained with different fluorochrome-labeled MHC multimers. This dual-color 
encoded MHC multimer approach has the ability to detect up to 15 different T cell 
populations when using 6 different fluorochromes 7. Therefore, a key advantage 
compared to single-tetramer staining is that the amount of patient peripheral 
blood cells needed is equal to just one labeling, making the technique very suit-
able when dealing with limited amounts of patient material. The combinatorial 
encoding approach can accommodate a wide range of different peptide-MHC 
multimers for several HLA molecules, which can be readily produced through 
UV-mediated ligand exchange 8;9. The versatility of these two methods makes the 
combinatorial encoding MHC multimer technique an excellent monitoring tool 
for detecting MiHA-specific CD8+ T cell responses against a panel of known MiHA. 
Furthermore, another potential application of the combinatorial encoding MHC 
multimer approach could be its use to identify new MiHA. Recently, the value of 
the method for antigen discovery has been demonstrated for the identification 
of melanoma-associated T cell epitopes 7. Here, we explored the use of the com-
binatorial MHC multimer technique for the detection of CD8+ T cell responses in 
transplanted patients against candidate MiHA defined through a reverse immu-
nology approach. Interestingly, we detected peptide-specific dual-tetramer posi-
tive CD8+ T cells against 8 out of 75 HLA-A2 binding peptides that were predicted 
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in silico from polymorphic hematopoietic-specific genes.
Collectively, our results illustrate that the combinatorial MHC multimer method 
is a suitable technique to analyze patients after SCT and DLI for the concurrent 
occurrence of MiHA-specific CD8+ T cells targeting known MiHA or candidate 
MiHA identified by reverse immunology approaches.
Materials and Methods
Patient material
All patients in this study were admitted in our transplantation program from May 
1996 onwards. Patients underwent HLA identical allogeneic SCT using a T cell-
depleted stem cell graft containing a fixed number of 0.5 x 106 T cells/kg body 
weight. Several patients also underwent subsequent prophylactic or therapeutic 
DLI. Peripheral blood samples of patients were collected after written informed 
consent in ongoing clinical stem cell transplantation protocols approved by the 
Radboud University Nijmegen Medical Centre (RUNMC) Institutional Review 
Board.  
Cell isolation and culture 
CD8+ T cell bulk cultures were generated from peripheral blood mononuclear cells 
(PBMC) obtained after SCT and cultured in Iscove’s modified Dulbecco’s medium 
(IMDM; Invitrogen, Carlsbad, CA) supplemented with 10% human serum (HS; 
Sanquin blood bank, Nijmegen, the Netherlands). After initial stimulation, 100 
IU/ml IL-2 (Chiron, Emeryville, CA) and 10 ng/ml IL-15 (BD) were added at day 2. 
Flow cytometric analysis was performed at day 7. All Epstein-Barr virus lympho-
blastoid cell lines (EBV-LCL) were cultured in IMDM/10% fetal calf serum (FCS; 
Integro, Zaandam, The Netherlands). 
SNP genotyping assays
Genotyping of HLA-matched SCT donor-recipient pairs for known MiHA was con-
ducted using the KASPar assay, a fluorescence-based competitive allele-specific 
PCR that utilizes non-labeled primers (KBioscience, Herts, UK). Details of the pro-
cess and primer sequence can be obtained from KBioscience. SNP genotyping 
for verification of immunogenic epitopes was performed by Taqman SNP geno-
typing according to manufacturer’s recommendation (Applied Biosystems [ABI], 
Foster City, CA). Briefly, 10ng of gDNA was amplified using ABI pre-designed SNP 
genotyping assays. 5ul of gDNA (2ng/µl) was combined with 12.5µl of TaqMan 
Universal PCR Master Mix (2x) and 1.25 µl appropriate genotyping assay reagent 
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containing specific forward and reverse primers and specific FAM/VIC probes 
(20x) in a total reaction volume of 25µl. Reactions were run on the ABI 9700 
thermal cycler in a 96 well format for 1 cycle at 95˚C x 10 minutes followed by 40 
cycles at 92˚C x 15 seconds, 60˚C x 1 minute. A post-PCR plate read for FAM/VIC 
was performed on the ABI 9700HT and genotype calls were generated using SDS 
2.3 software (ABI).
Prediction of HLA-A2-restricted candidate MiHA
To predict HLA-A2-restricted MiHA within hematopoiesis restricted gene prod-
ucts, adaptable software was written in the Java language. This software utilizes 
the Entrez retrieval system (http://www.ncbi.nlm.nih.gov/entrez) within the 
NCBI’s GenBank sequence repository to extract from a database of all known 
human amino acid sequences (ftp://ftp.ncbi.nlm.nih.gov/genomes/H_sapiens/
protein) the accession numbers of amino acid variations derived from allelic non-
synonymous SNPs, as represented in GenBank’s dbSNP database. The software 
algorithm then parses the retrieved files of polymorphisms and implements the 
predictive HLA-binding algorithm described by Parker et al. 10 on peptides from 
these files that encompass the polymorphism within a nine- or ten-mer offset 
window, using HLA-A2-specific coefficient files from the BIMAS website (http://
bimas.dcrt.nih.gov/molbio/hla_bind/hla_motif search_info.html). Algorithmic 
input of gene expression data for hematopoiesis biased genes included, but 
were not limited to, the following resources: downloadable gene expression data 
sets from the Whitehead Institute for Genomics Research pertaining to expres-
sion differences between ALL and AML 11, genes upregulated in ALLs carrying 
a chromosomal translocation involving the mixed-lineage leukemia gene (MLL) 
(http://www-genome.wi.mit.edu/cgi-bin/cancer/datasets.cgi); diffuse large 
B-cell lymphoma gene expression profiling data sets from the Lymphoma/Leuke-
mia Molecular Profiling Project website (http://llmpp.nih.gov/); a hematopoietic 
stem cell database at the Stem Cell Database website (http://stemcell.princeton.
edu/); and the human HapMap project at http://www.hapmap.org. In addi-
tion, manually retrieved accession numbers of hematopoietically biased genes 
described in the current literature represented a major source of input data for 
the algorithm. 
Generation of peptide-MHC multimers
Peptide-MHC multimers were produced by UV-mediated ligand exchange as 
previously described by Rodenko et al. 9. The ligand used for the construction 
of MHC class I was a UV-sensitive peptide containing a (2-nitro)phenylglycine 
residue which is cleaved upon UV irradiation, making the MHC molecule peptide-
receptive and capable of being loaded with epitopes of choice. The expression, 
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purification and refolding of MHC heavy and light chains were performed as 
described by Gorboczi et al.12.
Peptide-HLA-A2-based affinity ELISA
Affinity of the predicted MiHA epitopes to HLA-A2 was tested by an HLA-A2 affin-
ity streptavidin-based sandwich ELISA described by Rodenko et al. [9]. Briefly, 
96-well plates were coated with streptavidin to which biotinylated monomers, 
containing all different predicted peptides, were added. Next, an HRP-conju-
gated anti-β2m antibody was added, binding to all stable MHC class I molecules. 
2,2’-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid) was added and the green-
colored oxidation product was measured at OD 414 nm.
Enrichment of peptide-specific T cells
PBMCs were obtained from CMV+ and EBV+ buffy coats (Sanquin blood bank, 
Nijmegen, the Netherlands) or from patients after SCT or DLI. All enrichments 
were performed on cryopreserved material. PBMC were stained with PE-labeled 
MHC multimers (1 µl of each individual PE-multimer for 107 PBMC) for 1 hour 
at 4° C. In case of the CMV/EBV enrichment a total of 2 µl PE-multimer for each 
specific epitope was added, while in case of enrichment for the candidate MiHA 
panel a 79 µl PE-multimer mix consisting of 1 µl of each candidate and control 
MiHA epitope was added. Subsequently, cells were washed twice, and incubated 
with 20 µl magnetic beads coated with anti-PE antibody (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). Magnetically labeled cells were isolated by MACS 
(Miltenyi Biotech) using a MS Column following the manufacturer’s protocol. 
Eluted cells were washed and resuspended in IMDM supplemented with 10% 
human serum, 100 IU/ml IL-2 and 10 ng/ml IL-15 (BD). On day 1, 2x104 irradi-
ated (60Gy) autologous feeder cells were added along with 2,500 CD2/CD3/CD28 
loaded anti-Biotin MACSiBead Particles (Miltenyi Biotec). On day 8, to prevent 
overgrowth by CD4+ T cells, T-cell cultures were depleted of residual CD4+ T cells 
via the addition of 50 μl of BD IMag anti-human CD4 particles (BD Biosciences) 
per 107 total cells and treatment per manufacturers’ protocol. Cultures were split 
and refreshed biweekly with medium plus cytokines. After 2-3 weeks, cell cul-
tures were counted and tested for the presence of peptide-specific CD8+ T cells 
using combinatorial MHC multimer staining.
Combinatorial MHC multimer staining
Combinatorial MHC multimer stainings were performed on either thawed PBMC 
samples or ex vivo expanded T cell cultures. For this, 1x106 PBMCs or 1-5x105 
cultured T cells were incubated with 1 μl of every single MHC multimer (final 
concentration 2 μg/ml per MHC based on initial monomer concentration) in a 
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total volume of 80 μl for 15 min at room temperature in the dark. Subsequently, 
an antibody mixture consisting of 0.8 μl CD8-Alexa700 (Invitrogen, Carlsbad, CA), 
4 μl CD4-FITC (Beckman Coulter), 2 μl CD14-FITC (BD), 2 μl CD19-FITC (Dako), 6 
μl CD16-FITC (BD) was added, and cells were incubated for 30 min at 4°C. Finally, 
cells were washed twice and Sytox Blue (Invitrogen) was added at a final dilu-
tion of 1:5000 to allow dead cell exclusion. Data acquisition was performed on 
a Cyan-ADP analyzer (Beckman Coulter) and analyzed by Kaluza 1.1 software 
(Beckman Coulter). Antigen-specific T cells were quantified using an identical gat-
ing strategy as described by Hadrup et al. 7 and Velthuis et al 13. First, viable Sytox 
Blue-negative, single-cell lymphocytes were gated. Subsequently, CD8-positive 
and FITC (CD4, CD14, CD16, CD19) negative cells were selected. MHC multimer 
positive cells were gated as CD8+ T cells positive in two MHC multimer channels 
(APC, PE, Qdot605, Qdot655, Qdot705 and Qdot800) and negative in the four 
other MHC multimer channels. In order to validate dual-color coded CD8+ T cells, 
PBMC were cultured in IMDM 10% HS and stimulated with irradiated EBV-LCL 
expressing the appropriate HLA restriction molecule. After initial stimulation, 100 
IU/ml IL-2 (Chiron) and 10 ng/ml IL-15 (BD) was added at day 2. Primary T cell 
cultures were analyzed by flow cytometry at day 7. 
Results
Immunomonitoring of MiHA-specific CD8+ T cell responses using 
combinatorial MHC multimer staining
The success rate of immunological responses in patients post-SCT and DLI can 
be assessed by measuring the MiHA-specific T cells present in the blood of the 
patient 3-5.  Since patient material is often in short supply, we developed a tech-
nique that can screen for multiple MiHA-specific T cells in a limited amount of 
patient follow-up material. This technique makes use of dual-color-encoded MHC 
multimers to detect multiple antigen-specific T cells in one sample 7;14. In order to 
set up such a MiHA-multimer kit, we have chosen a set of 10 MiHA, each being 
encoded by two different fluorochromes coupled to an MHC multimer containing 
an individual peptide (Table 1).  
To determine whether the developed MiHA-multimer kit is suitable for the detec-
tion of multiple MiHA-specific T cells in blood samples of transplanted patients, 
we selected a cohort of patients transplanted with partially T-cell depleted stem
cell grafts from HLA- identical sibling donors. These patients also received pre-
emptive DLI if they did not develop significant GVHD after SCT. These patients 
and their respective donor were typed for MiHA mismatches using fluorescence-
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Table 1. MHC multimers and combinatorial encoding scheme as assembled in 
MiHA-multimer kit. 
MiHA HLA Peptide 
sequence
Reference Fluorochrome code
SMCY A2 FIDSYICQV 15 PE APC
HY B7 SPSVDKARAEL 16 PE Qdot605
HA-1 A2 VLHDDLLEA 1 PE Qdot655
LRH-1 B7 TPNQRQNVC 5 PE Qdot705
ADIR A2 SVAPALALAFPA 17 APC Qdot605
ACC-1 A24 DYLQYVLQI 6 APC Qdot655
HA-8 A2 RTLDKVLEV 18 APC Qdot705
SP110 A3 SLPRGTSTPK 19 Qdot605 Qdot655
PANE-1 A3 RVWDLPGVLK 20 Qdot605 Qdot705
HA-2 A2 YIGEVLVSV 21; 22 Qdot655 Qdot705
based competitive allele specific PCR (Table 2). The selected SCT recipients 
were mismatched for one or two MiHA with their HLA-identical donor and no 
tetramer+ T cells were observed in pre-SCT recipient PBMC (Table 2). For the dis-
parate MiHA a dual-color tetramer analysis was performed using both APC and 
PE labeled tetramers (Figure 1A). Since double positive events were scored, the 
dual-color tetramer stainings result in accurate detection of low frequency MiHA-
specific CD8+ T cells 14, even at relatively late time points post-SCT. Specific detec-
tion of these low frequency MiHA-specific-CD8+ T cell populations was verified 
after in vitro stimulation of peripheral blood mononuclear cells (PBMC) samples 
with MiHA peptide-pulsed EBV-LCL (Figure 1A). 
Knowing the MiHA-specific T cell status of the patient samples, we tested a 
second cryopreserved PBMC sample again by the new five-color combinatorial 
encoding MiHA-multimer kit (Figure 1B). Results of a representative patient (i.e. 
UPN348) can be seen in Figure 2A. For this patient’s cryopreserved PBMC sample 
at 31 weeks post-SCT, we observed 0.11% HY.B7-tetramer+ cells using dual-
color staining (Figure 1A), compared to 0.04% by the five-color MiHA-multimer 
kit (Figure 1B and 2A).  Specific detection of CD8+tetramer+ T cells was verified 
after in vitro stimulation of PBMC samples with HY-B7 peptide-pulsed EBV-LCL, 
showing 0.17% HY-B7-tetramer+ cells with the MHC-multimer kit (Figure 2B) 
compared to 0.15% by dual-color staining (Figure 1A). All different MiHA-specific 
CD8+ T cells found by dual-color staining could also be found in the thawed PBMC 
samples analyzed by the new five-color combinatorial encoded MiHA-multimer 
assay, although the frequency of MiHA-specific cells was somewhat lower 
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Figure 1. Detection of MiHA-specific CD8+ T cells in peripheral 
blood of patients after SCT and DLI.
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(A) PBMC collected post SCT stained with PE- and APC-conjugated tetramers, 
CD8 AlexaFluor 700, CD4-, CD14-, CD16- and CD19-FITC and Sytox Blue. The 
remaining PBMCs were stimulated once with the MiHA peptide pulsed (10 
μM) EBV-LCL of the donor and assayed on day 7 for tetramer+ CD8+ T cells.  (B) 
PBMC stained with combinatorial encoded MiHA multimers, CD8 AlexaFluor 
700, CD4-, CD14-, CD16- and CD19-FITC and Sytox Blue. Subsequently, cell 
populations were analyzed on the Cyan cytometer and re-analyzed by Kaluza 
1.1. Cells were gated on CD8+FITC-Sytox Blue- lymphocytes, and the percent-
age of tetramer+ cells among CD8+ T cells is depicted. 
(Table 2). These data demonstrate that circulating MiHA-specific CD8+ T cells can 
be detected concurrently using a combinatorial encoding MiHA-multimer kit, 
making this a valuable tool for immunomonitoring of SCT recipients using a lim-
ited amount of patient material.
Identification of novel candidate MiHA by reverse immunology 
Next, we studied the feasibility of the combinatorial encoding MHC-multimers 
as an identification tool for the discovery of novel MiHA. In order to predict HLA-
A2-restricted candidate MiHA within hematopoietically restricted gene products, 
we developed and tested an adaptable computer algorithm. An arbitrary mini-
mum predicted halftime of dissociation (T
(½)
) of 30 seconds was set for candidate 
HLA-A2 restricted MiHA, based on corroboration with known HLA-A2 peptide and 
MiHA binding affinities, which indicated that a peptide with moderate HLA-A2 
binding affinity would exhibit a predicted T
(½)
 of > 30 seconds. Subsequently, can-
didate MiHA were further selected, based upon either observed allele frequen-
cies in Caucasians or allele frequencies reported by dbSNP/HapMap.  Typically, 
only those candidate MiHA that had a reported allele frequency for the candidate 
MiHA-positive allele between 15% and 46% were pursued as candidate MiHA, 
since MiHA with frequencies within this range yield a theoretical clinical appli-
cability of more than 20% in HLA-A2 matched unrelated recipient-donor pairs.
Peptides of the predicted candidate MiHA were synthesized and HLA-A2 
monomers were generated using the UV-mediated ligand exchange method 9. 
All monomers were tested for stable binding of the predicted epitope using an 
ELISA-based HLA-affinity assay 9, which revealed that 75 out of 107 predicted 
potential MiHA bind HLA-A2 with high (OD ≥1.25) or intermediate (OD 0.4-1.24) 
affinity (Figure 3). As a positive control for successful peptide exchange, viral (EBV, 
CMV, FLU) HLA-A2 specific peptides were used, as well as negative controls of not 
applying UV light or not adding any peptide at all (data not shown). Peptides with 
low affinity to HLA-A2 (OD≤0.4) were discarded from further experiments and 
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Figure 2. Detection of peptide-specific T cells by the combinato-
rial encoding MiHA-multimer assay. 
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(A) Ten different flow cytometric dot plots showing thawed PBMC of rep-
resentative patient UPN348, stained with the combinatorial encoded MiHA-
multimer assay using the peptide set as described in Table 1. The combina-
tion of multimers coupled to PE and to Qdot605 shows a positive response, 
corresponding to multimer-SMCY.A2+ T cells. Cells were stained with MiHA 
multimers, CD8 AlexaFluor 700, CD4-, CD14-, CD16- and CD19-FITC and Sytox 
Blue. Subsequently, cell populations were analyzed by flow cytometry. Cells 
were gated on CD8+FITC-Sytox Blue- lymphocytes and corrected for single, 
triple or quadruple multimer-positive cells. The percentage of multimer+CD8+ 
T cells is depicted. (B) Ten different dot plots showing PBMC of representa-
tive patient UPN348 after culturing with SMCY.A2-peptide pulsed donor EBV-
LCL. Only the response observed in non-cultured PBMC show an increase of 
multimer-SMCY.A2+ T cells. Staining and analysis was performed as described 
under (A). 
MHC-only monomers harboring peptides that bound with high or intermediate 
strength were used for multimerization. This set of MHC multimers was color 
coded, resulting in 5 pools of 15 different MHC multimers and 1 pool of 4 differ-
ent MHC multimers (Supplemental Table S1). In addition to the predicted poten-
tial MiHA, pool A-D contained control MHC multimers for the MiHA HA-1.A2, 
HA-2.A2, HA-8.A2 and SMCY.A2. 
Concurrent detection of multiple peptide-specific CD8+ T cells after 
enrichment and expansion
To investigate whether peptide-specific CD8+ T cells could be found for the pre-
dicted MiHA epitopes that had high or intermediate affinity to HLA-A2, a cohort 
of 31 patients was selected for screening of the follow-up material collected after 
DLI. Approximately half of the patients selected, developed acute GVHD after 
SCT and/or acute or chronic GVHD after DLI. These observations show the pres-
ence of an allo-response that might have been mediated by MiHA-specific T cells 
making these patients attractive to look for candidate MiHA. To detect epitope-
specific-CD8+ T cells in the patient PBMC collected after DLI (average 18 weeks 
post DLI) we first enriched the samples using PE-labeled MHC multimers. Figure 
4 shows an example of an enriched culture containing low frequency CD8+ T cells 
specific for the HLA-A2-restricted EBV (GLCTLVAML) and CMV (NLVPMVATV) epi-
topes (respectively 0.03% and 0.38%) pre-culture. MHC multimer-based enrich-
ment and subsequent expansion yielded a CD8+ T cell population consisting of 
0.85% EBV-TET+ and 11.5% CMV-TET+ cells  after 16 days of culturing. This shows 
the potential of this method to increase low frequency T cells to sufficient cell 
numbers of multiple specificities for further experiments.
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To detect multiple MiHA peptide-specific CD8+ T cells against our pre-selected 
panel of 75 candidate HLA-A2-restricted peptides, we performed enrichments 
on 31 different patient samples of which 17 resulted in sufficient cell numbers 
for analysis. We detected peptide-specific CD8+ T cells in cultures of 5 differ-
ent patients (Table 3). Notably, we detected a CD8+ T cell response against the 
known MiHA SMCY.A2. Additional patients were transplanted with donor grafts 
mismatched for any of the control HLA-A2 MiHA included in the analysis as was 
determined by SNP genotyping. However, we did not observe specific T-cell 
responses for these MiHA. Results of a representative patient (UPN665) are 
shown in Figure 5A. 
Figure 3. ELISA-based HLA-A2 affinity assay for 107 in silico pre-
dicted potential MiHA. 
HLA-A2 monomers containing UV degradable peptide were exchanged with 
107 predicted MiHA peptides and HLA-A2 binding affinity was tested. Results 
show 32 low binders (OD≤0.39), 33 intermediate binders (OD 0.4-0.124) and 
42 high binders (OD≥1.25). Data are depicted as mean of triplicate wells.
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Figure 4. PBMC of a healthy donor enriched for virus-specific T 
cells. 
Peripheral blood of an HLA-A2+ healthy donor was enriched for EBV- and 
CMV-specific CD8+ T cells. Before culture there were low amounts of EBV- and 
CMV-specific CD8+ T cells present, which showed an increase after enrich-
ment and 16 days of culture.  Cells were stained with tetramers coupled to PE 
and gated on CD8+tetramer+. Analysis was performed on the Cyan cytometer. 
PBMC from this patient obtained at 14 weeks post DLI were enriched, expanded 
and analyzed for all 6 combinatorial MHC-multimer encoding pools. In pool A, two 
specific T cell populations were found. The combination of multimers coupled 
to APC and Qdot705 showed a positive response of 0.55% dual-color tetramer 
positive T cells, recognizing the WT-1-derived epitope RMFPNAPYL. In addition, 
the combination of multimers coupled to Qdot605 and Qdot655 showed a posi-
tive response of 0.07% dual-color tetramer positive T cells, recognizing the BPI-
derived epitope KLQPYFQTL. 
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Table 3. Percentage of dual-color tetramer+CD8+ T cells in PBMC samples of trans-
planted patients screened after MHC-multimer based enrichment and short-term 
expansion.
Gene Candidate 
MiHA
UPN 
466
UPN 
541
UPN 
655
UPN 
407
UPN 
427
WT-1 RMFPNAPYL 0.55a
PBPI KLQPYFQTL 0.28 0.09 0.07 0.04
LAG3 LTLGVLSLL 0,19b
IGLL1 LMNDFYLGI 0.01
GPR109b FLLEFLLPL 0.23 0.04
CCRL2 ILATLPEFV 0.07
CARD8 YLVPSDALL 0,01b
TLR10 IQLPHLKTL 0.47
SMCY.A2 FIDSYICQV 0,07b
aKnown WT-1 epitope. 
bT cell response confirmed by SNP genotyping.
To verify whether the observed T cell responses correlate with SNP mismatches 
at the DNA level, we performed allele specific genotyping of donor and recipient 
for the SNPs corresponding to the immunogenic epitopes found in the combi-
natorial MHC-multimer staining. Although several mismatched SNPs between 
donor and recipient were found, only 2 out of 8 epitopes found in the screen-
ing corresponded with their respective SNP genotype (underlined in Table 3). 
These two candidate MiHA (i.e. LAG3 derived LTLGVLSLL and CARD100 derived 
YLVPSDALL), as well as epitopes to which a high response was observed (epitopes 
derived from WT-1 and TLR10), were selected for further experiments. However, 
dual-color tetramer stainings using PE- and APC-conjugated tetramers could 
not confirm specific CD8+ T cells for the found peptides in non-cultured PBMC. 
Although we were not able to verify responses found in the analysis, the use of 
combinatorial encoding MHC multimer panels proved useful for high throughput 
concurrent detection of specific CD8+ T cells against a large panel of candidate 
MiHA peptides. 
Discussion
The monitoring of multiple MiHA-specific T cells in vivo can give important 
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Figure 5. Detection of multiple peptide-specific CD8+ T cells after 
enrichment of patient PBMC.
Fifteen different dot plots showing multimer-enriched PBMC of representa-
tive patient UPN665 stained with the combinatorial encoded MiHA assay 
using the multimers of pool A. Epitope-specific T cells were detected for 
RMFPNAPYL (APC and Qdot705) and KLQPYFQTL (Qdot605 and Qdot655). 
In addition to double positive cells, single positive cells for either APC, 
Qdot605, Qdot655 or Qdot705 are visible in their respective channels. Cells 
were stained with multimers, CD8 AlexaFluor 700, CD4-, CD14-, CD16- and 
CD19-FITC and Sytox Blue. Subsequently, cell populations were analyzed by 
flow cytometry. Cells were gated on CD8+FITC-Sytox Blue- lymphocytes and 
corrected for single, triple, quadruple or quintuple multimer positive cells. 
The percentage of tetramer+CD8+ T cells is depicted in the dot plots.  
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additional information on the clinical response and might lead to more insight
into the therapeutic applicability of specific MiHA. In this study, we report a novel 
approach for the monitoring of MiHA-specific T cells in a limited number of PBMC 
from patients after SCT and DLI, which we believe is of great value for the immu-
nomonitoring of SCT recipients. Cryopreserved PBMC samples from patients 
who underwent partially T cell depleted allogeneic SCT, in some cases followed 
by DLI, were simultaneously analyzed for 10 different MiHA-specific T cells. In 
all 6 patients analyzed with the set of combinatorial encoded MHC multimers, 
MiHA-specific T cells could be detected. These MiHA-specific T cells proliferated 
upon stimulation with MiHA-peptide, showing a peptide-dependent response. 
To confirm functionality of the MiHA-specific T cells, proliferation upon stimula-
tion with endogenously processed peptides should be measured. The specific-
ity of the cells found in the analysis corresponded to the results obtained by 
conventional T cell screenings. The use of a combinatorial MiHA-multimer kit 
gives a quick overall view of numerous MiHA-specific T cells within patient blood 
samples post SCT. Moreover the amount of patient material used is equal to what 
conventional screenings use for just one specific staining. This method already 
has been applied as a tool for the simultaneous detection of autoreactive CD8+ 
T cells in blood 13 and now we show that it is a valuable tool for the concur-
rent detection of multiple MiHA-specific T cells after allogeneic SCT and DLI. The 
MiHA-detection kit used in this study already covers 10 prevalent MiHA, though 
flexibility of the technique allows further expansion of the MiHA set. However, 
the current technical limitations regarding the synthesis of HLA-monomers pre-
vent implementation of certain MiHA, such as MiHA presented in HLA-B44. The 
MiHA-detection kit can be expanded by multimers coupled to additional fluoro-
phores such as Qdot800 or Qdot565 and Qdot585. It should be noted that these 
three fluorophores have a low intensity for which should be corrected when 
combining with other fluorophores 7. 
Because of the techniques’ potential to screen for large numbers of different spe-
cific T cells 13 and its success in the identification of melanoma-associated T cell 
epitopes 7, we tested the potential of the combinatorial encoding approach to 
identify new MiHA that were predicted from a set of polymorphic genes expressed 
by the hematopoietic system. For the development of adjuvant tumor-specific 
immunotherapy after SCT it is important to enlarge the spectrum of molecularly 
identified MiHA that are selectively expressed in the hematopoietic system and 
in hematologic malignancies. Investing in new high throughput methods for 
MiHA identification is in our opinion critically important. The recently developed 
technique using dual-color-encoded MHC multimers to detect multiple antigen 
specific T cells in one sample 7, was tested for this purpose. The combinatorial 
encoding approach already led to the discovery of a new melanoma-associated 
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epitope in a screening of T cells 7, showing its applicability in these kind of studies. 
Our present article describes the prediction of MiHA from genes with a hemato-
poietic restricted expression profile and the verification of these MiHA by screen-
ing for MiHA specific CD8+ T cells in patient PBMC following MHC multimer-based 
enrichment and a short-term expansion. A similar reverse immunology approach 
of predicting MiHA has already yielded a set of novel MiHA originating from the 
Y chromosome presented in HLA-A2 23. These male-specific MiHA were verified 
by means of ELISPOT showing some of these MiHA to be even more immuno-
genic than the well known SMCY.A2 male specific MiHA. Although this indicates 
that predicting MiHA can yield actual functional MiHA, this set of MiHA is not of 
therapeutic interest since it is not to be expected that these MiHA have a hema-
topoietically restricted expression profile. 
Here we performed an analysis using combinatorial encoded multimers specific 
for 75 different epitopes. Of the 31 enriched cultures we screened 17 and found 
multimer-positive T cells in 5 of the cultures. One of the specific T cell populations 
found was directed against the tumor associated antigen WT-1 for which specific 
T cells can be found in CML 24, MDS and AML patients 25;26. In the set of predicted 
candidate MiHA, the gene WT-1 was integrated because of the presence of SNP 
rs9332973 resulting in the substitution of a threonin for the alanin at position 6 
of the nonameric epitope. Multimers were made for both epitopes since they 
had high affinity to HLA-A2, however only the well known WT-1 epitope yielded 
an actual T cell response (0.55%) in patient UPN655 who was diagnosed with 
AML. Another epitope to which a high number of CD8+ T cells were observed 
was IQLPHLKTL derived from the gene TLR10, which could not be confirmed by 
genotyping of the respective recipient-donor pair. Interestingly, SNP rs11096955 
can also lead to the formation of the LQLPHLKTL epitope, which proved to have 
low affinity for HLA-A2 and was discarded for further experiments. However, the 
detected TLR10 peptide-specific T cells could be cross reactive between these two 
epitopes since the alternative amino acid is not present at the anchor side to the 
HLA molecule. Though several specific responses were detected in the screen-
ing of the enriched patient PBMC, none of these responses could be validated 
by conventional tetramer staining or culture methods. Known HLA-A2-restricted 
MiHA (i.e. HA-1, HA-2, HA-8 and SMCY) were added to the screening panel. How-
ever, we only found 1 response for the control MiHA SMCY.A2 (Table 3). DNA of 
all patients and their corresponding donors used in the screening was genotyped 
for the control MiHA. Mismatches for these MiHA were detected in 6 out of 17 
screened patients. Conventional tetramer staining of the PBMC of these patients 
followed by tetramer validation after stimulation with peptide pulsed EBV-LCL 
revealed MiHA T cell responses in 4 out of the 6 mismatched patients of which 3 
were not found by screening with the combinatorial encoding set.
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A potential benefit of our approach is that the epitopes were predicted from a 
set of genes with a restricted expression pattern, which gives an advantage when 
looking for tissue restricted MiHA. However, there are critical limitations of our 
algorithmic model and selection criteria for novel candidate MiHA. While the 
majority of MiHA identified thus far are derived from allelic SNPs that generate 
an amino acid disparity (i.e, nonsynonymous SNPs) between donor and recipient, 
other variables may mask the presence of MiHA or otherwise confound such 
analyses. Many MiHA are likely to be encoded by polymorphic cDNAs or ESTs 
that are simply not yet represented in GenBank as translated polypeptides, such 
as protein isoforms derived from relatively obscure alternative splicing variants 
3;4;20, cryptic translation products 27-29, or perhaps transposable elements (A.G.B. 
, manuscript in preparation). Another possibility is that even though a MiHA-
encoding gene is represented in GenBank, its relevant polymorphisms may 
not yet be fully characterized. Further complicating the algorithmic prediction 
of MiHA peptides is the demonstration that in certain instances, peptides can 
be excised and spliced in the proteasome prior to presentation by MHC 19;30. 
Another important caveat is that the selection of T cells specific for candidate 
antigens with MHC-multimer methodologies or T cell stimulation assays (i.e., 
ELISA, ELISPOT) with exogenously pulsed candidate antigenic peptides based on 
cDNA sequence occurs in the absence of knowledge of post-translational modi-
fications, which can be critical to determination of immunogenicity 31. Should 
reverse immunology approaches be further employed for the discovery of MiHA 
relevant to the immunotherapy of hematologic malignancies, it will be essential 
that discovery efforts are focused on those candidate MiHA polymorphisms with 
allele frequencies that ensure frequent donor/recipient disparity. Although prog-
ress has been made over the years to optimize epitope prediction by reversed 
immunology, there a still some hurdles to take before this can be implemented 
into a, preferably high throughput method to identify new clinical relevant MiHA. 
The concurrent detection of multiple epitope-specific CTL as described in this 
manuscript is a step forward in this process but the identification of novel MiHA 
by more conventional approaches should still be taken into consideration. These 
approaches make use of CTL clones generated from post-SCT recipients and 
recently genome-wide association study (GWAS) has been used for identifica-
tion of the epitope recognized by these CTL 32;33. The recent addition of several 
new MiHA identified by GWAS shows the high feasibility of this approach. Nev-
ertheless also this approach still is laborious as well as uncertain since clinical 
relevance of the discovered MiHA can only be studied in great detail after the 
identification has finished. 
In conclusion, this study describes the use of combinatorial encoding MHC-mul-
timers for the concurrent detection of MiHA-specific T cells after SCT and DLI. 
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Feasibility of this approach was demonstrated by applying five-color encoded 
MHC multimers for a set of 10 known MiHA. In addition, the amount of patient 
material required is far less than for conventional, single tetramer screening. In 
addition, we determined the potential value of combinatorial encoding MHC 
multimers in MiHA identification. A set of 75 candidate MiHA peptides was 
predicted from polymorphic genes with a hematopoietic expression profile. 
Monomer-enriched patient PBMC were screened for candidate MiHA and several 
epitope-specific T cells were detected during the screening. Although none of 
these epitope-specific T cells could be confirmed by conventional techniques, 
the concurrent detection of MiHA specific CD8+ T cells by combinatorial encoding 
shows potential as a tool for the detection of multiple T cell responses. 
Acknowledgements
The authors thank Ton Schumacher (Division of Immunology, The Netherlands 
Cancer Institute, The Netherlands) for providing vital methodology and help with 
the production of the MHC multimers.  
Proefschrift Broen_2.indd   129 18-3-2012   15:42:25
130
CHAPTER 5
2003;197:1489-1500.
7. Hadrup SR, Bakker AH, Shu CJ, Andersen 
RS, van VJ, Hombrink P, Castermans E, 
Thor SP, Blank C, Haanen JB, Heemskerk 
MH, Schumacher TN. Parallel detection 
of antigen-specific T-cell responses by 
multidimensional encoding of MHC 
multimers. Nat.Methods 2009;6:520-526.
8. Bakker AH, Hoppes R, Linnemann C, 
Toebes M, Rodenko B, Berkers CR, Hadrup 
SR, van Esch WJ, Heemskerk MH, Ovaa H, 
Schumacher TN. Conditional MHC class I 
ligands and peptide exchange technology 
for the human MHC gene products HLA-A1, 
-A3, -A11, and -B7. Proc.Natl.Acad.Sci.U.S.A 
2008;105:3825-3830.
9. Rodenko B, Toebes M, Hadrup SR, van 
Esch WJ, Molenaar AM, Schumacher TN, 
Ovaa H. Generation of peptide-MHC class 
I complexes through UV-mediated ligand 
exchange. Nat.Protoc. 2006;1:1120-1132.
10. Parker KC, Bednarek MA, Coligan JE. 
Scheme for ranking potential HLA-A2 
binding peptides based on independent 
binding of individual peptide side-chains. 
J.Immunol. 1994;152:163-175.
11. Armstrong SA, Staunton JE, Silverman LB, 
Pieters R, den Boer ML, Minden MD, Sallan 
SE, Lander ES, Golub TR, Korsmeyer SJ. 
MLL translocations specify a distinct gene 
expression profile that distinguishes a 
unique leukemia. Nat.Genet. 2002;30:41-
47.
12. Garboczi DN, Hung DT, Wiley DC. HLA-
A2-peptide complexes: refolding and 
crystallization of molecules expressed 
in Escherichia coli and complexed with 
single antigenic peptides. Proc.Natl.Acad.
Sci.U.S.A 1992;89:3429-3433.
13. Velthuis JH, Unger WW, Abreu JR, 
Duinkerken G, Franken K, Peakman M, 
Bakker AH, Reker-Hadrup S, Keymeulen 
B, Drijfhout JW, Schumacher TN, Roep 
BO. Simultaneous detection of circulating 
autoreactive CD8+ T-cells specific for 
different islet cell-associated epitopes 
using combinatorial MHC multimers. 
Diabetes 2010;59:1721-1730.
1. den Haan JM, Meadows LM, Wang W, 
Pool J, Blokland E, Bishop TL, Reinhardus 
C, Shabanowitz J, Offringa R, Hunt DF, 
Engelhard VH, Goulmy E. The minor 
histocompatibility antigen HA-1: a 
diallelic gene with a single amino acid 
polymorphism. Science 1998;279:1054-
1057.
2. Hambach L, Vermeij M, Buser A, Aghai Z, 
van der KT, Goulmy E. Targeting a single 
mismatched minor histocompatibility 
antigen with tumor-restricted expression 
eradicates human solid tumors. Blood 
2008;112:1844-1852.
3. Kircher B, Stevanovic S, Urbanek M, 
Mitterschiffthaler A, Rammensee HG, 
Grunewald K, Gastl G, Nachbaur D. 
Induction of HA-1-specific cytotoxic T-cell 
clones parallels the therapeutic effect of 
donor lymphocyte infusion. Br.J.Haematol. 
2002;117:935-939.
4. Marijt WA, Heemskerk MH, Kloosterboer 
FM, Goulmy E, Kester MG, van der Hoorn 
MA, van Luxemburg-Heys SA, Hoogeboom 
M, Mutis T, Drijfhout JW, Van Rood JJ, 
Willemze R, Falkenburg JH. Hematopoiesis-
restricted minor histocompatibility 
antigens HA-1- or HA-2-specific T cells can 
induce complete remissions of relapsed 
leukemia. Proc.Natl.Acad.Sci.U.S.A 
2003;100:2742-2747.
5. de Rijke B., van Horssen-Zoetbrood 
A, Beekman JM, Otterud B, Maas F, 
Woestenenk R, Kester M, Leppert M, 
Schattenberg AV, de WT, van de Wiel-
van Kemenade, Dolstra H. A frameshift 
polymorphism in P2X5 elicits an 
allogeneic cytotoxic T lymphocyte 
response associated with remission of 
chronic myeloid leukemia. J.Clin.Invest 
2005;115:3506-3516.
6. Akatsuka Y, Nishida T, Kondo E, Miyazaki M, 
Taji H, Iida H, Tsujimura K, Yazaki M, Naoe 
T, Morishima Y, Kodera Y, Kuzushima K, 
Takahashi T. Identification of a polymorphic 
gene, BCL2A1, encoding two novel 
hematopoietic lineage-specific minor 
histocompatibility antigens. J.Exp.Med. 
Reference list
Proefschrift Broen_2.indd   130 18-3-2012   15:42:25
131
CONCURRENT DETECTION  BY COMBINATORIAL ENCODING MULTIMERS
5
CH
A
PT
ER
minor histocompatibility antigen that is 
selectively expressed in B-lymphoid cells 
and B-CLL. Blood 2006;107:3779-3786.
21. den Haan JM, Sherman NE, Blokland E, 
Huczko E, Koning F, Drijfhout JW, Skipper 
J, Shabanowitz J, Hunt DF, Engelhard VH, . 
Identification of a graft versus host disease-
associated human minor histocompatibility 
antigen. Science 1995;268:1476-1480.
22. Pierce RA, Field ED, Mutis T, Golovina 
TN, Von Kap-Herr C, Wilke M, Pool J, 
Shabanowitz J, Pettenati MJ, Eisenlohr LC, 
Hunt DF, Goulmy E, Engelhard VH. The HA-2 
minor histocompatibility antigen is derived 
from a diallelic gene encoding a novel 
human class I myosin protein. J.Immunol. 
2001;167:3223-3230.
23. Ofran Y, Kim HT, Brusic V, Blake L, Mandrell 
M, Wu CJ, Sarantopoulos S, Bellucci R, 
Keskin DB, Soiffer RJ, Antin JH, Ritz J. Diverse 
patterns of T-cell response against multiple 
newly identified human Y chromosome-
encoded minor histocompatibility 
epitopes. Clin.Cancer Res. 2010;16:1642-
1651.
24. Wang ZD, Li D, Huang XJ. Graft-versus-
leukemia effects of Wilms’ tumor 1 
protein-specific cytotoxic T lymphocytes 
in patients with chronic myeloid leukemia 
after allogeneic hematopoietic stem 
cell transplantation. Chin Med.J.(Engl.) 
2010;123:912-916.
25. Keilholz U, Letsch A, Busse A, Asemissen 
AM, Bauer S, Blau IW, Hofmann WK, Uharek 
L, Thiel E, Scheibenbogen C. A clinical and 
immunologic phase 2 trial of Wilms tumor 
gene product 1 (WT1) peptide vaccination 
in patients with AML and MDS. Blood 
2009;113:6541-6548.
26. Scheibenbogen C, Letsch A, Thiel E, 
Schmittel A, Mailaender V, Baerwolf S, 
Nagorsen D, Keilholz U. CD8 T-cell responses 
to Wilms tumor gene product WT1 and 
proteinase 3 in patients with acute myeloid 
leukemia. Blood 2002;100:2132-2137.
27. Ho O, Green WR. Alternative translational 
products and cryptic T cell epitopes: 
expecting the unexpected. J.Immunol. 
14. Hadrup SR, Schumacher TN. MHC-based 
detection of antigen-specific CD8+ T cell 
responses. Cancer Immunol.Immunother. 
2010;59:1425-1433.
15. Meadows L, Wang W, den Haan JM, 
Blokland E, Reinhardus C, Drijfhout JW, 
Shabanowitz J, Pierce R, Agulnik AI, Bishop 
CE, Hunt DF, Goulmy E, Engelhard VH. 
The HLA-A*0201-restricted H-Y antigen 
contains a posttranslationally modified 
cysteine that significantly affects T cell 
recognition. Immunity. 1997;6:273-281.
16. Wang W, Meadows LR, den Haan 
JM, Sherman NE, Chen Y, Blokland E, 
Shabanowitz J, Agulnik AI, Hendrickson RC, 
Bishop CE, . Human H-Y: a male-specific 
histocompatibility antigen derived from 
the SMCY protein. Science 1995;269:1588-
1590.
17. van Bergen CA, Kester MG, Jedema I, 
Heemskerk MH, van Luxemburg-Heijs SA, 
Kloosterboer FM, Marijt WA, de Ru AH, 
Schaafsma MR, Willemze R, van Veelen 
PA, Falkenburg JH. Multiple myeloma-
reactive T cells recognize an activation-
induced minor histocompatibility 
antigen encoded by the ATP-dependent 
interferon-responsive (ADIR) gene. Blood 
2007;109:4089-4096.
18. Brickner AG, Warren EH, Caldwell JA, 
Akatsuka Y, Golovina TN, Zarling AL, 
Shabanowitz J, Eisenlohr LC, Hunt 
DF, Engelhard VH, Riddell SR. The 
immunogenicity of a new human minor 
histocompatibility antigen results from 
differential antigen processing. J.Exp.Med. 
2001;193:195-206.
19. Warren EH, Vigneron NJ, Gavin MA, Coulie 
PG, Stroobant V, Dalet A, Tykodi SS, Xuereb 
SM, Mito JK, Riddell SR, Van den Eynde 
BJ. An antigen produced by splicing of 
noncontiguous peptides in the reverse 
order. Science 2006;313:1444-1447.
20. Brickner AG, Evans AM, Mito JK, Xuereb 
SM, Feng X, Nishida T, Fairfull L, Ferrell 
RE, Foon KA, Hunt DF, Shabanowitz J, 
Engelhard VH, Riddell SR, Warren EH. 
The PANE1 gene encodes a novel human 
Proefschrift Broen_2.indd   131 18-3-2012   15:42:25
132
CHAPTER 5
2006;177:8283-8289.
28. Schwab SR, Li KC, Kang C, Shastri N. 
Constitutive display of cryptic translation 
products by MHC class I molecules. Science 
2003;301:1367-1371.
29. Yewdell JW, Anton LC, Bennink JR. Defective 
ribosomal products (DRiPs): a major source 
of antigenic peptides for MHC class I 
molecules? J.Immunol. 1996;157:1823-
1826.
30. Vigneron N, Stroobant V, Chapiro J, Ooms 
A, Degiovanni G, Morel S, van der BP, Boon 
T, Van den Eynde BJ. An antigenic peptide 
produced by peptide splicing in the 
proteasome. Science 2004;304:587-590.
31. Engelhard VH, Brickner AG, Zarling AL. 
Insights into antigen processing gained by 
direct analysis of the naturally processed 
class I MHC associated peptide repertoire. 
Mol.Immunol. 2002;39:127-137.
32. van Bergen CA, Rutten CE, van der Meijden 
ED, van Luxemburg-Heijs SA, Lurvink 
EG, Houwing-Duistermaat JJ, Kester 
MG, Mulder A, Willemze R, Falkenburg 
JH, Griffioen M. High-throughput 
characterization of 10 new minor 
histocompatibility antigens by whole 
genome association scanning. Cancer Res. 
2010;70:9073-9083.
33. Broen K, Levenga H, Vos J, van BK, Fredrix 
H, Greupink-Draaisma A, Kester M, 
Falkenburg JH, de MP, de WT, Griffioen M, 
Dolstra H. A Polymorphism in the Splice 
Donor Site of ZNF419 Results in the Novel 
Renal Cell Carcinoma-Associated Minor 
Histocompatibility Antigen ZAPHIR. PLoS.
One. 2011;6:e21699.
Proefschrift Broen_2.indd   132 18-3-2012   15:42:25
133
CONCURRENT DETECTION  BY COMBINATORIAL ENCODING MULTIMERS
5
CH
A
PT
ER
Supplemental 
Supplemental Table S1. Screening pool of high and intermediate 
binding HLA-A2 peptides set up with combinations of labeled MHC 
multimers
Peptide 
allelic 
peptides
HLA-A2 
binding 
capacity
Fluorochrome code
Pool A
1 YLATLTWML High PE APC
2 YLATFTWML High PE Qdot605
3 LLLGRLTGVI High PE Qdot655
4 KLNDVLLIQL High PE Qdot705
6 KLNDILLIQL High PE Qdot800
7 LLSEAHTCV High APC Qdot605
8 LLSEAHTCI High APC Qdot655
9 RMFPNAPYL High APC Qdot705
10 RMFPNTPYL High APC Qdot800
11 KLQPYFQTL High Qdot605 Qdot655
13 RLFQESFNM High Qdot605 Qdot705
16 LAQDYLQYV High Qdot605 Qdot800
22 VSYKSFTFV High Qdot655 Qdot705
27 FLTLGVLSL High Qdot655 Qdot800
HA-1 VLHDDLLEA Qdot705 Qdot800
Pool B
29 ILGVLSLLL High PE APC
30 TLGVLSLLL High PE Qdot605
32 LTLGVLSLL High PE Qdot655
35 ILPKMGIQNV High PE Qdot705
37 TLIKWSHSL High PE Qdot800
47 LMNDFYPGI High APC Qdot605
48 LMNDFYLGI High APC Qdot655
49 YMPQNFYCI High APC Qdot705
50 YMPQNFYCV High APC Qdot800
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51 FLLEFLLPL High Qdot605 Qdot655
52 FLLEFFLPL High Qdot605 Qdot705
53 AMFLLEFLL High Qdot605 Qdot800
54 AMFLLEFFL High Qdot655 Qdot705
HA-2  YIGEVLSV High Qdot655 Qdot800
55 FLLPLGIIL High Qdot705 Qdot800
Pool C
57 FLCKFVFTI High PE APC
58 FLCKFLFTI High PE Qdot605
67 KLSDTLHSL High PE Qdot655
68 RLSDTLHSL High PE Qdot705
75 LQVDQLWDV High PE Qdot800
76 LQVDQLWDA High APC Qdot605
81 ILATLPEFVV High APC Qdot655
82 ILATLPEYVV High APC Qdot705
83 ILATLPEFV High APC Qdot800
84 ILATLPEYV High Qdot605 Qdot655
95 VLFLSVNYL High Qdot605 Qdot705
96 FLVRDEVTV High Qdot605 Qdot800
HA-8 RTLDKVLEV High Qdot655 Qdot705
100 YLVPSDALL High Qdot655 Qdot800
101 LQHHEQWLV High Qdot705 Qdot800
Pool D
4 LLLGGLTGVI Intermediate PE APC
14 RIFQESFNM Intermediate PE Qdot605
15 LAQDYLQCV Intermediate PE Qdot655
17 KMHLAHSTL Intermediate PE Qdot705
18 KMHLAHSNL Intermediate PE Qdot800
21 VSYKSLTFV Intermediate APC Qdot605
28 FLILGVLSL Intermediate APC Qdot655
31 LILGVLSLL Intermediate APC Qdot705
36 ILPKMGIQNA Intermediate APC Qdot800
39 LVGEQVTVHV Intermediate Qdot605 Qdot655
41 QILQGLGFNL Intermediate Qdot605 Qdot705
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SMCY.A2 FIDSYICQV Intermediate Qdot605 Qdot800
90 ALQEAMEQL Intermediate Qdot655 Qdot705
44 CLAKNSSIYV Intermediate Qdot655 Qdot800
45 LLVWYCREFA Intermediate Qdot705 Qdot800
Pool E
46 LLVWYCRDFA Intermediate PE APC
61 LLLDPPWST Intermediate PE Qdot605
62 LLLNPPWST Intermediate PE Qdot655
63 VLLLDPPWST Intermediate PE Qdot705
64 VLLLNPPWST Intermediate PE Qdot800
65 LLLDPPWSTA Intermediate APC Qdot605
66 LLLNPPWSTA Intermediate APC Qdot655
91 FLVKCFDKT Intermediate APC Qdot705
72 VLTEPHLRLL Intermediate APC Qdot800
97 MVLEHPARV Intermediate Qdot605 Qdot655
102 SLMGILLR Intermediate Qdot605 Qdot705
85 KLCSFQEEMV Intermediate Qdot605 Qdot800
86 KLCSFQEEMA Intermediate Qdot655 Qdot705
87 KNWTERWFV Intermediate Qdot655 Qdot800
89 ILLDENCCV Intermediate Qdot705 Qdot800
Pool F
43 CLAKNNSIYV Intermediate Qdot655 Qdot705
71 VLTEPQLRLL Intermediate APC Qdot705
78 TLTEIVRFRC Intermediate Qdot605 Qdot655
79 IQLPHLKTL Intermediate Qdot605 Qdot705
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Abstract
Purpose: Allogeneic stem cell transplantation (allo-SCT) can induce remission in 
patients with hematological cancers due to the graft-versus-tumor (GVT) effect. 
This immune-mediated antitumor effect, however, is often accompanied by det-
rimental graft-versus-host disease (GVHD). Both the GVT effect and GVHD are 
mediated by minor histocompatibility antigen (MiHA)-specific T cells recognizing 
peptide products from polymorphic genes that differ between the recipient and 
donor. In this study, we evaluated whether mismatches in a panel of seventeen 
MiHA are associated with clinical outcome after partial T cell-depleted allo-SCT. 
Experimental Design: We retrospectively analyzed the impact of MiHA mis-
matches in a cohort of 327 adult patients who received HLA-matched, partial T 
cell-depleted allo-SCT because of a hematological malignancy. 
Results: DNA mismatches for one or more autosomal-encoded MiHA  is associated 
with increased relapse free survival in sibling transplants (P =0.04), particularly 
in patients suffering from multiple myeloma (P =0.02). Moreover, mismatches 
for the ubiquitous Y chromosome-derived MiHA resulted in a higher incidence 
of acute GVHD (grade 3-4; P <0.001), while autosomal MiHA mismatches, ubiq-
uitous or restricted to hematopoietic cells, were not associated with severe 
GVHD. Finally, we demonstrated considerable differences between MiHA in their 
capability to induce in vivo T cell responses using dual-color tetramer analysis of 
peripheral blood samples collected post-SCT. 
Conclusion: Our findings provide a rationale for deliberate mismatching of the 
transplant for known autosomal MiHA to induce and boost GVT immunity after 
HLA-matched allo-SCT.  
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Introduction
Allogeneic stem cell transplantation (allo-SCT) combined with donor lymphocyte 
infusion (DLI) is a potent treatment for patients with aggressive hematological 
cancers 1;2. Many clinical and experimental studies in human leukocyte antigen 
(HLA)-identical allo-SCT provide evidence that both the potentially curative graft-
versus-tumor (GVT) effect and graft-versus-host disease (GVHD) develop as a 
result of donor T cell responses directed against disparate minor histocompatibil-
ity antigens (MiHA) 3-5. These MiHA are polymorphic HLA-bound peptides derived 
from cellular proteins that can induce powerful alloreactive T cell responses. It 
has been demonstrated that emergence of MiHA-specific T cells precedes clini-
cal remission in patients treated with DLI 6-8. While various MiHA, including Y 
chromosome-encoded MiHA, are expressed ubiquitously, increasing numbers of 
autosomal-encoded MiHA are being identified that are exclusively expressed by 
hematopoietic cells and their malignant counterparts 9-11. The molecular identi-
fication of these GVHD- and GVT-associated MiHA has made it possible to study 
the clinical impact of MiHA mismatches and their specific T cell responses post-
transplantation.   
Several studies in HLA-matched allo-SCT have reported an association between 
mismatches in MiHA and clinical outcome. Mismatches in individual MiHA, includ-
ing HA-1, HA-2 and HA-8, have been associated with increased  GVHD occurrence 
and lower relapse rates 12-14, but other studies could not confirm these results 
15-17. Furthermore, previous studies have predominantly investigated cohorts 
of HLA-matched non-T cell-depleted transplants, and found only an increase in 
chronic GVHD (cGVHD) and reduced relapse rate upon HY MiHA disparity 18;19. 
Moreover, investigation of the role of MiHA incompatibility in transplant outcome 
is hampered by the requirements to restrict studies to specific HLA types and low 
frequencies of particular MiHA alleles. Recently however, it was reported that 
HLA-A2+ chronic myeloid leukemia (CML) patients who developed acute GVHD 
(aGVHD) showed an improved overall survival (OS) and relapse-free survival 
(RFS) when receiving a transplant from a HA1-mismatched donor 20.
In this study, we performed a retrospective analysis on the impact of a panel 
of seventeen immunogenic MiHA mismatches in a relatively large cohort of 
patients who received partial T cell-depleted allo-SCT. In sibling transplants, mis-
matches in one or more of the studied autosomal-encoded MiHA resulted in an 
improved RFS (P =0.04), especially in multiple myeloma (MM) patients (P =0.02). 
In contrast, no significant association between autosomal MiHA mismatches and 
acute or chronic GVHD was observed in the whole sibling cohort, whereas the 
occurrence of an HY disparity led to more grade 3-4 aGVHD (P <0.001). Finally, 
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this report describes for the first time the potential of disparate MiHA to induce 
productive T cell responses post-transplant. Tetramer analysis revealed that the 
ability of different MiHA to mount specific CD8+ T cell responses post-transplant 
varies strongly (0% - 60%). Together, these data provide evidence for deliberate 
mismatching of HLA-identical donor transplants for autosomal MiHA to induce 
GVT immunity, especially in MM patients and likely in other hematological malig-
nancies as well.
Patients, materials and methods
Patients and donors
Three hundred and twenty-seven (N=327) adult SCT recipients and their donors 
were included in this study. They were selected from the total transplant cohort 
of our centre treated between 1995 and 2010 with HLA-matched, partial T cell-
depleted allo-SCT for a hematological malignancy. HLA was typed using sequence-
specific PCR. In sibling transplants, patients were transplanted with an HLA-
identical sibling donor, and in matched unrelated transplants (MUD), patients 
were transplanted with a 8 to 10 out of 10 HLA-matched voluntary donor, not 
considering HLA-DP. Only patient-donor couples with the HLA types HLA-A1, -A2, 
-A3, -A24, -B7 -B8 or -B44 were included, because the selected set of MiHA was 
restricted to these HLA types. Furthermore, couples were selected based on the 
availability of both patient and donor material. The characteristics of patients, 
donors and SCT procedures are shown in Table 1. Patients and donors had given 
their informed consent to the prospective collection of data and samples for 
investigational use, which was approved by the Radboud University Nijmegen 
Medical Centre (RUNMC) Institutional Review Board. 
Table 1.  Recipient, donor, and SCT characteristics (N=327)
Characteristics
Recipient age, years, mean (range) 46 (18-67)
Donor age, years, mean (range) 46 (11-71)
Recipient gender male, no (%) 195 (60%)
Donor gender male no (%) 191 (58%)
Gender combination, no (%)
     Male patient/female donor
     Other
76 (23%)
251 (77%)
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Donor relation, no (%)
     Matched sibling donor
     Matched unrelated donor
264 (81%)
63 (19%)
Disease category, no (%)
     AML/MDS
     ALL
     CML
     NHL/CLL
     MM
118 (36%)
34 (10%)
53 (16%)
67 (20%)
55 (17%)
Stem cell source
     Peripheral blood, no (%)
     CD34 x106/kg, mean (range)
     CD3 x106/kg, mean (range)
     Bone marrow, no (%)
     CD34 x106/kg, mean (range)
     CD3 x106/kg, mean (range)
175 (54%)
6.0 (1.3-13.8)
0.5 (0.04-1.7)
152 (46%)
2.1 (0.5-6.5)
0.7 (0.5-1.1)
SCT date, no (%)
     1995-1999
     2000-2004
     2005-2010
98 (30%)
83 (25%)
146 (45%)
Ex-vivo T cell-depletion, no (%)
     CD3/CD19
     CD34
     Elutriation
     No T cell depletion
85 (26%)
87 (26.5%)
143 (44%)
12 (3.5%)
Conditioning regimens, no (%)
Myeloablative:
     (Ida)-Cy-Bus
     (Ida)-Cy-TBI
     Cy-ATG-Bus
     Cy-ATG-TBI
Non-myeloablative:
     Flu-Cy
     Flu-Cy-ATG
     TBI alone
18 (5.5%)
182 (55.5%)
8 (2.5%)
39 (12%)
50 (15.5%)
16 (5%)
14 (4%)
GVHD prophylaxis, no (%)
     Cyclosporine alone
     Cyclosporine/MMF
     None
305 (93%)
13 (4%)
9 (3%)
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Disease status, no (%)
     Early
     Intermediate
     Advanced
193 (59%)
81 (25%)
53 (16%)
Diagnosis before SCT, no (%)
     ≤ 1 year
     > 1 year
205 (62.5%)
122 (37.5%)
CMV status, no (%)
     Negative/negative
     Other combination
     Missing
76 (23%)
229 (70%)
22 (7%)
Gratwohl score, no (%)
     Score 0
     Score 1
     Score 2
     Score 3
30 (9%)
183 (56%)
93 (28.5%)
21 (6.5%)
Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome; 
ALL, acute lymphatic leukemia; CML, chronic myeloid leukemia; NHL, non-Hodgkin 
lymphoma; CLL, chronic lymphatic leukemia; MM, Multiple Myeloma; SCT, stem 
cell transplantation; Ida, idarubicin; Cy, Cyclophosphamide; Bus, budesonide; 
TBI, total body irradiation; ATG, anti-thymocyte globulin; Flu, fludarabine; MMF, 
mycophenolate mofetil; GVHD, graft-versus-host disease; CMV, cytomegalovirus. 
Treatment protocol
All patients were treated according to protocols described previously 21-23. Mye-
loablative conditioning regimens consisted of cyclophosphamide (60 mg/kg for 2 
days) in combination with either total body irradiation (TBI; 4.5 Gy for 2 days) or 
busulfan (4 mg/kg for 4 days). Idarubicin (42 mg/m2 in 48 hours intravenously) was 
often added to reduce the risk of relapse in the setting of partial T cell-depleted 
SCT 24. Non-myeloablative conditioning regimens consisted mainly of cyclophos-
phamide (1200 mg/m2 for 4 days) in combination with fludarabine (30 mg/m2 
for 4 days), sometimes only TBI (2 Gy). Patients receiving a MUD-graft received 
anti-thymocyte globulin (ATG) (2 mg/kg for 4 days). After conditioning, patients 
received a partial T cell-depleted graft derived from bone marrow (BM) or mobi-
lized peripheral blood (PB). In case of BM, mononuclear cells were first enriched 
by density gradient centrifugation using StemClear separation medium (ClearCell 
Technologies, Beernem, Belgium). Subsequently, T and B cells were depleted by 
counterflow centrifugation or immunomagnetic separation by CliniMACS® Plus 
cell selector (Miltenyi Biotec, Bergisch-Gladbach, Germany). In case of PBSCT, 
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the transplant was infused after depletion of CD3+ and CD19+ cells or following 
selection of CD34+ cells by CliniMACS®. The mean number of CD34+ stem cells in 
the graft was 2.1x106 cells/kg (range 0.5-6.5) for BM and 6.0x106 cells/kg (range 
1.3-13.8) for PB, and the mean number of CD3+ T cells in BM grafts was 0.7x106 T 
cells/kg and in PB grafts 0.5x106 T cells (Table 1). GVHD prophylaxis consisted of 
cyclosporine A (CsA) only in almost all patients, and was dosed 1.5 mg/kg bidaily 
(bid) intravenously for the first two weeks, and thereafter 1 mg/kg bid intrave-
nously or 2.5-3 mg/kg bid orally. Tapering of CsA was started in the absence of 
GVHD after two months and stopped at three months. Several patients received 
prophylactic or therapeutic DLI following transplantation. Prophylactic DLI was 
restricted to patients who had stopped CsA for at least three months and had not 
developed cGVHD or aGVHD grade ≤2. 
Definition of outcome variables
Acute GVHD was graded according to the criteria of Przepiorka et al. 25 and cGVHD 
was classified according to the revised Seattle criteria of Lee et al. 26. Patient risk 
scores for outcome were determined according to the Gratwohl score 27. OS, RFS, 
and non-relapse mortality (NRM) were defined according to the standard criteria 
proposed by the EBMT. 
MiHA genotyping using the KASPar system
HLA-matched SCT donor-recipient pairs were genotyped for a panel of MiHA by 
the KASPar assay system (KBioscience, Hoddesdon, UK), which is a fluorescence-
based competitive allele-specific PCR using non-labeled primers. Details of this 
method can be found at http://www.kbioscience.co.uk. 
Tetramer staining and validation by T cell culture
PE- and APC-labeled MiHA tetramers were produced as described previously 28. 
Tetramer stainings were performed directly on cryopreserved PBMC after thaw-
ing and 7 days after stimulation with the appropriate MiHA peptide 29. For this, 
PBMCs were stimulated once with MiHA peptide-pulsed (10 μM) Epstein-Barr 
virus lymphoblastoid cell lines (EBV-LCL) on day 0. MiHA peptides were loaded 
on a corresponding EBV-LCL stably transduced with either HLA-A2, -A3, or -B7. 
For additional HLA types (i.e. HLA-A24 and HLA-B8) matching healthy donor 
EBV-LCL were used. After initial stimulation, 100 IU/ml IL-2 (Chiron, Emeryville, 
CA) and 10 ng/ml IL-15 (BD) was added at day 2 and 5. For tetramer staining of 
approximately 1x106 cells, cells were stained with 0.2 μg tetramer for 15 min at 
room temperature. After washing with PBS/0.5% bovine serum albumin (BSA; 
Sigma, St Louis, MO, USA), cells were labeled with AlexaFluor700-conjugated CD8 
(Invitrogen) in combination with FITC-conjugated CD4, CD14, CD16 and CD19 
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(Beckman Coulter) for 30 min at 4°C. Finally, cells were washed and resuspended 
in PBS/0.5% BSA containing 0.2 μM Sytox Blue (Invitrogen) to allow dead-cell 
exclusion. Data acquisition was performed on a Cyan-ADP analyzer (Beckman 
Coulter) and analyzed using Kaluza 1.1 software (Beckman Coulter). CD8+ T cells 
were defined as viable Sytox Blue-negative, single-cell lymphocytes, CD8-positive 
and FITC (CD4, CD14, CD16, CD19) negative cells. Within the CD8+ T cell popula-
tion, cells positive for both tetramers (APC, PE) were quantified (Supplementary 
Figure 1). 
Patients were classified as having a positive tetramer response, when MiHA-spe-
cific CD8+ T cells (≥0.01% tetramer+ cells within the CD8+ T cell population) were 
found in PBMC either directly after thawing and/or 7 days after peptide stimu-
lation using peripheral blood samples obtained during the effector or memory 
phase of the immune response.
Statistical analysis
Associations of MiHA disparity with the occurrence of aGVHD and cGVHD after 
allo-SCT were tested using the chi-square test or Fisher Exact test, if appropriate, 
and univariable logistic regression analysis. To correct for possible confounders, 
we used multivariable logistic regression analyses. OS, RFS and NRM were ana-
lyzed using Kaplan Meier curves and the log-rank test. Analyses were performed 
using SAS 8.2 software. P values <0.05 were considered statistically significant. 
MiHA mismatch parameters were defined as disparate HY (HY MiHA restricted to 
HLA-A2, -B7 or -B8), disparate HA1 and disparate autosomal MiHA (mismatched 
for one or more MiHA listed in Table 2, except for HY).
Results
Clinical outcome parameters after HLA-matched allo-SCT
We analyzed the clinical outcome post partial T cell-depleted allo-SCT in patients 
suffering from a hematological malignancy. The median follow up of patients alive 
at last follow up was 7.1 years (range 0.5-17), and 1.1 years (range 0.05-12.6) 
in those who died. In Figure 1A-B, the survival curves for OS (5 year: 68%) and 
RFS (5 year: 44%) are depicted for the complete cohort. NRM after 5 years was 
15.6% (i.e. 43.4% of all deaths, Figure 1C) and 40.4% of the patients experienced 
relapse. Acute GVHD occurred in 19.6% of patients and was severe (grade 3-4) 
in only 6.5%. Of 309 patients who could be evaluated, 22.7% developed limited 
cGVHD and 14.2% extensive cGVHD.  
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Figure 1. Clinical outcome parameters after partial T cell-
depleted allo-SCT. 
Within the complete cohort of allo-SCT recipients, (A) overall survival, (B) 
relapse-free survival and (C) the cumulative incidence of non-relapse mor-
tality (NRM) was analyzed using Kaplan Meier analysis. Allo-SCT, allogeneic 
stem cell transplantation. 
MiHA allele frequency and phenotype disparity rate 
To determine the MiHA allele frequency and disparity rate, recipient and donor 
DNA was typed. Paired couples were only genotyped when the appropriate 
HLA-molecule was expressed to which the MiHA is restricted, leading to actual 
immunogenic disparity rates. HY.A2, HY.B7 or HY.B8 disparity was scored when a 
female-donor-male-recipient (FDMR) transplantation was performed. 
The highest disparity rates, within the restricting HLA type, were observed for all 
Y chromosome-derived MiHA (20.9%-26.5%) as well as for ACC2 (25.0%), LRH1 
(19.6%) and HA1 (16.4%). Overall, 60 (18.2%) and 137 (41.6%) of the 327 pairs 
were disparate for Y-chromosome or autosomal chromosome encoded MiHA, 
respectively (Table 2).
HY disparity is associated with increased aGVHD 
Univariable analysis of all patient and donor characteristics showed several sta-
tistical significant associations with clinical outcome measures (Supplementary 
Table 1). Multivariable analysis confirmed the association for HY incompatibility 
with a higher incidence of aGVHD grade 3-4 (P <0.001, Figure 2A). In agreement, 
FDMR transplants were also associated with grade 3-4 aGVHD (Univariable analy-
sis P <0.001, Supplementary Table 1). 
Notably, none of the other MiHA mismatched categories (HA1 or autosomal 
MiHA mismatched) showed an association with acute or chronic GVHD (Figure 
2A-B), possibly because of the restricted tissue expression of the majority of the 
autosomal MiHA tested.
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Table 2. MiHA disparity rate 
MiHA HLA Peptide 
sequence
Reference NA Disparity 
rate 
comple 
cohortB
HA3 A1 VTEPGTAQY 42 82/87 3 (3.7%)
HA1 A2 VLHDDLLEA 43 195/197 32 (16.4%)
HA2 A2 YIGEVLVSV 44;45 195/197 6 (3.1%)
HA8 A2 RTLDKVLEV 46 194/197 22 (11.3%)
HY A2 FIDSYICQV 47 197/197 42 (21.3)
ADIR A2 SVAPALALAFPA 48 195/197 30 (15.4%)
HwA11 A2 CIPPDSLLFPA 49 195/197 6 (3.1%)
SP110 A3 SLPRGTSTPK 50 92/93 7 (7.6%)
PANE1 A3 RVWDLPGVLK 51 92/93 5 (5.4%)
ACC1 A24 DYLQYVLQI 52 54/54 6 (11.1%)
ACC2 B44 KEFEDDIINW 53 97/98 16 (25.0%)
LRH1 B7 TPNQRQNVC 54 98/98 19 (19.6%)
HY B7 SPSVDKARAEL 55 64/67 26 (26.5%)
ECGF B7 RPHAIRRPLAL 56 97/98 5 (5.2%)
ZAPHIR B7 IPRDSWWVEL 57 97/98 12 (12.4%)
HY B8 LPHNMTDL 58 67/67 14 (20.9%)
HEATR B8 ISKERAEAL 59 64/65 8 (12.5%)
AN = number of patient donor couples typed, within the total number of couples 
presenting the correct HLA molecule. BDisparity rate of a particular MiHA within 
all typed couples presenting the correct HLA-molecule.
Autosomal MiHA disparity is associated with improved relapse-f
ree survival in sibling transplants
Statistical analysis revealed that mismatches in the studied MiHA did not have 
an impact on relapse-free survival in the complete transplant cohort (Figure 3A). 
Because recipients transplanted with a MUD graft might have a HLA-DP mis-
match as well as a higher change of unknown MiHA mismatches, we separately 
analyzed the effect of known MiHA mismatches on clinical outcome in the sibling 
cohort (N=264). Interestingly, recipients transplanted with an autosomal MiHA-
mismatched sibling graft showed significantly better RFS in multivariable analysis, 
when corrected for SC source, patient age, year of transplantation, diagnosis and
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Figure 2. Occurrence of GVHD post MiHA-mismatched trans-
plantation. 
Within the whole cohort, the incidence of (A) aGVHD grade 3-4 and (B) lim-
ited/extensive cGVHD was analyzed using the Fisher Exact test. Groups were 
categorized based on MiHA disparity in mismatched and matched at the DNA 
level. GVHD, graft-versus-host-disease; MiHA, minor histocompatibility anti-
gen.
conditioning (P =0.04; Figure 3B). Furthermore, HY disparity in sibling allo-SCT 
was again associated with a higher incidence of grade 3-4 aGVHD (Fisher Exact P 
<0.001). Analysis of clinical outcome in recipients of a MUD graft (N=61) showed 
no significant associations of MiHA disparity with neither RFS (Figure 3C) nor 
aGVHD (data not shown). Notably in the MUD cohort, OS decreased when a dis-
parate HY was present probably due to occurrence of more severe aGVHD (Uni-
variable analysis P =0.06). Taken together, these data indicate that recipients of 
an HLA-identical sibling donor graft that is mismatched for the studied autosomal 
MiHA may have improved GVT immunity post-SCT.
MM patients show improved RFS upon transplantation with a MiHA-
mismatched sibling graft
Next, we investigated the influence of MiHA mismatches on clinical outcome in 
different diagnosis sub-groups. Remarkably, in MM patients we observed signifi
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Figure 3. Autosomal MiHA disparity is associated with increased 
relapse-free survival after transplantation with a sibling graft.
Relapse-free survival was analyzed for (A) the complete cohort of recipients 
versus patients transplanted with (B) a sibling graft or (C) an unrelated graft. 
Groups were categorized based on autosomal MiHA disparity in mismatched 
(black line) and matched (grey line) at the DNA level using the log-rank test. 
Allo-SCT, allogeneic stem cell transplantation; N, number of patients within 
the group; MiHA, minor histocompatibility antigen. When significant, P val-
ues of multivariable analyses (corrected for SC source, patient age, year of 
transplantation, diagnosis and conditioning) are given.
cant correlations between the occurrence of a disparate autosomal MiHA and 
clinical outcome. In contrast, analysis of other diagnosis sub-groups did not show 
significant associations with clinical outcome (data not shown). Transplanted 
MM patients showed a higher RFS (P =0.02, Figure 4A) and less relapse (P =0.03,
Figure 4B) when at least one autosomal MiHA mismatch was present. Further-
more, the occurrence of a disparate MiHA was also correlated with an increase 
in limited cGVHD (P =0.03, Figure 4C). Notably, the effects on clinical outcome 
parameters were not a result of differences in disease status between MiHA 
matched and mismatched patients (Figure 4D). Interestingly, 22.6% of the MiHA 
mismatched MM patients had a HA1 disparity (Figure 4E). HA1 disparity was 
previously reported to be associated with improved RFS in CML patients who 
developed aGVHD 30. Altogether, these data suggest that mismatches in the stud-
ied MiHA induce improved graft-versus-myeloma immunity following partial T 
cell-depleted sibling allo-SCT. 
Ability to induce tetramer+ MiHA-specific T cell responses varies 
among MiHA
Although genetic MiHA incompatibility shows significant differences on clini-
cal outcome post-SCT, this does not necessarily mean that corresponding T cell 
responses actually occur. Therefore, we investigated the potential of 15 of the 
17 studied MiHA to induce productive MiHA-specific T cell responses in vivo. For 
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Figure 4. Multiple myeloma patients transplanted with a related 
MiHA-mismatched graft show improved relapse-free survival.
Multiple myeloma patients transplanted with a sibling graft were grouped 
on autosomal MiHA disparity in mismatched and matched at the DNA level. 
Between these subgroups differences in (A) relapse-free survival and (B) 
relapse were analyzed using the log-rank test. N = number of patients within 
the group. P values of univariable analyses are given. (C) The incidence of 
cGVHD and (D) disease status were analyzed using the Fisher Exact test. (E) 
Within the total of mismatched MiHA, the relative contribution of each MiHA 
was depicted. Allo-SCT, allogeneic stem cell transplantation; cGVHD, chronic 
graft-versus-host-disease; Lim, limited; Ext, extensive; Int, intermediate dis-
ease; Adv, advanced disease; n.s., not significant; MiHA, minor histocompat-
tibility antigen.
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this, we analyzed recipient PBMC material obtained at the median of 9 months 
(range 2-70 months) after allo-SCT using a dual-color MiHA-multimer approach. 
Patients were classified as having a positive tetramer response, when MiHA-
specific CD8+ T cells were detected directly after thawing and/or after peptide 
stimulation. 
Positive detection of MiHA tetramer+ CD8+ T cells at variable time points reflects 
either an ongoing effector immune response or a sustained effector-memory 
response after immune contraction. In Figure 5A, representative tetramer screen-
ings of three different allo-SCT recipients are depicted. Already in freshly thawed 
samples low numbers of MiHA-specific CD8+ T cells were observed in 27 out of 
40 (67.5%) MiHA T cell responsive patients. In addition, in 13 out of 40 (32.5%) 
responsive patients, tetramer+ T cells were detectable after 1 week stimulation 
with MiHA peptide-pulsed EBV-LCL. Notably, when examining the whole cohort 
of MiHA-mismatched recipients, certain MiHA-specific T cell responses were 
observed more frequently than others (Figure 5B). Especially, disparity for HA1, 
HA2, PANE1, LRH1, ACC1 and the HY-chromosome encoded antigens HY.A2 and 
HY.B7 resulted in MiHA-specific CD8+ T cell responses in 25-60% of the MiHA-
mismatched patients. HA8-, SP110- and ZAPHIR-specific CD8+ T cells were found 
in 10-20%. In contrast, no productive CD8+ T cell responses against ADIR, HwA11, 
ECGF, HEATR and HY.B8 were observed, despite genetic disparity. Together, these 
results demonstrate that certain MiHA are relatively more productive in inducing 
MiHA-specific CD8+ T cell responses after partial T cell-depleted allo-SCT. 
Discussion
As the dominant target antigens in HLA-matched allo-SCT, MiHA play a pivotal 
role in both GVT response as well as GVHD. Precise understanding of involved 
MiHA-specific T cell responses may lead to a better prediction of clinical out-
come in allo-SCT recipients. Statistical analysis of immunogenic MiHA disparity 
rates in sibling transplants revealed that DNA mismatches in autosomal-encoded 
MiHA are associated with improved clinical outcome post-SCT. In particular, MM 
patients show lower incidence of relapse and increased RFS when transplanted 
with a MiHA-mismatched sibling transplant. Furthermore, we demonstrated con-
siderable variance in the relative immunogenicity of different MiHA in inducing 
productive T cell responses post-transplantation. 
Characteristics of all recipients and their corresponding donors were analyzed for 
clinical outcome parameters (Supplementary Table 1). In accordance with litera-
ture, we observed several known parameters like patient age, patient-donor rela
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Figure 5. Tetramer+ MiHA-specific CD8+ T cell responses in MiHA-
mismatched allo-SCT recipients. 
Recipient PBMC samples obtained after allo-SCT were analyzed for presence 
of MiHA-specific CD8+ T cells using the dual-color MiHA-multimer flow cytom-
etry assay. Patients were classified as having a positive tetramer response, 
when MiHA-specific CD8+ T cells were found directly after thawing or 7 days 
after stimulation with peptide-loaded EBV-LCL. (A) The number in the dot 
plots indicates the percentage of MiHA-specific cells positive for both tetra-
mers (PE and APC) within the CD8+, CD4-, CD14-, CD16-, CD19- T cell popula-
tion. Three representative examples are shown. (B) For each disparate MiHA, 
the number of tetramer+ responses (white bars) within the total number of 
screenings (grey bars) is depicted for the whole cohort of MiHA-mismatched 
recipients. Percentages indicate the relative number of productive responses.
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tion and prophylactic DLI, associated with clinical outcome 31-34. Importantly, 
we observed that mismatched autosomal MiHA, including those with a ubiqui-
tous expression pattern, were not correlated with higher incidences of severe 
acute or chronic GVHD after partially T cell-depleted SCT. Only the HY MiHA 
were associated with increased frequency of grade 3-4 aGVHD. In agreement, 
univariable analysis showed that FDMR transplants were also associated with 
grade 3-4 aGVHD (P <0.001; Supplementary Table 1). Similar findings were pre-
viously reported by Gratwohl et al. 19 and Stern et al. 35 who used female-to-
male alloreactivity as a model for MiHA HY mismatches. Not only MiHA play an 
important role in the FDMR transplants, also non-inherited maternal/paternal 
antigens (NIMA and NIPA) are involved. In non-T cell-depleted haploidentical 
sibling NIMA-mismatched allo-SCT, lower aGVHD rates were observed than in 
NIPA-mismatched recipients 36. In our current study, we have no information on 
the NIMA or NIPA status of the transplant couples and cannot exclude the influ-
ence of these antigens on clinical outcome after partial T cell-depleted allo-SCT. 
Moreover, unknown MiHA might be important as well. Therefore, we analyzed 
patients transplanted with a sibling donor separately, thereby circumventing the 
higher likelihood of unknown polymorphic differences between recipients and 
donors. Analysis showed again a role for a disparate HY MiHA, and although more 
cases of severe aGVHD (grade 3-4) were observed, this gender mismatch had a 
favorable effect on relapse as was described previously 19. 
Interestingly, a disparity in at least one known autosomal MiHA was associated 
with higher RFS, without increasing aGVHD incidence or severity. This contribu-
tion of autosomal MiHA mismatches in the sibling transplant setting becomes 
even more apparent when compared to patients transplanted with a MUD graft. 
In the MUD cohort, effects of mismatched MiHA on RFS could not be observed, 
while HY disparity was associated with lower OS probably to the higher incidence 
of GVHD (data not shown). Furthermore, these MUD patients received ATG 37, 
leading to an additional in vivo T cell depletion, thereby reducing the chance of 
inducing tumor-reactive MiHA-specific T cell responses. 
Besides the role of alloreactive T cells in the GVT response, the underlying malig-
nancy of the recipients is important, as shown by analyzing diagnosis-subgroups. 
When focusing on patients suffering from MM within the sibling cohort, an 
evident role for disparate MiHA on both relapse incidence as well as RFS was 
observed, independent of disease status. However, the occurrence of disparate 
MiHA was also associated with a higher incidence of limited cGVHD. These results 
show that especially MM patients can benefit from a MiHA-driven GVT effect in 
the presence of an acceptable degree of cGVHD. 
This retrospective analysis in a partial T cell-depleted allo-SCT setting, shows 
promising results on clinical outcome by mismatching HLA-identical patient-
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donor couples for autosomal MiHA. The effect was clearly observed in MM 
patients, but may also hold true for patients suffering from other hematological 
malignancies. However, the whole patient cohort studied is relatively small and 
heterogeneous, and our MiHA-panel consists of both tissue-restricted and ubiq-
uitously expressed MiHA. Ideally, analysis should be performed on the occur-
rence of in vivo MiHA-specific CD8+ T cell responses in a larger and homogenous 
cohort of allo-SCT recipients.
Overall, we observed low incidence of aGVHD (6.5% grade 3-4) in our partial 
T cell-depleted setting, even when ubiquitous expressed MiHA mismatches 
were present. This indicates that there is a potential safe clinical application of 
transplant mismatching of certain strongly immunogenic MiHA in allo-SCT. Previ-
ously, the MiHA HA1, HA2, LRH1 and ACC1 have been implicated to selectively 
induce a GVT effect without GVHD 38-41. We show that they are also potent in 
inducing MiHA-specific T cells in vivo, adding to the promise of these MiHA not 
only in transplant mismatching but also in vaccination or adoptive T cell strate-
gies. However, timing of the tetramer-based analysis of post-transplant PBMC 
samples is crucial in detecting MiHA-specific T cell responses. In addition, some 
of the MiHA-specific T cell responses could be masked (subdominant) by other 
(un)known MiHA. Moreover, the underlying malignancy might skew the MiHA-
specific T cell repertoire towards a particular hematopoietic compartment such 
as the BM, which may prevent the detection of MiHA-specific T cells in PB. There-
fore, absence of tetramer+ T cells during analysis does not necessarily mean a 
complete lack of MiHA-specific T cells in vivo. 
In conclusion, this study shows that the occurrence of MiHA mismatches is 
associated with improved clinical outcome after partial T cell-depleted HLA-
matched allo-SCT, particularly in MM and maybe other hematological cancers. 
The observed positive effects might be attributed to MiHA-specific CD8+ T cells 
inducing GVT responses. However, not all MiHA show the same potential to 
induce MiHA-specific T cells as was shown by tetramer analysis of PBMC samples 
collected post-transplant. By studying the MiHA that are most productive in this 
respect, we can further select hematopoietic-restricted MiHA as safe and potent 
target antigens in allo-SCT in order to prevent or treat tumor recurrences by post-
transplant immunotherapy strategies.
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Supplemental 
Supplemental Table 1. Univariable analysis of patient 
characteristics and clinical outcome.
Characteristics P-value (univariable)
aGVHD 
grade 2-4
Age patient 0.004; OR 1.04 (1.01-1.07)
Donor relation <0.001
aGVHD 
grade 3-4
HY <0.001
Female donor/male recipient <0.001
Donor relation 0.02
cGHVD lim/
ext
Year of transplantation 0.02
Age patient <0.001; OR 1.04 (1.02-1.06)
Conditioning <0.001
T cell depletion method 0.02
aGVHD 2-4 <0.0001
cGHVD ext Age patient 0.005; OR 1.05 (1.01-1.08)
Donor relation 0.05
aGVHD 2-4 <0.001
NRM overall Year of transplantation <0.0001
Age patient 0.0002; OR 1.06 (1.02-1.08)
Gratwohl 0.001
Donor relation 0.0006
CMV combination 0.01
aGVHD 2-4 0.02
Relapse 
overall
Year of transplantation 0.03
Diagnosis <0.0001
Conditioning 0.02
SC source 0.04
cGVHD lim/ext 0.003
Prophylactic DLI <0.0001
Relapse-free 
survival
Year of transplantation <0.001
Diagnosis 0.008
Gratwohl score 0.003
Donor relation 0.007
Conditioning 0.03
SC source 0.0006
cGVHD lim/ext 0.007
Prophylactic DLI <0.0001
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Overall 
survival
Year of transplantation <0.0001
Age patient <0.001
Diagnosis 0.02
Gratwohl score <0.001
Donor relation <0.001
CMV combination 0.05
Prophylactic DLI 0.008
Abbreviations: aGVHD, acute graft-versus-host-disease; cGVHD, chronic graft-
versus-host-disease; NRM, non-relapse mortality; CMV, cytomegalovirus; SC, 
stem cell; DLI, donor lymphocyte infusion.
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Figure S1. Gating strategy for detection of tetramer+ MiHA-specific 
T cell responses. 
Recipient PBMC samples, obtained after allo-SCT or DLI were stained with MiHA-
multimers in PE and APC, CD8-AlexaFlour 700, CD4-, CD14-, CD16-, and CD19-
FITC and Sytox Blue. Subsequently, cell populations were analyzed by flow cytom-
etry. Sytox Bleu- single cells were selected and gated on CD8+FITC- lymphocytes. 
Within this population the percentage of cell positive for both tetramers was 
determined. 
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Summary and General Discussion
Allogeneic stem cell transplantation (allo-SCT) followed by donor lymphocyte 
infusion (DLI) is an effective treatment for patients with hematological malignan-
cies1;2. This therapy has also been explored as an experimental treatment for solid 
tumors in the past. However, transplant related complications, such as opportu-
nistic infections and graft-versus-host disease (GVHD), remain a major drawback 
of allo-SCT. During pre-transplant conditioning, usually irradiation and chemo-
therapy are applied which compromise the integrity of the tissues. This results 
in release of cytokines and chemokines and, especially in the gastro-intestinal 
tract, in translocation of bacterial products. As a consequence an inflammatory 
environment is created in which T cells can attack non-tumor tissues leading to 
GVHD. Efforts to improve this highly personalized immunotherapy are ongo-
ing, which focus on the reduction of GVHD and infectious complications while 
improving the graft-versus-tumor (GVT) effect. We studied the influence on the 
outcome of allo-SCT of genetic polymorphisms generating minor histocompat-
ibility antigens (MiHA) or in signal molecules involved in the immune response.
Many clinical and experimental studies in human leukocyte antigen (HLA)-iden-
tical allo-SCT provide evidence that both the potentially curative GVT effect and 
GVHD develop as a result of donor T cell responses directed against disparate 
minor histocompatibility antigens (MiHA) 3-5. MiHA are polymorphic HLA-bound 
peptides derived from cellular proteins that can induce strong alloreactive CD8+ 
T cell responses. MiHA present on tumor tissues evoke a GVT effect, while the 
presence of MiHA op healthy tissues can leads to GVHD. Therefore, MiHA-specific 
T cell responses might prove essential when aiming at the induction of a selective 
GVT effect with minimal risk for GVHD, creating a targeted immune response. 
The molecular identification of GVHD- and GVT-associated MiHA has made it 
possible to study the clinical impact of MiHA mismatches and their specific CD8+ 
T cell responses post-transplantation. In addition, MiHA are investigated as target 
antigens in new therapeutic approaches.   
In this thesis, the effect of non-HLA polymorphisms on the outcome of allo-
SCT was studied. We studied the non-HLA polymorphisms that could influence 
expression or function of cytokine and chemokine receptors. In addition we stud-
ied the polymorphisms that cause the immunogenicity of MiHA which has led to 
the identification of a novel MiHA called ZAPHIR.
In Chapter 2 we performed a retrospective study to investigate the effects of 
polymorphisms in the IL-23 receptor (IL-23R) and in chemokine receptor CCR6 on 
post transplantation outcome in 161 recipients of partially T cell-depleted allo-
SCT. We did not find a relation between the  IL-23R SNPs and clinical outcome,
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contrary to several other studies in which the IL-23R donor genotype was associ-
ated with a reduced risk of acute GVHD 6-8 or fungal infections 8.  For the poly-
morphisms in CCR6 we found that disparities in the CCR6 tagSNP rs2301436 
as well as the intronic SNP rs3093023 were independently associated with the 
occurrence of chronic GVHD. Moreover, tagSNP rs2301436 was associated with 
an increased incidence of invasive fungal disease (IFD). In multivariate analysis, 
patients receiving a transplant from a homozygous rs2301436 G allele donor 
showed less chronic GVHD, as was the case for a homozygous donor rs3093023 
G allele. In parallel, the donor GG genotype at rs2301436 was associated with a 
higher incidence of IFD at day 100 after allo-SCT. Our study is the first to show an 
association with the donor-genotype of polymorphisms in the CCR6 gene and the 
occurrence of chronic GVHD and IFD. We think that these findings provide new 
clues for further research with regards to antigen presenting cell (APC) and T cell 
subset function as well as homing patterns. We conclude that patients undergo-
ing allo-SCT may benefit from typing for these particular SNPs when looking for 
a suitable stem cell donor, although further research on the consequences for 
CCR6 gene functionality due to the described polymorphisms is required.
To date the study of non-HLA polymorphisms that influence expression or func-
tion of cytokines, chemokines and its receptors and PAMP-receptors, has not yet 
led to changes in the allo-SCT treatment strategy.  MiHA on the other hand, have 
been explored as target antigens in (post)transplantation immunogenic strate-
gies. However, to make MiHA-based immunotherapy available on a larger scale, 
more MiHA that could evoke a selective GVT effect should be added to the tool-
box of immunologists.  In Chapter 3 we describe the process that led to the iden-
tification of the novel MiHA designated ZNF419 alternatively spliced polymorphic 
histocompatibility antigen in RCC (ZAPHIR). ZAPHIR is selectively expressed on 
renal cell carcinoma (RCC) cells as well as on chronic myeloid leukemia (CML) 
cells. 
We found that ZAPHIR is recognized by a CTL clone isolated from a metastatic 
RCC patient with partial regression of lung metastases after reduced-intensity 
allo-SCT. The isolated CTL was able to efficiently target RCC cell lines, while bone 
marrow (BM) derived fibroblasts pre-treated with inflammatory cytokines were 
not. A genome wide association study (GWAS) revealed that this CTL recognizes a 
MiHA that arises due to a SNP in a splice donor site of the ZNF419 gene resulting 
in alternative splicing of intron 4 and the formation of a formerly unknown splice 
variant. This provides further evidence that alternative splicing due to intronic 
SNPs is an important mechanism for generating MiHA after allo-SCT. Furthermore, 
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tetramer analysis showed that ZAPHIR-specific CD8+ T cell responses emerged in 
the transplanted RCC patient, from whom the original CTL clone was isolated, 
as well as a CML patient treated with therapeutic DLI. Importantly, in both cases 
ZAPHIR-specific CD8+ T cells were present in the absence of GVHD. Additional 
research on the tissue distribution pattern as well as the types of tumors express-
ing ZAPHIR should be performed. This will clarify whether ZAPHIR represents a 
new target antigen for the development of adjuvant immunotherapy for RCC and 
hematological malignancies after allo-SCT. 
In parallel, we evaluated MiHA-specific T cell responses in another transplanted 
RCC patient with stable disease after RIC-SCT and DLI. From this patient we iso-
lated a MiHA-specific CTL clone recognizing the HLA-A2-restricted SMCY antigen. 
Although it has been reported that the SMCY antigen is ubiquitously expressed, 
tetramer analysis in this RCC patient showed strong emergence of SMCY-specific 
CD8+ T cells without clinical manifestation of GVHD. Therefore, our clinical find-
ings suggest that emergence of SMCY-specific CTL may have played a role in sta-
bilization of the tumor growth in the RCC patient after allo-SCT.
To date, only one other MiHA, C19orf48, has been described that is aberrantly 
expressed on RCC 9. In addition to a RCC specific MiHA, another immunogenic 
antigen expressed on metastatic RCC has been described, HERV-E which is derived 
from a human endogenous retrovirus 10. New developments in the treatment of 
metastatic RCC with tyrosine-kinase inhibitors have changed the treatment strat-
egy for these patients, but their prognosis is still dismal. Nevertheless, the role of 
allo-SCT for the treatment of metastatic RCC remains unclear. Next to decreasing 
transplant-related toxicity and mortality, a broad panel of RCC-associated anti-
gens recognized by alloreactive CTL is absolutely necessary to make specific allo-
geneic T cell therapy applicable to a significant proportion of patients with RCC. 
The finding that ZAPHIR-specific CD8+ T cell responses can also be mounted in a 
transplanted CML patient opens opportunities for ZAPHIR as therapeutic target 
for hematological malignancies.
The role of MiHA-specific T cells as important effectors in immunotherapy is 
illustrated in Chapter 4, where the characterization of a novel HLA-A3-restricted 
MiHA-specific CTL, isolated from a multiple myeloma (MM) patient is described. 
Interestingly, this patient obtained long-term remission after treatment with RIC 
followed by partial T cell-depleted allo-SCT, DLI and subsequent recipient den-
dritic cell (DC) vaccination. Previously, we showed that adjuvant immunotherapy 
boosted the graft-versus-myeloma effect with limited GVHD and mortality 11. 
Now, we isolated an HLA-A3-restricted MiHA-specific CTL clone that efficiently 
targets MM tumor cells and MM tumor cell lines, while BM derived fibroblasts 
and donor DC were not recognized. Quantitative analysis of the CTL-specific T cell 
receptor (TCR) revealed the emergence of the CTL in both peripheral blood and 
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BM. Remarkably, a strong increase of CTL-specific TCR transcripts at the tumor 
site was observed following DLI and recipient DC vaccination, while the TCR sig-
nal in peripheral blood decreased. This study shows that the approach of partial 
T cell-depleted SCT followed by DLI and DC vaccination induces MiHA-specific T 
cell responses targeting MM tumor cells. Furthermore, our findings suggest that 
DC vaccination results in boosting or increased trafficking of MiHA-specific CTL 
to the BM. No attempts were made to identify the polymorphism underlying 
the MiHA recognized by the MiHA-specific CTL. The frequency of this particular 
epitope (≈ 70% expression in healthy donors) was unfavorable for therapeutic 
purposes and the current status of the identification method used is not suitable 
for HLA-A3 restricted MiHA. Identification of the antigenic targets of alloreac-
tive T cells remains important for understanding the GVT response in different 
malignancies and for development of strategies to selectively target tumor cells 
after allo-SCT.
Since the therapeutic effect of allo-SCT and DLI are largely dependent on recogni-
tion of MiHA by donor-derived CD8+ T cells, the monitoring of multiple MiHA-
specific CD8+ T cell responses may prove to be valuable for evaluating the efficacy 
of allo-SCT. Most analysis focus on the detection of CD8+ T cell responses to single 
MiHA epitopes using conventional techniques such as single-tetramer staining 
or the ELISPOT assay. In Chapter 5, we investigated the use of the combinatorial 
encoding MHC multimer technique to simultaneously detect MiHA-specific CD8+ 
T cells in peripheral blood of SCT recipients. Feasibility of this approach was dem-
onstrated by applying dual-color encoding MHC multimers for a set of 10 known 
MiHA. Single staining using a fluorochrome- and Qdot-based five-color combina-
tion showed comparable results to dual-color staining for most MiHA-specific 
CD8+ T cell responses.  These findings demonstrate the potency of the combi-
natorial MHC multimer approach in the monitoring of CD8+ T cell responses to 
MiHA in limited amounts of peripheral blood from allo-SCT recipients.
The combinatorial encoding approach can accommodate a wide range of differ-
ent peptide-MHC multimers for several HLA molecules, which can be readily pro-
duced through UV-mediated ligand exchange 12. The availability of large amount 
of various tetramers enabled us to examine the potential value of combinatorial 
encoding MHC multimers in MiHA identification. The value of the method for 
antigen discovery has been demonstrated for the identification of melanoma-
associated T cell epitopes 13. We predicted a set of 100 candidate MiHA peptides 
from polymorphic genes with a hematopoietic expression profile. Further selec-
tion for high and intermediate binding affinity for HLA-A2 resulted in 75 potential 
MiHA for which we screened a cohort of SCT recipients. First the patient cells 
were enriched for the 75 potential MiHA and subsequently the cultures were 
screened for the presence of MiHA-specific T cells by a set combinatorial encoded 
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tetramers. Although several epitope-specific T cells were found, only CD8+ T cell 
responses for LAG3 and TLR10 derived polymorphic peptides could be confirmed 
by genotyping of the respective SNPs. Validation of these epitopes as MiHA 
should be performed by generating epitope-specific T cell cultures. 
The therapeutic effect of the GVT response is mainly attributed to MiHA-specific 
T cells. Emergence of these MiHA-specific CD8+ T cells has been show to pre-
cede clinical remission in patients treated with DLI 4;14;15. In Chapter 6 we studied 
whether disparate MiHA are associated with improved clinical outcome, indeed. 
We performed a retrospective analysis on 327 patients who received a partially T 
cell-depleted allo-SCT because of a hematological malignancy. In a multivariable 
statistical analysis we correlated the occurrence of HY or autosomal MiHA mis-
matches to clinical outcome. We observed that, especially in patients transplanted 
for MM, an autosomal MiHA disparity on DNA level associates with increased 
relapse-free survival (RFS) in sibling transplants. In addition, mismatches for the 
ubiquitous Y chromosome-encoded MiHA resulted in more acute GVHD (grade 
3-4), while other MiHA mismatches, either ubiquitous or restricted to hemato-
poietic cells, were not associated with GVHD. This study provides a rationale for 
the pre-transplantation mismatching of autosomal MiHA to induce GVT immu-
nity specifically in MM and possibly in other hematological malignancies. 
Although disparate MiHA on DNA level show significant differences on clinical 
outcome post-SCT, genetic MiHA incompatibility does not necessarily mean 
that corresponding T cell responses actually occur. Therefore we assessed the 
development of MiHA-specific T cell responses by dual-color tetramer staining. 
There were considerable differences between MiHA in the capability to induce 
in vivo T cell responses post-transplantation (0% - 60%). The MiHA HA1, HA2, 
PANE1, LRH1, ACC1 and the HY-chromosome encoded antigens HY.A2 and HY.B7 
did show the capacity to induce MiHA-specific CD8+ T cells, while ADIR, C19orf48, 
ECGF, HEATR and HY.B8 did not.  However, timing of the tetramer-based analysis is 
crucial in detecting MiHA-specific T cell responses. Depending on the time point 
of analysis during the expansion, contraction and memory phase of the MiHA-
T cell response substantial variation in MiHA-specific T cell frequencies can be 
found. In addition, some of the MiHA-specific T cell responses could be masked 
(subdominant) by other (un)known MiHA. Moreover, the type of the underlying 
malignancy might skew the MiHA-specific T cell repertoire towards a particular 
hematopoietic compartment such as the BM, which may prevent the observation 
of MiHA-specific T cells in PB. 
In conclusion, the studies described in this thesis suggest that non-HLA polymor-
phisms do influence the clinical outcome of allo-SCT. For the chemokine recep-
tor CCR6 we were the first to describe the impact of the donor GG genotype in 
chronic GVHD and invasive fungal disease (IFD). This shows the involvement of 
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CCR6 and immune cells influenced by CCR6 in both GHVD and IFD. Moreover, 
this provides a first clue for the development of a therapeutic approach involving 
CCR6 to suppress both deleterious processes. A special class of non-HLA poly-
morphism, encoding for MiHA, proved to have potential in the development of 
allo-SCT and post transplantation immunotherapy. We were able to add a new 
MiHA termed ZAPHIR to the repertoire of therapeutically relevant MiHA. Fur-
thermore we developed an immunomonitoring tool to assess the allogeneic 
response induced by SCT and DLI making use of combinatorial encoding. Finally 
we showed an association of disparities in known MiHA with RFS and GVHD upon 
partial T cell depleted stem cell transplantation. This shows that MiHA mismatch-
ing donor and recipient prior to transplantation could be a potential new strategy 
to improve clinical outcome of allo-SCT.
Proefschrift Broen_2.indd   169 18-3-2012   15:42:55
170
CHAPTER 7
Srinivasan R, Lundqvist A, Malinzak E, Geller 
N, Lerman MI, Childs RW. Regression of 
human kidney cancer following allogeneic 
stem cell transplantation is associated with 
recognition of an HERV-E antigen by T cells. 
J.Clin.Invest 2008;118:1099-1109.
11. Levenga H, Schaap N, Maas F, Esendam 
B, Fredrix H, Greupink-Draaisma A, de 
WT, Dolstra H, Raymakers R. Partial 
T cell-depleted allogeneic stem cell 
transplantation following reduced-intensity 
conditioning creates a platform for 
immunotherapy with donor lymphocyte 
infusion and recipient dendritic cell 
vaccination in multiple myeloma. Biol.Blood 
Marrow Transplant. 2010;16:320-332.
12. Rodenko B, Toebes M, Hadrup SR, van 
Esch WJ, Molenaar AM, Schumacher TN, 
Ovaa H. Generation of peptide-MHC class 
I complexes through UV-mediated ligand 
exchange. Nat.Protoc. 2006;1:1120-1132.
13. Hadrup SR, Bakker AH, Shu CJ, Andersen 
RS, van VJ, Hombrink P, Castermans E, 
Thor SP, Blank C, Haanen JB, Heemskerk 
MH, Schumacher TN. Parallel detection 
of antigen-specific T-cell responses by 
multidimensional encoding of MHC 
multimers. Nat.Methods 2009;6:520-526.
14. Kircher B, Stevanovic S, Urbanek M, 
Mitterschiffthaler A, Rammensee HG, 
Grunewald K, Gastl G, Nachbaur D. 
Induction of HA-1-specific cytotoxic T-cell 
clones parallels the therapeutic effect of 
donor lymphocyte infusion. Br.J.Haematol. 
2002;117:935-939.
15. Marijt WA, Heemskerk MH, Kloosterboer 
FM, Goulmy E, Kester MG, van der Hoorn 
MA, van Luxemburg-Heys SA, Hoogeboom 
M, Mutis T, Drijfhout JW, Van Rood JJ, 
Willemze R, Falkenburg JH. Hematopoiesis-
restricted minor histocompatibility antigens 
HA-1- or HA-2-specific T cells can induce 
complete remissions of relapsed leukemia. 
Proc.Natl.Acad.Sci.U.S.A 2003;100:2742-
2747.
1. Appelbaum FR. Haematopoietic cell 
transplantation as immunotherapy. Nature 
2001;411:385-389.
2. Horowitz MM, Gale RP, Sondel PM, Goldman 
JM, Kersey J, Kolb HJ, Rimm AA, Ringden 
O, Rozman C, Speck B, . Graft-versus-
leukemia reactions after bone marrow 
transplantation. Blood 1990;75:555-562.
3. Bleakley M, Riddell SR. Molecules and 
mechanisms of the graft-versus-leukaemia 
effect. Nat.Rev.Cancer 2004;4:371-380.
4. Goulmy E. Human minor histocompatibility 
antigens: new concepts for marrow 
transplantation and adoptive immuno-
therapy. Immunol.Rev. 1997;157:125-140.
5. Riddell SR, Berger C, Murata M, Randolph 
S, Warren EH. The graft versus leukemia 
response after allogeneic hematopoietic 
stem cell transplantation. Blood Rev. 
2003;17:153-162.
6. Elmaagacli AH, Koldehoff M, Landt O, 
Beelen DW. Relation of an interleukin-23 
receptor gene polymorphism to graft-
versus-host disease after hematopoietic-cell 
transplantation. Bone Marrow Transplant. 
2008;41:821-826.
7. Gruhn B, Intek J, Pfaffendorf N, Zell R, 
Corbacioglu S, Zintl F, Beck JF, Debatin 
KM, Steinbach D. Polymorphism of 
interleukin-23 receptor gene but not of 
NOD2/CARD15 is associated with graft-
versus-host disease after hematopoietic 
stem cell transplantation in children. Biol.
Blood Marrow Transplant. 2009;15:1571-
1577.
8. Carvalho A, Cunha C, Di IM, Pitzurra L, Aloisi 
T, Falzetti F, Carotti A, Bistoni F, Aversa F, 
Romani L. Prognostic significance of genetic 
variants in the IL-23/Th17 pathway for 
the outcome of T cell-depleted allogeneic 
stem cell transplantation. Bone Marrow 
Transplant. 2010
9. Tykodi SS, Fujii N, Vigneron N, Lu SM, 
Mito JK, Miranda MX, Chou J, Voong LN, 
Thompson JA, Sandmaier BM, Cresswell P, 
Van den EB, Riddell SR, Warren EH. C19orf48 
encodes a minor histocompatibility antigen 
recognized by CD8+ cytotoxic T cells from 
renal cell carcinoma patients. Clin.Cancer 
Res. 2008;14:5260-5269.
10. Takahashi Y, Harashima N, Kajigaya S, 
Yokoyama H, Cherkasova E, McCoy JP, 
Hanada K, Mena O, Kurlander R, Abdul T, 
Reference list
Proefschrift Broen_2.indd   170 18-3-2012   15:42:55
171
SUMMARY AND GENERAL DISCUSSION
7
CH
A
PT
ER
Proefschrift Broen_2.indd   171 18-3-2012   15:42:55
172
CHAPTER 8
Proefschrift Broen_2.indd   172 18-3-2012   15:42:55
173
NEDERLANDSE SAMENVATTING
8
CH
A
PT
ER
Chapter 8
Nederlandse Samenvatting
Dankwoord
Curriculum vitae
List of publications
List of abbreviations
Proefschrift Broen_2.indd   173 18-3-2012   15:42:56
174
CHAPTER 8
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Allogene stamceltransplantatie (allo-SCT) kan een effectieve behandeling zijn voor 
patiënten met een hematologische maligniteit. Hierbij worden hematopoëtische 
stamcellen van een humaan leukocyten antigeen (HLA)-identieke donor aan een 
patiënt gegeven waardoor het beschadigde beenmerg van de patiënt wordt ver-
vangen. Echter het uiteindelijke therapeutische doel is een afweerreactie door 
het donor immuunsysteem op te wekken tegen de nog aanwezige tumorcellen 
van de patiënt, het zogenaamde graft-versus-tumor (GVT) effect. In geval van 
een volledig of gedeeltelijk T cel gedepleteerde allo-SCT worden vaak additio-
nele T cellen gegeven in de vorm van een donor-lymfocyten-infusie (DLI) waar-
door het GVT effect wordt versterkt. Naast de behandeling van hematologische 
maligniteiten is allo-SCT in het verleden ook toegepast als een experimentele 
behandeling voor patiënten met gemetastaseerde solide tumoren. Helaas blijven 
transplantatie-gerelateerde complicaties, zoals opportunistische infecties en de 
zogenaamde graft-versus-host ziekte (GVHD), een groot nadeel van allo-SCT. 
Opties om deze zeer individuele vorm van immuuntherapie te verbeteren, focus-
sen op het terugdringen van GVHD en infecties en tegelijkertijd het verhogen van 
het GVT effect. In het geval van HLA-identieke allo-SCT komen zowel het poten-
tieel genezend GVT effect als GVHD tot stand door donor T cellen die gericht zijn 
tegen de zogenaamde minor histocompatibiliteits (weefselspecifieke) antigenen 
(MiHA). Deze MiHA zijn polymorfe, aan HLA gebonden peptiden afgeleid van 
cellulaire eiwitten en deze kunnen krachtige T cel reacties veroorzaken gericht 
tegen de tumorcellen, maar soms ook gezond weefsel, van de patiënt. Wan-
neer MiHA alleen op tumorcellen aanwezig zijn, ontstaat een GVT effect, terwijl 
de aanwezigheid van MiHA op gezonde cellen leidt tot de ongewenste GVHD. 
Daardoor zijn MiHA-specifieke T cel reacties essentieel voor de inductie van een 
selectief GVT effect met minimale risico’s voor GVHD. De moleculaire identifica-
tie van GVHD- en GVT-geassocieerde MiHA heeft het mogelijk gemaakt om het 
klinische effect van MiHA te bestuderen evenals hun specifieke T cel responsen 
na transplantatie. Daarnaast worden MiHA bestudeerd als doel-antigenen in 
nieuwe therapeutische toepassingen.
In dit proefschrift is het effect op de uitkomst van allo-SCT bestudeerd dat wordt 
veroorzaakt door genetische polymorfismen die MiHA veroorzaken of polymor-
fismen in signaal moleculen die betrokken zijn bij een alloreactieve immuunre-
spons. Bij het bestuderen van genetische verschillen wordt gebruik gemaakt van 
‘single nucleotide polymorphisms’ (SNP) die het genetisch verschil tussen indivi-
duen uitdrukken. We bestudeerden SNPs die de expressie of de functie kunnen 
beïnvloeden van cytokine- en chemokinereceptoren. Daarnaast hebben we SNP 
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bestudeerd die ten grondslag liggen aan de immunogeniciteit van de MiHA wat 
heeft geleid tot de identificatie van een nieuwe MiHA genaamd ZAPHIR.
In Hoofdstuk 2 hebben we een retrospectieve studie uitgevoerd om de effecten 
van polymorfismen in de IL-23 receptor (IL-23R) en de chemokine receptor CCR6 
te bestuderen in relatie tot de uitkomst van de transplantatie zoals die is uitgevo-
erd in 161 patiënten. We hebben geen relatie gevonden tussen de IL-23R SNPs en 
het klinisch verloop van de transplantatie, in tegenstelling tot een aantal andere 
studies. Multivariant analyse, uitgevoerd voor de polymorfismen in CCR6 toonde 
aan dat patiënten getransplanteerd met een transplantaat van een homozygote 
rs2301436 G allel donor minder vaak chronische GVHD ontwikkelden wat ook het 
geval was voor een transplantaat van een homozygote rs3093023 G allel donor. 
Ook was het donor GG genotype op rs2301436 geassocieerd met een hogere 
incidentie van invasieve schimmelinfecties na allo-SCT. In onze studie wordt 
voor het eerst een relatie beschreven tussen het donor-genotype van SNPs in 
het CCR6 gen en het voorkomen van chronische GVHD en invasieve schimmelin-
fecties. We concluderen dat patiënten die een allo-SCT moeten ondergaan bij 
voorkeur een transplantatie zouden moeten ontvangen van een geschikte donor 
met deze specifieke SNPs. Verder onderzoek is nodig om de consequenties van 
de polymorfismen op CCR6 functionaliteit te onderzoeken. 
Tot op heden heeft het bestuderen van polymorfismen die de expressie of func-
tie van cytokines, chemokines, chemokine receptoren en PAMP-receptoren beïn-
vloeden, nog niet geleid tot aanpassingen in de allo-SCT therapie. MiHA aan de 
andere kant, zijn wel bestudeerd als aangrijpingspunten voor immuuntherapie 
na transplantatie. Om immuuntherapie gericht tegen weefselspecifieke MiHA op 
grotere schaal beschikbaar te maken, zullen meer MiHA die een selectief GVT 
effect kunnen bewerkstelligen moeten worden toegevoegd aan het bestaande 
repertoire. Hoofdstuk 3 beschrijft de identificatie van een nieuwe MiHA, die 
wij ZNF419 alternatief gespliced polymorf histocompatibiliteits antigeen in RCC 
(ZAPHIR) hebben genoemd. 
We hebben gevonden dat ZAPHIR wordt herkend door een CTL kloon geïsoleerd 
uit een patiënt met gemetastaseerd NCC in de long, wat gedeeltelijk was verd-
wenen na ‘reduced-intensity’ allo-SCT. De betreffende CTL was cytotoxisch tegen 
NCC cel lijnen maar niet tegen fibroblasten geïsoleerd uit het beenmerg (BM) die 
waren voorbehandeld met ontsteking inducerende cytokines. 
Uit een genoombrede associatiestudie bleek dat deze CTL een MiHA herkent die 
ontstaat door een SNP in de splice donorpositie van het ZNF419 gen wat leidt tot 
alternatieve splicing van intron 4 waardoor er een, tot op dat moment onbek-
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ende, splice variant ontstaat. Bovendien liet een  tetrameer analyse zien dat niet 
alleen een ZAPHIR-specifieke CD8+ T cel respons ontstond in de getransplant-
eerde NCC patiënt waaruit we de originele CTL kloon hadden geïsoleerd, maar 
ook in een chronische myeloide leukemie (CML )patiënt die was behandeld met 
therapeutische DLI zonder dat deze GVHD ontwikkelde. Deze bevindingen laten 
zien dat ZAPHIR mogelijk een nieuw doelwitantigeen kan zijn bij het ontwikkelen 
van nieuwe immuuntherapie voor NCC en hematologische maligniteiten. 
In parallel hebben we de MiHA-specifieke T cel reactie bestudeerd in een andere 
NCC patiënt met stabiele ziekte na ‘reduced-intensity’ allo-SCT en DLI. Van deze 
patiënt hebben we een MiHA-specifieke T cel kloon geïsoleerd die het HLA-A2 
gerestricteerde SMCY antigen herkent. Hoewel het SMCY antigen in alle lichaam-
scellen tot expressie komt, liet een tetrameer analyse in de NCC patiënt een 
sterke verhoging zien van SMCY-specifieke CD8+ T cellen zonder klinische verschi-
jnselen GVHD. Onze klinische bevindingen suggereren dan ook dat het opkomen 
van een SMCY-specifieke CTL een rol kan hebben gespeeld bij het stabiliseren van 
de tumorgroei in de NCC patiënt na allo-SCT. 
De belangrijke rol van MiHA-specifieke T cellen in immuun therapie wordt ook 
geïllustreerd in Hoofdstuk 4 waarin we een nieuwe HLA-A3-gerestricteerde 
MiHA-specifieke T cel hebben gekarakteriseerd geïsoleerd uit een multipel 
myeloom (MM) patiënt. Deze patiënt is in langdurige remissie na behandeling 
met een ‘reduced-intensity’ allo-SCT, DLI en vervolgens een vaccinatie met den-
dritische cellen (DC) afkomstig van de patiënt zelf. In het verleden hebben we 
met succes de mogelijkheden bestudeerd om door middel van post-transplanta-
tie immuuntherapie het graft-versus-myeloom effect te verbeteren terwijl weinig 
GVHD en sterfte voorkwam. We hebben een HLA-A3-gerestricteerde MiHA-spec-
ifieke T cel geïsoleerd die efficiënt MM tumorcellen en cellijnen doodt, terwijl 
fibroblasten niet werden herkend. Kwantitatieve analyse van de CTL-specifieke 
T cel receptor (TCR) liet zien dat de CTL in zowel BM als perifeer bloed aanwezig 
was. Opmerkelijk is de sterke stijging van het TCR transcript in de tumorlocatie in 
het BM na DLI en DC vaccinatie, terwijl in perifeer bloed het signaal van de TCR 
afnam. Deze studie laat zien dat onze aanpak van eerst een gedeeltelijke T cel 
gedepleteerde allo-SCT, gevolgd door DLI en DC-vaccinatie, een MiHA-specifieke 
T cel respons induceert die MM tumorcellen aangrijpt. Bovendien suggereren 
onze bevindingen dat  DC-vaccinatie kan leiden tot een verhoogd aantal MiHA-
specifieke CTL in het BM, dan wel een verhoogde migratie van deze  CTL naar het 
BM. 
Aangezien het therapeutisch effect van allo-SCT en DLI met name afhankelijk is 
van de herkenning van MiHA door CD8+ T cellen afkomstig van de donor, kan het 
monitoren van meerdere MiHA-specifieke CD8+ T cel responsen waardevol bli-
jken bij het evalueren van de werkzaamheid van allo-SCT. De meeste analytische 
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methoden beperken zich tot de detectie van CD8+ T cel responsen en het analy-
seren van een enkele MiHA epitope daarbij gebruik makend van conventionele 
technieken zoals enkel-kleur tetrameer analyse of de ELISPOT assay. In Hoofdstuk 
5 hebben we het gebruik van de zogenaamde ‘combinatorial encoding’ techniek 
onderzocht bij het gelijktijdig detecteren van verschillende MiHA-specifieke CD8+ 
T cellen in perifeer bloed van SCT ontvangers. De haalbaarheid van deze techniek 
is aangetoond door dubbel-kleur tetrameer combinaties toe te passen op een 
set van 10 bekende MiHA. De kleuringen gedaan met een op flourochromen en 
Qdots-gebaseerde vijf-kleuren combinatie liet vergelijkbare resultaten zien met 
de dubbel-kleur combinatie voor de meeste MiHA-specifieke CD8+ T cel respon-
sen. Deze bevindingen demonstreren de potentie van de ‘combinatorial encod-
ing’ aanpak bij het monitoren van CD8+ T cel responsen gericht tegen MiHA in 
een beperkte hoeveelheid perifeer bloed van allo-SCT ontvangers.
De ‘combinatorial encoding’ aanpak is geschikt voor een breed scala aan ver-
schillende peptide-MHC multimeren voor verscheidene HLA moleculen, die 
gemakkelijk kunnen worden geproduceerd door middel van UV-gemedieerde 
ligand uitwisseling. De beschikbaarheid van de grote hoeveelheid verschillende 
tetrameren heeft ons in staat gesteld om de potentiële waarde van ‘combinato-
rial encoding’ in MiHA identificatie te bestuderen. Daarom hebben we eerst een 
set van 100 kandidaat-MiHA peptides van polymorfe genen met een hematopoi-
etische expressieprofiel voorspeld. Verdere selectie voor hoge en middel affinit-
eit voor de binding aan HLA-A2 resulteerde in 75 potentiële MiHA waarvoor wij 
een cohort SCT ontvangers hebben getest om de aanwezigheid van specifieke 
T cellen tegen deze MiHA set. Eerst werden de specifieke T cellen verrijkt voor 
de 75 potentiële MiHA en vervolgens werden de kweken gescreend op de aan-
wezigheid van MiHA-specifieke T cellen door een set ‘combinatorial encoding’ 
tetrameren. Hoewel verschillende epitoop-specifieke T cellen werden gevonden, 
konden we alleen CD8+ T cel responsen voor van LAG3 en TLR10 afgeleide poly-
morfe peptiden bevestigen door middel van genotypering van de respectievelijke 
SNPs.
Het therapeutisch effect van de GVT respons kan hoofdzakelijk worden toege-
schreven aan MiHA-specifieke T cellen waarvan het opkomen vooraf gaat aan 
klinische remissie in patiënten die behandeld zijn met DLI. In Hoofdstuk 6 heb-
ben we bestudeerd of een verbetering kan worden geobserveerd in de uitkomst 
van allo-SCT wanneer donor en ontvanger verschillen in MiHA. Daarom hebben 
we een retrospectieve analyse uitgevoerd op 327 patiënten met een hematolo-
gische maligniteit die allemaal een deels T cel gedepleteerde allo-SCT hebben 
ontvangen. In een multivariante statistische analyse hebben we het voorkomen 
van HY of autosomale MiHA verschillen kunnen correleren aan de klinische 
uitkomst. Patiënten, getransplanteerd vanwege MM en een autosomaal MiHA 
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verschil op DNA niveau hadden een verbetering van de ziektevrije overleving. 
Daarnaast laten verschillen in de op het Y chromosoom gecodeerde MiHA zien 
dat meer acute GVHD (graad 3-4) voorkomt, terwijl verschillen in andere MiHA, 
zowel breed voorkomend als beperkt tot hematologische cellen, niet geasso-
cieerd zijn met GVHD. Deze studie is dan ook een indicatie om voor transplantatie 
specifieke patiënt-donor koppels te selecteren gebaseerd op verschillen in auto-
somale MiHA, om op deze manier een GVT effect te bewerkstelligen. 
Hoewel significante verschillen in de klinische uitkomst van allo-SCT ontstaan door 
MiHA verschillen op DNA niveau, betekent dit niet dat ook altijd MiHA-specifieke 
T cel reacties aanwezig zijn.  Daarom hebben wij de MiHA-specifieke T cellen die 
ontstaan bestudeerd door middel van dubbel-kleur tetrameer analyses. Dit liet 
aanmerkelijke verschillen zien tussen de capaciteit van de verschillende MiHA 
om in vivo T cel reacties op te wekken na transplantatie (0%-60%).
De studies beschreven in dit proefschrift suggereren dat de uitkomst van allo-SCT 
kan worden beïnvloed door niet-HLA polymorfismen. In het geval van de chemo-
kine receptor CCR6 beschreven wij voor het eerst de effecten van het donor GG 
genotype in chronische GVHD en invasieve schimmelinfecties. Hiermee laten we 
zien dat CCR6 en immuuncellen die beïnvloed worden door CCR6, betrokken zijn 
bij GHVD en infecties. Op deze manier geeft dit onderzoek een eerste aanwijzing 
voor het ontwikkelen van een therapie waarin deze twee processen onder con-
trole te houden zijn. Een speciale klasse van niet-HLA polymorfismen die coderen 
voor MiHA laten een hoge potentie zien binnen allo-SCT en post-transplantatie 
immuuntherapie. Door de identificatie van het nieuwe MiHA ZAHPIR waren we in 
staat om een nieuw therapeutisch relevant MiHA aan het bestaande repertoire 
toe te voegen. Verder hebben we een immunomonitoring instrument ontwik-
keld dat de ‘combinatorial encoding’ techniek toepast en dat geschikt is voor de 
beoordeling van de allogene immuun response die geïnitieerd wordt na SCT en 
DLI. Tot slot toonden we een verband aan tussen verschillen in bekende MiHA 
en ziektevrije overleving en GVHD na allo-SCT. Dit toont aan dat het selecteren 
van patiënt-donor koppels die verschillen in autosomale MiHA vooraf aan de 
transplantatie, een potentieel nieuwe strategie is om de klinische uitkomst van 
allo-SCT te verbeteren.
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Dankwoord
Het laatst geschreven, maar het meest gelezen hoofdstuk van dit manuscript. 
Terwijl ik dit dankwoord schrijf zie ik steeds meer gezichten aan me voorbij gaan 
die ik vooral niet moet vergeten. En die lange lijst is niet uniek, niemand pro-
moveert in z’n eentje en ik ben blij dat ik dat ook niet heb hoeven doen.
Allereerst gaat mijn dank uit naar Harry. Als co-promoter was jij voor 100% bij 
mij en mijn project betrokken. Je deur stond altijd voor me open en je had het 
beste met me voor. Ik hoef jou niet te vertellen welke ups en downs er zijn wan-
neer je onderzoek doet, want ik stel me zo voor dat je geregeld flashbacks had 
naar je eigen promotietijd. Bij het identificeren van minors komt creativiteit en 
teamwork kijken. Wij waren een creatief team en zonder jou was dit proefschrift 
er nooit geweest.
Beste Theo, beste promoter. De rol van promotor is een bijzondere en al sta je wat 
verder van de labtafel af, je had al heel wat promovendi voorbij zien komen. Zo 
kon je de promotie-, en keuzestress voor mij goed relativeren en heb ik genoten 
van je verhalen over je dochters die je als referentiekader gebruikte. Dankjewel 
voor de fijne samenwerking. 
Dan de paranimfen, officieel mijn begeleiders tijdens de verdediging maar vooral 
een steun gedurende de afgelopen 4 jaar. Willemijn, ik vond onze samenwerk-
ing prettig, al hebben we soms ook wel eens gebotst doordat we toch ook con-
collega’s waren. Maar dat hoort erbij als je ergens vol voor gaat en zo eigenzinnig 
bent als wij allebei kunnen zijn. Ondanks dat je minder ver in je promotietraject 
zat dan ik heb ik toch naar je opgekeken om je harde werken en vasthoudendheid 
(en niet te vergeten: je kwaliteit om lijstjes te maken!). Ik waardeer je als collega 
maar bovenal waardeer ik onze vriendschap. 
Bonny, lieve zus. Als jongste van de familie heb toch altijd je eigen weg gezocht 
en ben je lekker onafhankelijk. Ondanks je voorliefde voor genieten van alle leuke 
en mooie dingen in het leven ben je ook een harde werker en ga je op je doel af. 
Ik neem graag een voorbeeld aan jou luchtigheid en vind het fijn dat je op deze 
speciale dag naast me staat.
Als analist van een AIO heb je het soms niet makkelijk. Annemieke, het project 
overdragen aan een ‘groentje’ zoals ik gaf je toch wel wat zorgen, maar we waren 
al snel goed op elkaar ingespeeld als ‘dynamisch duo’. Dit was ook wel nodig, 
zeker toen bleek dat het identificeren van ZAPHIR helemaal niet zo’n gesneden 
koek was en het leek of we alleen maar verder verwijderd raakten van het eind-
doel. Dat het uiteindelijk toch gelukt is, is mede aan jou te danken. Door je 
precisie (wat een prachtige labjournaals!) en zorg voor de CTLs en onze CEPH 
families is de basis gelegd voor de uiteindelijke identificatie. Annelies, jij kwam 
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aan mijn project werken toen het onderzoek al wat verder gevorderd was en er al 
heel wat zijwegen waren ingeslagen. Dat maakte dat je soms niet meer wist welk 
weggetje we nu weer aan het bewandelen waren als ik (of Harry) weer eens met 
een nieuw experiment kwam aanzetten. Toch bleef je alles bijhouden (in nette 
lijstjes!) en was jij altijd kalm, ook al kwam bij mij de stoom uit m’n oren (heerlijk 
Gronings). Hanny, rots in de branding. Je werkte niet echt op mijn project, maar 
hebt mij toch een aantal keren uit de brand geholpen. Je hebt al meer AIOs een 
poging zien doen een minor te identificeren en je was dan ook niet onbekend met 
het opzetten en uitvoeren van experimenten in bulk. Je draait je hand niet om 
voor het verwerken van een paar honderd DNA-preps of het uitvoeren van een 
experiment met een dozijn condities en hebt dan ook nog aan een half woord 
genoeg. Dames, dank voor jullie harde werk en prettige samenwerking. Zonder 
dit, aangevuld met een fijne vriendschap, was ik niet zover gekomen.
Wieger, Sandra, Willemijn, Anniek: Vanaf het begin waren we een gezellig kliekje 
dat al een titel verdiende in onzin verkondigen, maar toch wisten we door de 
jaren heen steeds verstandigere dingen te zeggen over T cellen en DCs. Samen 
hebben we het AIO-zijn meegemaakt, zowel de leuke momenten als de stress 
periodes. Gelukkig hadden jullie altijd een luisterend oor. Zo was er altijd begrip 
als ik weer eens stoom kwam afblazen op onze kamer, maar gelukkig waren jul-
lie er ook bij als we wat te vieren hadden (of niet ;) met een borrel. Ik kijk met 
veel plezier terug op onze gezamenlijke congressen en de bijbehorende vakan-
ties. Op die manier hebben we veel samen gedeeld: Op het lab soms letterlijk 
bloed, zweet en tranen, maar ook tenten en bedden, deo’s en zonnebrandcrème, 
biertjes en champagne. Mij zal vooral de gezelligheid en vriendschap bijblijven. Ik 
wens jullie succes bij het afronden van jullie eigen promotie en hoop dat we onze 
gezamenlijke etentjes nog lang blijven voortzetten. 
Frans, Jan, Marleen, Jeannette, Basav, Marij, Robbert, Rob, Jeroen, Karishma, 
Ingrid, Viviènne, Niken, Marian, Thomas: De CTI groep is niet compleet zonder 
jullie. Door de jaren heen is de samenstelling wel wat veranderd, maar de goede 
werksfeer en gezelligheid bleven altijd behouden. Ik wil jullie allemaal bedanken 
voor alle hulp die ik gekregen heb, de soms hilarische momenten tijdens de lunch 
en koffie en het warme hart dat jullie mij toedragen.
Kim, Mariëlle, Paulien, Desirée, Julia en Floris, jullie kwamen stage lopen op het 
hematologische lab waar ik jullie wegwijs mocht maken in de wetenschap, en 
dan nog wel in het bijzonder de identificatie van minor antigenen. Ik stel me 
zo voor dat jullie je dikwijls hebben afgevraagd wanneer die grote doorbraak 
nou kwam…………Die is er uiteindelijk toch gekomen, ook omdat jullie daaraan 
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meegewerkt hebben. Wetenschap gaat doorgaans in kleine stapjes en die heb ik 
jullie ook zien maken. En ik, ik heb veel van jullie geleerd! Zo weet ik nu dat je niet 
duidelijk genoeg kunt zijn in je uitleg, maar ook dat een opgekookte albumine 
oplossing geen oplossing meer is.
Bij het doen van patiëntgebonden onderzoek is een goede samenwerking met 
de kliniek essentieel. Ik stapte in het onderzoek waar jij, Henriëtte, al langer aan 
had gewerkt. Het duurde een hele tijd voordat het einde bereikt was, maar tus-
sen je drukke werkzaamheden en gezin door hebben we toch een mooi paper 
kunnen publiceren. Walter, ook bij jou kriebelt het om tussen de bedrijven door 
onderzoek te doen. We hebben een productieve samenwerking opgezet waarbij 
jij me op sleeptouw nam in de wereld van de statistiek. Ook dacht je altijd mee bij 
de opzet van de paper en voelde je je zeer verantwoordelijk bij het tot een goed 
einde brengen van het onderzoek. Tot slot, Michel, samen hebben we veel gaten 
opgevuld in de bestaande lijstjes, overzichten en materiaalopslag. Ook jij dacht 
mee over de opzet van projecten waarbij ik veel leerde over de hematologie. Ik 
dank jullie allemaal voor jullie harde werk en fijne samenwerking. 
Promoveren betekend ook dat je zo nu en dan buiten je eigen vakgebied een 
kijkje gaat nemen en dat deed ik ook bij onze ‘buren’, de moleculaire research. 
Saskia en Ruth, bedankt voor alle praktische tips, zonder jullie waren m’n gel-
letjes nooit zo mooi geworden. Alle anderen ook bedankt voor de gezelligheid 
tijdens het borrelen op vrijdagmiddag bij de Aesculaaf, AIO-retraites (Maaike, 
wat waren we goede roomies), NVH congressen en bierproeverijen. Succes bij 
het afronden van jullie promoties!
De BMT was onontbeerlijk voor het verzamelen en bewerken van patiëntens-
amples. Ook de moleculaire diagnostiek was altijd bereid om te helpen wanneer 
we weer DNAtjes nodig hadden en niet te vergeten hun helpdesk (lees ‘Louis’) 
voor alle PCR-problemen.  Dankjewel allemaal evenals alle andere collega’s die 
mij met raad en daad hebben bijgestaan!
Minor antigenen zijn groot in Nederland en dus kwamen we jullie, collegae uit 
Leiden, op menig congres tegen. Daar sloegen we dan meteen spijkers met kop-
pen en dat betekende voor mij dat er weer nieuwe stappen gezet konden wor-
den. Uiteindelijk heeft onze samenwerking zelfs geleidt tot het identificeren van 
ZAPHIR. Marieke, Kees, Michel en Fred, bedankt voor jullie snelle en bereidwil-
lige hulp en jullie frisse kijk op mijn werk.
En zo ben ik dan terecht gekomen in het OMC te Sittard. Hier leiden Joop, Renée 
en Bernadette mij op tot klinisch chemicus. Jullie staan voor de taak om mij als 
onderzoeker om te vormen naar een KC met een brede vakkennis en goede com-
municatie skills. Ik zie de toekomst vol vertrouwen tegemoet en kijk vooruit op 
een prettige samenwerking op het KCHL.
Weer terug zijn in Limburg voelt heel vertrouwd. Ik ben dan ook eigenlijk nooit 
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echt weg geweest. Al jaren, soms vanaf de kleuterschool, heb ik een mooie set 
vrienden om me heen waarmee ik door de jaren heen al heel wat heb meege-
maakt. De scouting was voorheen onze bindende factor en nu doen we dat 
gewoon als ‘normale’ mensen. Ik geniet van onze gezamenlijke feestjes, uitjes, 
weekendjes of gewoon koffiedrinken. Met dit boekje op schoot krijgen jullie 
misschien eindelijk een idee waar het nou allemaal om draaide de afgelopen 
jaren, en het wordt zeker een mooi feest!
Ook aan de ‘andere kant’, Wouters kant, zijn er mooie vriendschappen waarvan 
ik mag meegenieten. Het fijne is dat jij, Jasper, hier ook altijd bij bent en zo heer-
lijk nuchter kunt zijn. Een welkome afwisseling in de soms stressvolle promotie-
periode. Kortom, een lekker zooitje ongeregeld waar ik zo nu en dan eens heerlijk 
mee uit de band kan springen. 
Dan rest mij nog de mensen die het dichtst bij mij staan. Jullie gunnen mij en 
Wouter het allerbeste en dat is hart verwarmend. Jan en Marianne, wat zijn jullie 
toch betrokken en geïnteresseerd. We worden altijd met open armen door jullie 
en de kinderen ontvangen en dat voelt goed.
Neeltje, een tweede moeder, ook al zo begaan met mij. Jouw huis is nog een 
thuis voor mij en ik weet dat ik je vertrouwen en steun heb.
Pap, Mam, Cindy, Nancy en Bonny, mijn familie, mijn steun en mijn vangnet. Ook 
voor jullie bleef het lang onduidelijk waar ik nu toch mee bezig was in dat lab. 
Hier ligt het voor jullie, het proefschrift. Dat is nu klaar, maar jullie zullen er altijd 
zijn voor mij. Dankjewel en ik hou van jullie.
Tenslotte nog een paar allerlaatste woorden voor jou, Wouter. We hebben dit 
samen meegemaakt, ook jij deed je promotieonderzoek de afgelopen jaren. Ik 
hoef je dan ook niets meer te vertellen en we weten allebei wat er voor nodig 
was om dit tot een goed einde te brengen. Samen kunnen we bergen verzetten. 
Ik hou van je.
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Curriculum Vitae
Kelly Broen werd op 17 november 1980 geboren te Echt. Hier doorliep zij de 
middelbare school en haalde in 1999 haar VWO diploma. Datzelfde jaar startte 
zij de opleiding Milieuhygiëne aan de Wageningen Universiteit, maar koos er in 
2000 voor om Biologie te gaan studeren aan de Universiteit Utrecht. Hier haalde 
zij in 2003 haar bachelordiploma en vervolgde haar studie met de master Infec-
tion & Immunity van de studie Biomedische Wetenschappen. Gedurende deze 
masteropleiding deed zij twee onderzoeksstages. De eerste stage deed zij op 
de UU aan de Faculteit Diergeneeskunde, Afdeling Virologie. Onder begeleiding 
van Dr. Tom Würdinger werkte zij aan de ontwikkeling van een oncolytisch coro-
navirus. De tweede stage werd op het Nederlands Vaccin Instituut te Bilthoven 
gelopen waar zij werkte onder begeleiding van Dr. Peter van der Ley. Hier maakte 
zij kinkhoest-bacterie-varianten met als doel het toenmalige kinkhoest-vaccin te 
verbeteren. Na het schrijven van een scriptie over de gevolgen van malaria voor 
het ongeboren kind studeerde zij in 2005 af. 
Na een voorbereidende fase begon zij in 2006 als junior onderzoeker aan het 
Universitair Medisch Centrum St. Radboud te Nijmegen in de groep van Dr. Frank 
van Kuppeveld. Dit onderzoek had als doel meer inzicht te krijgen in de manier 
waarop picornavirussen het immuunsysteem ontwijken. 
In 2007 startte zij haar promotieonderzoek bij het Centraal Hematologisch Labo-
ratorium, wederom aan het RUNMC. Onder begeleiding van Dr. Harry Dolstra 
voerde zij het onderzoek uit zoals beschreven in dit proefschrift. Naast het onder-
zoek behaalde zij haar SMBWO Immunologie aantekening. Het proefschrift werd 
afgerond in september 2011. In december 2011 startte zij haar opleiding tot 
klinisch chemicus in het Orbis Medisch Centrum te Sittard. 
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List of Abbreviations
5FU    5-fluorouracil
7AAD   7-amino-actinomycin D
Ab   antibody
ALL   acute lymphoid leukemia
AML   acute Myeloid Leukemia
APC   antigen-presenting cell
ATG   anti-thymocyte globulin
Bid   bi-daily
BM   bone marrow
BSA   bovine albumin serum
Bus    busulfan
CEPH   centre d’Etude Polymorpphism Humain
CFSE   carboxyfluorescein succinimidyl ester
CLL   chronic lymphoid leukemia
CML   chronic myeloid Leukemia
CMV   cytomegalovirus
CsA   cyclosporine A
CR   clinical remission 
CTL   cytotoxic T lymphocyte
Cy   cyclophosphamide
DC   dendritic cell
DNA   deoxyribonucleic adic
DLI   donor lymphocyte infusion
EBV-LCL  epstein-Barr virus lymphoblastoid cell line
EDTA    ethylene di-amine-tetra-acetate
ELISA   enzyme-linked immuno sorbent assay
ELISPOT  enzyme-linked immunosorbent spot
FACS   fluorescence-activated cell sorting
FCS   fetal calf serum
FDMR   female-donor-male-recipient
FITC   fluorescein isothiocyanate
Flu    fludarabine
G-CSF   granulocyte Colony Stimulation Factor
GM-CSF  granulocyte Macrophage Colony Stimulation Factor
GVHD   graft versus host disease
GVT   graft-versus-tumor
GWAS   genome wide association study
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HBSS   hank’s balanced salt solution
HS   human serum
ICAM-1   inter-cellular adhesion molecule 1
Ida   idarubicin
IMDM   iscove’s modified Dulbecco’s medium
IFNγ   interferon γ
IL   interleukin
KLH   keyhole limpet hemocyanin
MACS   magnetic activated cell sorting
MHC   major histocompatibility complex
MiHA   minor histocompatibility antigen
MDS   myelodysplastic syndrome
MM   multiple Myeloma
MMF    mycophenolate mofetil
na    not applicable 
ne    not evaluated
NHL   non-Hodgin’s lymphoma
NK   natural killer
NRM   non relapse mortality
OS   overall survival
PBGD   porphobilinogen deaminase
PBMC   peripheral blood mononuclear cell
PCR   polymerase chain reaction
PD    progressive disease 
PE   phycoercythrin
PHA-M   phytohaemagglutinin-M
PR    partial remission
RCC   renal cell carcinoma
RFS   relapse free survival
RIC   reduced intensity conditioning
RNA   ribonucleic acid
RT    reverse transcriptase
RT   radio therapy
SC    stem cell
SCT   stem cell transplantation
SD    stable disease
SNP   single nucleotide polymorphism
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TBI   total body irradition
TCR   T cell receptor
Tet   tetramer
Th   T helper
TNFα   tumor necrosis factor-alpha
TRM   treatment related mortality
UPN   unique patient number
VNTR   variable number tandem repeat
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